



Is it getting easier to access individual participant data for secondary research? A systematic review of individual participant data meta-analyses

Journal:	<i>BMJ</i>
Manuscript ID	BMJ.2016.036543
Article Type:	Research
BMJ Journal:	BMJ
Date Submitted by the Author:	14-Nov-2016
Complete List of Authors:	Nolan, Sarah; University of Liverpool, Biostatistics Marson, Anthony; University of Liverpool, Molecular and Clinical Pharmacology Davie, Becky; University of Liverpool, Biostatistics Reynolds, Sally; University of Liverpool, Biostatistics Williams, Lisa; University of Liverpool, Biostatistics Tudur Smith, Catrin; University of Liverpool, Biostatistics
Keywords:	individual participant data meta analysis, data sharing, data transparency, Cochrane Collaboration, Epilepsy, individual patient data, IPD

SCHOLARONE™
Manuscripts

1
2
3 1 **Is it getting easier to access individual participant data for secondary**
4
5 2 **research? A systematic review of individual participant data meta-analyses**
6
7

8 3 **Sarah J Nolan, Anthony G Marson, Becky Davie, Sally Reynolds, Lisa Williams, Catrin Tudur**
9 4 **Smith**

10
11
12 5 ***Correspondence address**

13
14
15 6 Sarah Nolan

16
17 7 Department of Biostatistics

18
19 8 University of Liverpool

20
21 9 Block F, Waterhouse Building

22
23 10 1-5 Brownlow Street

24
25 11 Liverpool

26
27 12 L69 3GL

28
29 13 E-mail: sjn16@liverpool.ac.uk

30
31 14 **Abstract:**

32
33
34
35
36 15 **Objective:** To investigate whether the success rate of retrieving individual participant data (IPD) for
37 16 the purpose of IPD meta-analysis (IPDMA) has increased over time, and explore characteristics
38 17 associated with IPD retrieval.

39
40
41
42 18 **Design:** Systematic review of published IPDMA, supplemented by a reflection of the Cochrane
43 19 Epilepsy Group's 20 years of experience in requesting IPD

44
45
46 20 **Data sources:** Eligible IPDMA were identified from a systematic search of MEDLINE, Central, SCOPUS,
47 21 Web of Science, CINAHL Plus and PsycINFO up to August 2015

48
49
50 22 **Eligibility criteria for selecting studies:** IPDMA of studies of all designs and all clinical areas published
51 23 in English

52
53
54
55 24 **Results:** 760 IPDMA which identified studies via systematic methods published between 1987 and
56 25 2015 were included. Only a quarter of these IPDMA retrieved 100% of the eligible IPD for analysis
57
58
59
60

1 with a half of all IPDMA retrieving less than 80% of relevant IPD. There is insufficient evidence to
2 suggest that IPD retrieval rates have improved over time. IPDMAs that included only randomised
3 trials, had an authorship policy, included fewer eligible participants and were conducted outside of
4 the Cochrane Database of Systematic reviews, were associated with a high or complete IPD retrieval
5 rate. There was no association between the source of funding of the IPDMA and IPD retrieval rate.
6 The IPD retrieval rate of the Cochrane Epilepsy Group has declined from 83% (up to 2005) to 65%
7 (between 2012 and 2015) and reported reasons for lack of data availability have changed in recent
8 years.

9 **Conclusions:** IPDMA are considered to be the 'gold-standard' approach to synthesise data from
10 clinical research studies, however only one in four published IPDMA have had access to all IPD. It is
11 hoped that the growing awareness of data sharing and transparency will improve this proportion in
12 future years.

13 **What is known on this subject?**

- 14 • Individual participant data meta-analysis (IPDMA) is widely regarded as the gold standard
15 approach to the synthesis of clinical research study data but are susceptible to bias if only a
16 proportion of IPD is available for analysis
- 17 • IPDMA are often poorly reported in terms of proportion of IPD for retrieved and reasons for
18 non-availability of IPD
- 19 • Recent years have seen a shift in attitudes and awareness towards data sharing. Improved
20 access to IPD should therefore which could improve the proportion of IPD retrieved in an
21 IPDMA

22 **What this study adds:**

- 23 • This systematic review of 760 IPDMA published between 1987 and 2015 showed that one in
24 four IPDMA retrieved 100% of the eligible IPD for analysis, but half retrieved less than 80%.
- 25 • Despite the significant drive towards improving access to clinical research data, the IPD
26 retrieval rate across 760 published IPDMAs has not improved over time.
- 27 • IPDMAs that included randomised trials only, contained fewer eligible participants, used an
28 authorship policy and were conducted outside of a Cochrane Review, were associated with a
29 higher IPD retrieval rate.

1 Introduction

2 Systematic reviews are considered to be the highest level of evidence in many contexts of medicine¹
3 and individual participant data (IPD) meta-analysis is widely regarded as the gold standard approach
4 to the synthesis of clinical trial data with many documented advantages over traditional aggregate
5 data (AD) meta-analysis.²⁻⁷ Recent years have shown a sharp increase in the number of published IPD
6 meta-analyses (IPDMA),⁸⁻¹⁰ with an average of 49 published per year between 2005 and 2009⁹ and
7 an estimated increase of around 4 published IPDMA per year.¹⁰ IPDMA have been shown recently
8 to directly influence the design and conduct of clinical trials¹¹ and clinical practice guidelines.¹²

9 While an IPDMA may offer many advantages it is well recognised that greater resources are required
10 to conduct them⁵⁻⁷ and they are subject to a risk of selection bias and 'availability bias;' in that they
11 may only include studies for which IPD is made available, which may not be representative of the
12 whole evidence base.^{13 14} Lack of transparent processes and barriers to accessing IPD may also
13 substantially delay projects or even prevent the completion of planned IPD analyses.¹⁵⁻¹⁸ Review
14 articles have shown that around a quarter of IPDMA published up to 2001,¹⁹ up to 2005¹³ and even
15 as recently as 2012¹⁰ obtained IPD for less than 80% of eligible participants. These reviews also
16 reveal poor reporting particularly in regard to the amount of included IPD, with between 10 and 20%
17 of IPDMA not clearly stating how many studies and participants were eligible, requested and
18 included in analysis.^{8 10 13 19} The most recent of these reviews found that reasons for unavailability of
19 IPD were reported in only 23% of a sample of 100 IPDMA.⁸

20 The culture of clinical trial data sharing has changed in recent years. Authors of published trials have
21 reported an increased willingness to share data in surveys conducted in 2011^{20 21} compared to an
22 empirical study conducted in 2009.¹⁷ The publication of data transparency strategies and policies by
23 the Institute of Medicine²² and the European Medicines Agency,²³ a proposed policy by the
24 International Committee of Medical Journal Editors²⁴ and initiatives across the wider research
25 community as a whole^{21 25-27} may go some way to improving the sharing of IPD. Indeed, the launch of
26 data sharing initiatives such as Clinical Study Data Request (CSDR),²⁸ a platform allowing researchers
27 to request IPD from nearly 3000 clinical trials of thirteen pharmaceutical sponsors, should make
28 access to IPD easier and faster. However, researchers have reported mixed experiences of using data
29 sharing portals such as CSDR suggesting that the increased safeguards may have an unintended
30 negative impact on the conduct of IPDMA.²⁹⁻³²

31 In this study we examine whether the shift in attitudes and awareness, and the increased number of
32 options available for accessing IPD is reflected by a positive impact on IPDMA. We conduct a

1 systematic review of all published IPDMA to assess whether availability of IPD has improved over
2 time, and explore characteristics associated with the retrieval of IPD. We also supplement this
3 quantitative data by reflecting upon our research group's 20 years of experience in requesting IPD to
4 undertake IPDMA in the field of epilepsy.

5 **A systematic review of IPD meta-analyses (IPDMA)**

6 The primary aim of this systematic review was to investigate whether the success rate of retrieving
7 IPD for the purpose of IPDMA has increased over time. We also wanted to explore the characteristics
8 associated with IPD retrieval.

9 **Methodology: Search strategy and screening**

10 We searched MEDLINE, Central, SCOPUS, Web of Science, CINAHL Plus and PsycINFO up to August
11 2015 using systematic search strategies adapted from the review of Riley *et al* 2010.^{9,13} We also
12 consulted the reference list of two reviews of individual participant data meta-analyses; Riley *et al*
13 2010^{9,13} (provided by review author) and of Huang *et al* 2014¹⁰ (available as an online appendix).

14 One author (SJN) performed title, abstract and full text screening of articles identified in electronic
15 searches according to Inclusion and Exclusion Criteria described below and discussed any
16 uncertainties with the senior author (CTS). We recorded principle reason for exclusion of all articles.
17 For accuracy, two authors (BD and SR) screened a random sample of between 50 and 100 identified
18 articles for eligibility; agreement between authors was good and any discrepancies were resolved by
19 discussion.

20 **Inclusion and Exclusion Criteria**

21 IPDMA of studies of all types (randomised, observational, diagnostic etc.) and all clinical areas
22 published in English were eligible for inclusion. Articles were included if IPD was requested from
23 original study investigators, if IPD was already available to review authors or if review authors were
24 able to extract IPD from published articles.

25 Methodological articles, conference abstracts, review protocols, non-clinical reviews (e.g.
26 engineering articles etc.) were excluded. Articles including the analysis of IPD from a single study as a
27 supplement to an AD meta-analysis or articles in which the primary analysis was not a synthesis (e.g.
28 prognostic model validation studies, cost-effectiveness analysis) were excluded. Where duplicate
29 publications relating to the same IPDMA were identified (e.g. identical publication across multiple
30 journals) the most recently published article was retained.

1 **Data extraction**

2 Information was extracted from eligible IPDMA using a piloted data extraction form (Appendix 1).
3 Information extracted included year of publication, authorship policy, source of funding, clinical
4 area, type of studies, type of analysis, number of eligible studies providing IPD or AD, reasons for IPD
5 not being provided and details of any sensitivity analyses performed to account for missing IPD.

6 One author (SJN) extracted information from all eligible IPDMA and three authors (BD, SR, LW)
7 independently extracted from a subset of around 40% of the IPDMA. Agreement between authors
8 was good and any discrepancies were resolved by discussion.

9 **Data analysis and presentation of results**

10 Multivariable logistic regression was performed in Stata version 14 to examine associations between
11 the following IPDMA characteristics and a high IPD retrieval rate (at least 80% compared to less than
12 80% or unknown proportion of IPD provided) or complete IPD retrieval rate (100% compared to less
13 than 100% or unknown proportion of IPD provided) (see Appendix 2 for further statistical details):

- 14 • Age of publication (calculated as years before 2016, log transformed due to skew)
- 15 • Number of participants eligible for inclusion in IPDMA (log transformed due to skew)
- 16 • Inclusion of randomised studies only in IPDMA compared to IPDMAs including non-
17 randomised studies, diagnostic test accuracy studies or a combination of randomised and
18 non-randomised studies
- 19 • IPDMA performed as a Cochrane Review compared to non-Cochrane IPDMAs
- 20 • IPDMAs with an authorship policy (individual authorship for those providing IPD or
21 collaborative group) compared to no authorship policy
- 22 • IPDMAs with a commercial source of funding (pharmaceutical or manufacturer) compared to
23 non-commercial sources of funding only, no funding or no information regarding funding
24 provided.

25 Results of multivariable regression are presented as odds ratios and 95% confidence intervals. Other
26 numerical results are presented as medians and ranges or numbers and percentages as appropriate.

27 **Patient involvement**

28 No patients were involved in setting the research question or the outcome measures, nor were they
29 involved in the design and implementation of the study. There are no plans to involve patients in the
30 dissemination of results.

1 Results

2 Characteristics of Individual Participant Data Meta-Analyses

3 We identified 1278 eligible articles describing 1280 IPDMA published to August 2015 (see Figure 1
4 for study flow diagram of our searching and screening process and Appendix 3 for reference list of
5 eligible articles). A non-systematic method of identifying studies for inclusion, such as collaboration
6 of a group of researchers with available IPD, had been used in 520 IPDMA. These analyses were
7 mostly conducted with only the IPD which was already available to the analysts; therefore IPD
8 retrieval rate is not relevant in these 520 IPDMA and we do not report any further results for this
9 subgroup of reviews.

10 For the remaining 760 systematic IPDMA the number of eligible studies was reported in 746 (98%)
11 IPDMA with a median number of eligible studies of 14 (range 2 to 923). The number of eligible
12 participants within an IPDMA was only reported in 510 (67%) systematic IPDMAs with a median of
13 2369 (range 16 to 33369) patients.

14 IPD retrieval rate

15 IPD was provided from 100% of eligible studies in only 189 (25%) and from 100% of participants in
16 only 188 (25%) out of 760 systematic IPDMA (Table 1); one IPDMA provided with IPD from 100% of
17 studies received an incomplete dataset for one study. IPD from at least 80% of studies was retrieved
18 in 375 systematic IPDMA (49%) and from 80% of participants in 324 systematic IPDMA (43%). IPD
19 was retrieved for less than 50% of studies in 136 systematic IPDMA (18%) and for less than 50% of
20 participants in 71 systematic IPDMA (9%). For 257 IPDMAs, the proportion of IPD retrieved could
21 not be calculated where the number of eligible participants and/or the number of participants
22 excluded from IPD analysis due to lack of IPD was not reported. Figure 2 shows the number of
23 IPDMAs published by year and the proportion of IPD retrieved.

24 Table 1 shows the characteristics of the 760 systematic IPDMAs overall as well as separated
25 according to IPD retrieval rate. Cochrane IPDMAs and IPDMAs with a higher number of eligible
26 participants were less likely to retrieve a high proportion or all IPD. IPDMAs of Randomised trials
27 were around 2.7 times more likely, and IPDMAs with an authorship policy were around 3.4 times
28 more likely to retrieve at least 80% of IPD. There was no association between the IPD retrieval rate
29 and source of funding or the date of publication of IPDMAs (Table 2).

30

1 Unavailability of IPD and the impact on analysis

2 Out of the 571 systematic IPDMA that failed to retrieve 100% of the IPD, 201 (34%) had
3 supplemented IPD with aggregate data (AD) extracted from study publications. The additional AD
4 had been included from a median of 5 (range 1 to 541) studies and a median of 683 (range 9 to
5 1,180,505) participants.

6 At least one study had been excluded from the meta-analysis due to lack of IPD or AD in 419 (55%)
7 systematic IPDMA. Across these, a median of 4 (range 1 to 342) studies and a median of 478 (range 8
8 to 1,792,339) participants were excluded from IPDMAs but 241 systematic IPDMA (32%) failed to
9 state how many participants were excluded from analysis.

10 Up to six reasons were reported for unavailability of IPD (Table 3); unspecific reasons, such as 'data
11 was not available for analysis' were reported in 341 out of 571 systematic IPDMA (58%). The most
12 common specific reasons for not obtaining IPD were that investigators could not be contacted,
13 investigators had declined to share data or that data had been lost or destroyed. In 24 systematic
14 IPDMA it was reported that data was not requested for all studies; mainly due to the size or quality
15 of these studies.

16 In 143 (25%) out of the 571 systematic IPDMA there was no acknowledgement of potential bias
17 resulting from missing IPD. In 199 (34%) of the systematic IPDMA additional analyses using AD had
18 been performed and in a further 66 (11%) systematic IPDMA, a narrative description of the studies
19 without IPD or a narrative comparison to an aggregate data meta-analysis had been provided. The
20 remaining 183 (31%) systematic IPDMA make reference to the missing data; some acknowledging
21 this may result in bias; without any further investigation of the implication on the conclusions of the
22 review.

23 Changes in data sharing over time in epilepsy

24 The Cochrane Epilepsy Group have been making IPD requests to the authors of anti-epileptic drug
25 (AED) monotherapy trials since the mid-1990s with eight reviews for IPDMA of pair-wise AED
26 comparisons published to date since 2000.³³⁻⁴⁰

27 It is believed that with effective AED treatment, up to 70% of individuals with active epilepsy have
28 the potential to become seizure-free and go into long-term remission shortly after starting therapy
29 with a single AED. Over fifty AEDs are available worldwide for the treatment of epileptic seizures;
30 therefore the correct choice of first-line AED for individuals with newly diagnosed epilepsy is of great

1 importance taking into account the highest quality evidence regarding the relative effectiveness and
2 tolerability of AEDs appropriate to given seizure types are compared to one another.⁴¹

3 IPD is particularly desirable for meta-analysis of AED trials to allow complete re-analysis of important
4 time-to-event outcomes such as time to withdrawal of randomised treatment due to poor seizure
5 control or adverse effects, the recommended primary outcome of AED monotherapy trials⁴² and to
6 allow investigation of interaction between treatment and epilepsy type, as well as other potential
7 prognostic factors of interest.⁴³ The group have also published an IPD network meta-analysis (NMA)
8 including participants randomised to one of eight AEDs⁴⁴ in the earlier phase of reviews. This NMA is
9 now currently being expanded and updated as a full Cochrane review of 10 AEDs.⁴¹

10 Supplementary Table 1 shows IPD retrieval rates and reasons given to us for unavailability of IPD
11 (where applicable) categorised by the year in which requests for IPD were initiated and according to
12 type of study sponsorship; pharmaceutical sponsored studies, government sponsored studies and
13 academic studies defined as studies conducted within a university or hospital setting without clear
14 pharmaceutical or government sponsorship or involvement.

15 **Early data requesting and data sharing experiences**

16 For the reviews and NMA published up to 2007,^{33 44-50} we requested IPD for a total of 5887
17 participants from 29 randomised trials and we successfully received IPD for 4703 (80%) participants
18 from 18 (62%) of these eligible trials. In addition, we had IPD available from our own 'SANAD' trial,
19^{51 52} the largest ever in epilepsy at the time, which randomised 2437 participants. Over 90% of IPD
20 requested from pharmaceutical and government sponsored studies was successfully received (data
21 provided for 3695 out of 4084 participants from 12 out of 14 studies (86%)). However, only 56% of
22 IPD (from 1008 out of 1803 participants) requested from 6 out of 15 academic sponsored studies
23 (40% of studies) could be retrieved (Supplementary Table 1).

24 We failed to retrieve IPD from a total of 11 eligible trials recruiting 1184 participants (38% of all
25 eligible trials); for the majority of these trials, data had been lost or was no longer available due to
26 the time elapsed since the trial (Supplementary Table 1).

27 We emphasise that many of the data requests were initiated at a time when IPD meta-analysis was a
28 relatively novel design and when e-mail was not commonly used. Exchanges were conducted by
29 letter, fax, telephone and via face to face meetings with trial investigators. Some datasets supplied
30 had never been computerised. Due to the informal nature of many of these requests, no data
31 sharing agreements were exchanged and very little documentation was retained regarding the time

1 to complete data requests. Therefore, we are unable to make formal numerical comparisons
2 between early and recent data requests; all comparisons are anecdotal.

3 **Recent data requesting and data sharing experiences**

4 Since our original NMA, additional AEDs have been used in clinical practice and additional clinical
5 trials have been conducted which has prompted the need to update our original NMA. A new search
6 for clinical trials was conducted⁴¹ which identified 39 further eligible trials to be included with the
7 previously received IPD. Data requesting for these eligible studies began in January 2012 and the
8 database was closed at the end of 2015 to begin analysis (see Figure 3). In total IPD for 8261
9 participants from 39 additional trials were requested. Four of the requests for pharmaceutical
10 studies were made via ClinicalStudyDataRequest.com (CSDR) (or original platform 'GSK Share'
11 between May 2013 and January 2014). All other requests were made directly to the relevant
12 sponsor.

13 For each trial meeting our inclusion criteria, a data request was sent to the first and/or
14 corresponding author of the trial or to the trial sponsor where appropriate. Requests were sent by as
15 many methods as possible (e-mail, postal mail, fax). In the event of no response to our IPD request,
16 we sent a follow-up communication to the author / sponsor previously contacted. If we still received
17 no response for a particular trial, we attempted to contact another trial author or sponsor where
18 possible.

19 At the close of the database at the end of December 2015, IPD had been received for 5335
20 participants (65% of the total requested) from 15 (38%) clinical trials (Supplementary Table 1). For
21 these trials, the median time from initial request to receiving data was similar between 24 academic
22 studies (343 days (range 154 to 861 days)) and 14 pharmaceutical studies (363 days (range 280 to
23 725 days)). The time taken to receive IPD for a single trial via CSDR was 364 days. We note that the
24 request was first submitted in June 2013 when the platform was newly initiated and processes still
25 under development so this may not reflect current timelines to providing data in CSDR.

26 We failed to retrieve IPD from 24 trials conducted between 1989 and 2012. We were provided with
27 a reason in 11 trials that had recruited 1537 participants; the median time from initial request to
28 negative response from these 11 studies was 287 days (range 1 to 784 days).

29 Reasons for negative response were (i) country specific restrictions over anonymisation of data (one
30 request submitted to CSDR for a pharmaceutical study conducted in 2005), (ii) cost of retrieving and
31 preparing data prohibitive due to age of study (two requests submitted to CSDR for pharmaceutical

1 studies conducted in 2002 and 2007), (iii) data cannot be made available, no more specific details
2 provided (three requests directly to pharmaceutical sponsors for studies conducted between 1997
3 and 2007), (iv) concerns regarding ethical approval for sharing data (one academic author, study
4 conducted 2011), (v) the data we requested were not recorded (one academic author, study
5 conducted 2005) and (vi) data were lost (three academic authors of studies conducted between
6 1992 and 2012; one of which provided additional unpublished summary data).

7 For the remaining 13 trials, two (one government and one academic) had indicated an initial positive
8 response to our data requests but data was not provided by the close of database, whilst 11 studies
9 (nine academic and two pharmaceutical) gave no response at all; these 13 data requests were closed
10 at a median of 972 (range 640 to 1448 days) after initial request (Figure 3, Supplementary Table 1).

11 Therefore at the close of database, the total number of participants data provided for network
12 meta-analysis was 10038 out of 14148 participants (71% of total eligible participants requested)
13 from 33 out of 68 studies (49% of eligible studies requested).

14 Figure 4 shows the networks of studies with and without IPD, including the IPD available to us for
15 2437 participants from two trials conducted at our institution.^{51 52} On visual inspection, there are no
16 clear differences demonstrated between the networks. Furthermore, on examination of trial and
17 participant characteristics and published results, there were no clear differences between studies
18 providing IPD and those not providing IPD. Therefore, we deduce that the 29% of data not provided
19 to us is likely to be missing 'at random' and unlikely to systematically impact on the resulting NMA.

20

1 Discussion

2 Statement of principle findings

3 To the best of our knowledge at the time of writing, our systematic review includes the largest
4 cohort of published IPDMAs to date. Recent years have shown an increase in development of
5 statistical methodology for the synthesis of IPD⁵³ as well as a rapid increase in the uptake of
6 methods, with the number of systematic and non-systematic IPD meta-analyses published per year
7 increasing to an average of 105 published per year between 2009 and 2015 compared to 49 per year
8 published between 2005 and 2009.⁹ However, these rapid increases do not seem to be mirrored by
9 improved IPD retrieval rates.

10 The first Cochrane Epilepsy Group IPDMA was published in 2000 when such an approach was
11 relatively novel and methodology limited.³³ This meta-analysis included IPD from 63% of total
12 studies and 83% of total participants, a good retrieval rate in the wider context of all IPDMAs;
13 however, of concern is that the success rate has declined from over 80% (up to 2005) to 65%
14 (between 2012 and 2015). The findings of our systematic review showed that Cochrane reviews
15 were less likely to retrieve all or a high proportion of IPD than non-Cochrane reviews. This may be
16 explained by the inclusion of thorough search methods within Cochrane reviews leading to the
17 identification of more eligible studies including more grey literature studies where IPD may be
18 difficult to retrieve with resources available to Cochrane review authors.

19 Also of concern are changes in the reported reasons for lack of data availability. Our results
20 demonstrate that loss of datasets is an issue for academic trials and has been for many years,
21 highlighting a need for better methods of data curation and solutions for long-term storage and
22 access. During our more recent requests the 'prohibitive costs' have prevented the sharing of
23 pharmaceutical data. Additional costs and resources associated with IPDMA are generally
24 considered to be incurred by the meta-analysts,⁵⁻⁷ however in this new era of commercial data
25 sharing platforms²⁸ and requirement of high level data de-identification, costs to data providers have
26 certainly increased and should be taken under consideration when planning an IPDMA.⁵⁴
27 Collaboration, financial or otherwise, between meta-analysts and data providers may assist in
28 sharing costs and resources, potentially maximising retrieval rates of IPD.

29 Despite our highlighted concerns, recent changes in methods of data sharing have resulted in several
30 benefits to our analyses. Our most common reason for not retrieving data, an issue only for
31 academic trials, was due to failing to make contact with data providers; data sharing platforms

1 provide a clear and transparent pathway of communication between data requestors and providers.
2 In addition to improvements in Good Clinical Practice over time, resulting from regulations such as
3 the European Union Clinical Trials Directive,⁵⁵ a greater focus on data privacy and additional
4 preparation required to share a dataset has resulted in 'cleaner' datasets provided to us in recent
5 requests compared to previous requests. While under the new framework of data sharing platforms,
6 additional time and resources must allow for constructing a research proposal, independent
7 scientific review, signing of data sharing agreements and de-identification of data; recent datasets
8 provided to us have required much less data cleaning prior to analysis than in previous years;
9 implying a shift in the time required to perform an IPDMA, rather than an increase.

10 **Strengths and weaknesses of the study**

11 We aimed to systematically identify all published IPD meta-analyses regardless of use of a systematic
12 design to identify studies, resulting in a large cohort of nearly 1300 IPD meta-analyses. Our inclusion
13 criteria were wide and reasons for exclusion were documented for all references identified in
14 electronic searches. We were unable to include 90 abstracts which could not be matched to full text
15 articles, despite our best efforts. Due to the size of the cohort of this study, double reference
16 screening and data extraction was performed on only a subset of the articles. Agreement was good
17 and all discrepancies were minor and easily resolved therefore we believe that any errors made in
18 screening and extraction would be minimal and unlikely to influence the overall findings of the
19 study.

20 We emphasise when interpreting the timelines of our requests between 2012 and 2015, that data
21 sharing policies and platforms were under development, and that all of the pharmaceutical sponsors
22 we contacted directly at the time of request have since committed to CSDR or an equivalent data
23 sharing platform such as YODA.⁵⁶

24 **Relation to other studies and implications**

25 Our results have shown that a quarter of systematic IPDMAs published since 1987 retrieved all IPD
26 for analysis and only half retrieved at least 80% of relevant IPD. This latter finding is higher than
27 previous results which reported that around 25% of IPD meta-analyses had included less than 80% of
28 IPD,^{8 10 13 19} however previous work has been based on smaller cohorts of IPDMAs, has mostly
29 focused on IPDMAs of RCTs only and has been conducted over smaller time frames.

30 In line with previous work,^{8 10 13 19} our results show that important inadequacies around conduct and
31 reporting of IPDMA remain. Non-systematic methods, mostly based on the known availability of IPD,

1 had been used to select eligible studies for inclusion in 41% of the initial cohort of IPD meta-analyses
2 we identified. It was outside the scope of this study to further examine the design of these analyses;
3 however, we recommend that non-systematic pooling of IPD is conducted in the framework of a
4 prospective meta-analysis⁵⁷ and that the conclusion of such analyses must be made taking the
5 inevitable selection bias into account.

6 Our results also highlight the importance of clear reporting of study and participant numbers
7 contributing to different stages of the IPD meta-analysis. The total number of eligible participants
8 and the total number of participants' data requested was unclear in 34% of published IPD meta-
9 analyses; hence it is unknown on how much of the relevant evidence the results are based and the
10 implications on the conclusions of the meta-analysis. Furthermore, in 58% of the IPDMAs that failed
11 to retrieve 100% of eligible IPD, there were no specific reasons provided for the unavailability of
12 data, making interpretation of IPDMA results and conclusions in the presence of potential
13 'availability bias' difficult. Our own experiences of data requesting show that this issue is not
14 restricted to the reporting of IPD reviews and meta-analysis and also exists at the study request
15 level; IPD from three out of 35 studies was 'not available' to us with no further reason stated (Table
16 3).

17 We hope that uptake of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
18 Analyses) guidelines for the conduct and reporting of IPD meta-analyses,⁵⁸ in addition to guidance on
19 the use of IPD meta-analysis to synthesise the results of randomised controlled trials,⁵⁹ will lead to
20 improved conduct and reporting in IPDMAs, particularly regarding transparent reporting of the
21 number of eligible studies and participants, how much data was requested and obtained with clear
22 reasons for non-availability of IPD, preferably via a flow diagram. Discussion of limitations and
23 impact on conclusions due to missing IPD is essential.

24 **Conclusions**

25 Individual participant data (IPD) meta-analyses are resource demanding, time consuming and
26 methodologically challenging but when conducted well,⁵⁹ ideally following a registered protocol⁶⁰
27 and adhering to the PRISMA-IPD guidance,⁵⁸ can provide more detailed and potentially more reliable
28 results than a meta-analysis of aggregate data. Meta-analysts must carefully consider the
29 appropriateness of an IPD analysis and demonstrate awareness of potential biases induced by
30 missing IPD. Only one in four published systematic IPD meta-analyses have had access to all IPD; we
31 hope that this proportion will grow in future years with the growing awareness of data sharing and
32 transparency in the pharmaceutical industry and beyond.^{21-23 25-27} However, the research community

1
2
3 1 must ensure that procedures to access IPD do not become over-burdensome, over-costly and
4
5 2 prohibitive, and that common sense and responsible risk proportionate approaches should be
6
7 3 used.^{22 26}
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Details of contributors: SJN, AGM and CTS conceived and designed the research question. SJN, BD, SR and LW extracted data. SJN analysed data. SJN and CTS interpreted results. SJN wrote the manuscript under the supervision of AGM and CTS.

All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

SJN acts as the guarantor of the study and affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Ethics approval: No ethics approval was required for the study

Data Sharing: Data underlying Tables and Figures is available on request from the corresponding author

Funding source: the time of SJN was funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme [Grant Reference Number RP-PG-0606-1062] and the University of Liverpool. BD, SR and LW were funded by NIHR research methods fellowships. These funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. No other source of funding was provided to the authors or the study.

Licence for publication: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to

1 third party material where-ever it may be located; and, vi) licence any third party to do
2 any or all of the above.

3 **References**

- 5 1. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine.
6 *Plast Reconstr Surg* 2011;**128**(1):305-10.
- 7 2. Lambert PC, Sutton AJ, Abrams KR, et al. A comparison of summary patient-level covariates in
8 meta-regression with individual patient data meta-analysis. *J Clin Epidemiol* 2002;**55**(1):86-
9 94.
- 10 3. Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-
11 analyses. *Bmj* 2000;**320**(7249):1574-7.
- 12 4. Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised
13 controlled trials on a cohort of systematic reviews. *Bmj* 2010;**340**:c365.
- 14 5. Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews
15 using individual patient data. *Eval Health Prof* 2002;**25**(1):76-97.
- 16 6. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated
17 individual patient data. *Stat Med* 1995;**14**(19):2057-79.
- 18 7. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a
19 difference? *Lancet* 1993;**341**(8842):418-22.
- 20 8. Simmonds M, Stewart G, Stewart L. A decade of individual participant data meta-analyses: A
21 review of current practice. *Contemp Clin Trials* 2015;**45**(Pt A):76-83.
- 22 9. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct,
23 and reporting. *BMJ* 2010;**340**:c221.
- 24 10. Huang Y, Mao C, Yuan J, et al. Distribution and epidemiological characteristics of published
25 individual patient data meta-analyses. *PLoS One* 2014;**9**(6):e100151.
- 26 11. Tierney JF, Pignon JP, Gueffier F, et al. How individual participant data meta-analyses have
27 influenced trial design, conduct, and analysis. *J Clin Epidemiol* 2015;**68**(11):1325-35.
- 28 12. Vale CL, Rydzewska LH, Rovers MM, et al. Uptake of systematic reviews and meta-analyses based
29 on individual participant data in clinical practice guidelines: descriptive study. *Bmj*
30 2015;**350**:h1088.
- 31 13. Riley RD, Simmonds MC, Look MP. Evidence synthesis combining individual patient data and
32 aggregate data: a systematic review identified current practice and possible methods. *J Clin*
33 *Epidemiol* 2007;**60**(5):431-9.
- 34 14. Ahmed I, Sutton AJ, Riley RD. Assessment of publication bias, selection bias, and unavailable data
35 in meta-analyses using individual participant data: a database survey. *Bmj* 2012;**344**:d7762.
- 36 15. Jaspers GJ, Degraeuwe PL. A failed attempt to conduct an individual patient data meta-analysis.
37 *Syst Rev* 2014;**3**:97.
- 38 16. Hrobjartsson A. Why did it take 19 months to retrieve clinical trial data from a non-profit
39 organisation? *Bmj* 2013;**347**:f6927.
- 40 17. Savage CJ, Vickers AJ. Empirical study of data sharing by authors publishing in PLoS journals. *PLoS*
41 *One* 2009;**4**(9):e7078.
- 42 18. Vickers AJ. Whose data set is it anyway? Sharing raw data from randomized trials. *Trials*
43 2006;**7**:15.
- 44 19. Simmonds MC, Higgins JP, Stewart LA, et al. Meta-analysis of individual patient data from
45 randomized trials: a review of methods used in practice. *Clin Trials* 2005;**2**(3):209-17.
- 46 20. Rathi VK, Strait KM, Gross CP, et al. Predictors of clinical trial data sharing: exploratory analysis of
47 a cross-sectional survey. *Trials* 2014;**15**:384.

- 1 21. Rathi V, Dzara K, Gross CP, et al. Sharing of clinical trial data among trialists: a cross sectional
2 survey. *Bmj* 2012;**345**:e7570.
- 3 22. Institute of Medicine (IOM) Committee on Strategies for Responsible Sharing of Clinical Trial
4 Data. *Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk*, 2015.
- 5 23. European Medicines Agency. European Medicines Agency policy on publication of clinical data
6 for medicinal products for human use (POLICY/0070), 2014.
- 7 24. Taichman DB, Backus J, Baethge C, et al. Sharing Clinical Trial Data--A Proposal from the
8 International Committee of Medical Journal Editors. *N Engl J Med* 2016;**374**(4):384-6.
- 9 25. Zarin DA. Participant-level data and the new frontier in trial transparency. *N Engl J Med*
10 2013;**369**(5):468-9.
- 11 26. Tudur Smith C, Hopkins C, Sydes MR, et al. How should individual participant data (IPD) from
12 publicly funded clinical trials be shared? *BMC Med* 2015;**13**:298.
- 13 27. Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. *N Engl J*
14 *Med* 2013;**369**(5):475-8.
- 15 28. Clinical Study Data Request. <https://clinicalstudydatarequest.com/> (Accessed 20/04/2016).
- 16 29. Geifman N, Bollyky J, Bhattacharya S, et al. Opening clinical trial data: are the voluntary data-
17 sharing portals enough? *BMC Med* 2015;**13**:280.
- 18 30. Strom BL, Buyse M, Hughes J, et al. Data sharing, year 1--access to data from industry-sponsored
19 clinical trials. *N Engl J Med* 2014;**371**(22):2052-4.
- 20 31. Homer P, Gross M. Data Unleashed: Cooperation Among Competitors. *Pharmaceutical Executive*,
21 2016.
- 22 32. Mayo-Wilson E, Doshi P, Dickersin K. Are manufacturers sharing data as promised? *BMJ*
23 2015;**351**.
- 24 33. Marson AG, Williamson PR, Hutton JL, et al. Carbamazepine versus valproate monotherapy for
25 epilepsy. *Cochrane Database Syst Rev* 2000(3):CD001030.
- 26 34. Nolan SJ, Sudell M, Tudur Smith C, et al. Topiramate versus carbamazepine monotherapy for
27 epilepsy: an individual participant data review. *Cochrane Database Syst Rev*
28 2016(11):CD012065.
- 29 35. Nolan SJ, Marson AG, Weston J, et al. Phenytoin versus valproate monotherapy for partial onset
30 seizures and generalised onset tonic-clonic seizures: an individual participant data review.
31 *Cochrane Database Syst Rev* 2016;**4**:Cd001769.
- 32 36. Nolan SJ, Tudur Smith C, Pulman J, et al. Phenobarbitone versus phenytoin monotherapy for
33 partial onset seizures and generalised onset tonic-clonic seizures. *Cochrane Database Syst*
34 *Rev* 2013;**1**:CD002217.
- 35 37. Nolan SJ, Muller M, Tudur Smith C, et al. Oxcarbazepine versus phenytoin monotherapy for
36 epilepsy. *Cochrane Database Syst Rev* 2013;**5**:CD003615.
- 37 38. Nolan S. J., Tudur Smith C., Weston J., et al. Lamotrigine versus carbamazepine monotherapy for
38 epilepsy. *Cochrane Database Syst Rev* 2016(11):CD001031.
- 39 39. Nolan SJ, Marson AG, Weston J, et al. Carbamazepine versus phenytoin monotherapy for
40 epilepsy: an individual participant data review. *Cochrane Database Syst Rev*
41 2015;**8**:CD001911.
- 42 40. Nolan SJ, Marson AG, Weston J, et al. Carbamazepine versus phenobarbitone monotherapy for
43 epilepsy: an individual participant data review. *Cochrane Database Syst Rev*
44 2015;**7**:CD001904.
- 45 41. Nolan SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network
46 meta-analysis. *Cochrane Database Syst Rev* 2014(12):CD011412.
- 47 42. International League Against Epilepsy. Considerations on designing clinical trials to evaluate the
48 place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients
49 with epilepsy. *Epilepsia* 1998;**39**(7):799-803.
- 50 43. Williamson PR, Marson AG, Tudur C, et al. Individual patient data meta-analysis of randomized
51 anti-epileptic drug monotherapy trials. *J Eval Clin Pract* 2000;**6**(2):205-14.

- 1
2
3 1 44. Tudur Smith C, Marson AG, Chadwick DW, et al. Multiple treatment comparisons in epilepsy
4 2 monotherapy trials. *Trials* 2007;**8**:34.
5 3 45. Tudur Smith C, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy
6 4 for epilepsy. [Review] [21 refs]. *Cochrane Database of Systematic Reviews*
7 5 2003(1):CD001904.
8 6 46. Tudur Smith C, Marson AG, Clough HE, et al. Carbamazepine versus phenytoin monotherapy for
9 7 epilepsy. [Review] [47 refs]. *Cochrane Database of Systematic Reviews* 2002(2):CD001911.
10 8 47. Tudur Smith C, Marson AG, Williamson PR. Phenytoin versus valproate monotherapy for partial
11 9 onset seizures and generalized onset tonic-clonic seizures. [Review] [40 refs]. *Cochrane*
12 10 *Database of Systematic Reviews* 2001(4):CD001769.
13 11 48. Taylor S, Tudur Smith C, Williamson PR, et al. Phenobarbitone versus phenytoin monotherapy for
14 12 partial onset seizures and generalized onset tonic-clonic seizures. [Review] [16 refs].
15 13 *Cochrane Database of Systematic Reviews* 2001(4):CD002217.
16 14 49. Muller M, Marson AG, Williamson PR. Oxcarbazepine versus phenytoin monotherapy for
17 15 epilepsy. [Review] [20 refs]. *Cochrane Database of Systematic Reviews* 2006(2):CD003615-
18 16 50. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for
19 17 epilepsy. *Cochrane Database Syst Rev* 2006(1):CD001031.
20 18 51. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of
21 19 carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of
22 20 partial epilepsy: an unblinded randomised controlled trial. *The Lancet* 2007;**369**(9566):1000-
23 21 15.
24 22 52. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate,
25 23 lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded
26 24 randomised controlled trial. *The Lancet* 2007;**369**(9566):1016-26.
27 25 53. Debray TP, Moons KG, van Valkenhoef G, et al. Get real in individual participant data (IPD) meta-
28 26 analysis: a review of the methodology. *Res Synth Methods* 2015;**6**(4):293-309.
29 27 54. Tudur Smith C, Nolan S, Appelbe D, et al. Resource implications of preparing Individual
30 28 Participant Data from a clinical trial to share with external researchers (submitted).
31 29 55. European Union Clinical Trials Directive. Directive 2001/20/EC of the European Parliament and of
32 30 the Council of 4 April 2001 on the approximation of the laws, regulations and administrative
33 31 provisions of the Member States relating to the implementation of good clinical practice in
34 32 the conduct of clinical trials on medicinal products for human use, 2001.
35 33 56. YODA: the Yale School of Medicine's Open Data Access (YODA) Project. Secondary YODA: the
36 34 Yale School of Medicine's Open Data Access (YODA) Project. <http://yoda.yale.edu/>.
37 35 57. Zanchetti A, Mancia G. Searching for information from unreported trials--amnesty for the past
38 36 and prospective meta-analyses for the future. *J Hypertens* 1998;**16**(2):125.
39 37 58. Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic Review and
40 38 Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *Jama*
41 39 2015;**313**(16):1657-65.
42 40 59. Tierney JF, Vale C, Riley R, et al. Individual Participant Data (IPD) Meta-analyses of Randomised
43 41 Controlled Trials: Guidance on Their Use. *PLoS Med* 2015;**12**(7):e1001855.
44 42 60. Booth A, Clarke M, Dooley G, et al. The nuts and bolts of PROSPERO: an international prospective
45 43 register of systematic reviews. *Syst Rev* 2012;**1**:2.
46
47
48
49
50 44
51
52
53
54
55
56
57
58
59
60

IPDMA Characteristic	All Systematic IPDMA (N)	IPDMA retrieving 100% of IPD (n and % of N)	IPDMA retrieving ≥80% of IPD (n and % of N)	IPDMA retrieving <80% or unknown proportion of IPD ¹ (n and % of N)
Total	760	188 (25%)	324 (43%)	436 (57%)
Clinical area of meta-analysis				
Breast Cancer	40	8 (20%)	22 (55%)	18 (45%)
Cancer (other)	53	14 (26%)	27 (51%)	26 (49%)
Cardiology	105	30 (29%)	53 (51%)	52 (49%)
Central Nervous System, Neurology and Brain Injury	50	13 (26%)	20 (40%)	30 (60%)
Cervical Cancer and Ovarian Cancer	16	1 (6%)	7 (44%)	9 (56%)
Gastroenterology, Colorectal and Gastric Cancer	49	11 (22%)	17 (35%)	32 (65%)
Diabetes and Endocrinology	30	8 (27%)	13 (43%)	17 (57%)
Gynaecology, Pregnancy and Neonatology	35	13 (37%)	18 (51%)	17 (49%)
Head and Neck Cancer	16	4 (25%)	8 (50%)	8 (50%)
Hepatitis and Liver Disease	19	7 (37%)	8 (42%)	11 (58%)
HIV	17	6 (35%)	8 (47%)	9 (53%)
Infection and Infectious Diseases	31	6 (19%)	9 (29%)	22 (71%)
Injuries and Wounds	21	2 (10%)	4 (19%)	17 (81%)
Haematology, Leukaemia and Blood Cancer	43	11 (26%)	20 (47%)	23 (53%)
Lung Cancer	32	9 (28%)	15 (47%)	17 (53%)
Mental and Psychiatric Disorders	32	7 (22%)	12 (38%)	20 (62%)
Musculoskeletal and Pain	34	9 (26%)	11 (32%)	23 (68%)
Otolaryngology, Ophthalmology and Periodontology	22	3 (14%)	5 (23%)	17 (67%)
Other ²	26	5 (19%)	9 (34%)	15 (66%)
Renal and Urology	17	3 (18%)	6 (35%)	11 (65%)
Respiratory and Pulmonary	21	7 (33%)	11 (52%)	10 (48%)

Stroke, Thrombosis and Hypertension	51	12 (24%)	21 (41%)	30 (59%)
Design of included studies				
Randomised	405	117 (29%)	222 (55%)	183 (45%)
Non-Randomised	253	58 (23%)	81 (32%)	172 (68%)
Diagnostic Test Accuracy	34	5 (15%)	9 (26%)	25 (74%)
Both Randomised and Non-Randomised	68	8 (12%)	12 (18%)	56 (82%)
Type of included studies				
Diagnostic Test Accuracy	34	5 (15%)	9 (26%)	25 (74%)
Drug or device	348	102 (29%)	183 (53%)	165 (47%)
Epidemiological	185	38 (21%)	58 (31%)	127 (69%)
Non-drug (interventional)	193	43 (22%)	74 (38%)	119 (62%)
Type of IPDMA				
Cochrane Review	64	10 (16%)	25 (39%)	39 (61%)
Non Cochrane Review	696	178 (26%)	299 (43%)	397 (57%)
Authorship Policy				
Individual authorship	243	84 (35%)	116 (48%)	127 (52%)
Collaborative Group	264	40 (15%)	119 (45%)	145 (55%)
None ³	253	64 (25%)	89 (35%)	164 (65%)
Source of Funding				
Non-commercial ⁴	383	70 (18%)	155 (40%)	228 (60%)
Commercial ⁵	72	26 (36%)	37 (51%)	35 (49%)
Mixed ⁶	35	8 (23%)	20 (57%)	15 (43%)
No funding	77	25 (32%)	34 (44%)	43 (56%)
Not stated	193	59 (31%)	78 (40%)	115 (60%)
Number of eligible studies				
2 to 5	102	72 (71%)	83 (81%)	19 (19%)
6 to 10	174	67 (39%)	98 (56%)	76 (44%)
11 to 15	120	16 (13%)	47 (39%)	73 (61%)
16 to 20	87	12 (14%)	29 (33%)	58 (67%)
21 to 30	101	6 (6%)	30 (30%)	71 (70%)
31 to 40	50	3 (6%)	11 (22%)	39 (78%)
41 to 50	29	2 (7%)	5 (17%)	24 (83%)
over 50	83	10 (12%)	19 (23%)	64 (77%)
Not stated	14	0 (0%)	2 (14%)	12 (86%)
Number of eligible participants				
under 100	18	14 (78%)	16 (94%)	1 (6%)
101 to 200	20	13 (65%)	16 (80%)	4 (20%)

201 to 500	45	21 (47%)	25 (56%)	20 (44%)
501 to 1000	67	35 (52%)	45 (67%)	22 (33%)
1001 to 5000	198	70 (35%)	134 (68%)	64 (32%)
5001 to 10000	62	13 (21%)	37 (60%)	25 (40%)
10001 to 50000	100	22 (22%)	53 (53%)	47 (47%)
Not stated	250	0 (0%)	0 (0%)	250 (100%)

Table 1: Characteristics of all systematic IPD meta-analyses (IPDMA) according to proportion of IPD provided

1. Including 257 IPDMA where the proportion of IPD provided was unknown where the number of eligible participants and/or the number of participants excluded from IPD analysis due to lack of IPD was not reported.
2. Other defined as lifestyle, nutrition, emergency medicine, patient care, patient preference, Pharmacokinetics and Forensics
3. Including 83 IPDMA where IPD was extracted from published study reports (IPD not requested from original study authors)
4. Non-commercial sources included institutional, government, charity, research council or research foundation funding.
5. Commercial sources were defined as pharmaceutical or manufacturer funding.
6. Multiple commercial and non-commercial sources.

IPD MA Characteristic ¹	100% of IPD retrieved compared to less than 100% of IPD			At least 80% of IPD retrieved compared to less than 80% of IPD		
	Odds Ratio	95% Confidence Interval	P value	Odds Ratio	95% Confidence Interval	P value
Age of publication ²	1.081	0.885 to 1.320	0.445	1.153	0.938 to 1.418	0.177
Number of eligible participants ²	0.851	0.800 to 0.904	<0.001	0.889	0.837 to 0.943	<0.001
Includes randomised studies only	1.415	0.919 to 2.182	0.115	2.735	1.755 to 4.262	<0.001
Cochrane IPD-MA	0.402	0.189 to 0.859	0.019	0.427	0.218 to 0.835	0.013
Authorship Policy	1.667	1.074 to 2.585	0.022	3.366	2.183 to 5.190	<0.001
Commercial source of funding	1.291	0.762 to 2.187	0.341	1.043	0.568 to 1.914	0.892

Table 2: Multivariable logistic regression models: Characteristics associated with retrieving 100% of IPD or receiving more than 80% of IPD in 503 IPDMAs

1. See Appendix 2 for statistical details and definitions of characteristics
2. Log transformation applied due to skewed distribution of data

Reasons reported for not retrieving 100% of eligible IPD	Number of IPDMA ^{1,2,3}
Data not available ²	341 (60%)
No contact could be made with study authors	104 (18%)
Investigators declined but no reason given	74 (13%)
Data lost or destroyed	65 (11%)
Data could not be extracted ³	55 (10%)
Trial was still ongoing	42 (7%)
Data quality issues	29 (5%)
Failed to provide data in time for the IPDMA	26 (5%)
Data not requested	24 (4%)
Ethical / ownership restrictions	15 (3%)
Reason unclear	11 (2%)
Approach reported to account for missing IPD	Number of IPDMA ^{1,2,3}
None stated	143 (25%)
Separate meta-analyses are conducted including IPD only and IPD plus available AD	81 (14%)
Stated that missing IPD is a limitation of the meta-analysis and / or that availability bias may be present	76 (13%)
AD included in primary analysis	61 (11%)
Sensitivity analysis with AD performed	57 (10%)
Stated that the missing IPD is unlikely to change results	56 (10%)
Results from the studies without IPD summarised narratively	48 (8%)
Stated that the majority of data is included in analysis	47 (8%)
Narrative comparison to an AD meta-analysis	18 (3%)
Intend to include data in an update	14 (2%)

Table 3: Reasons reported for unavailability of IPD and approach to accounting for missing IPD in 571 systematic IPD meta-analyses (IPDMA) without 100% of IPD retrieved

IPD – individual participant data, AD – aggregate data, NA –not applicable

- 189 IPDMA with 100% of IPD provided not included in the table.
- IPDMAs reported up to six reasons for unavailability of IPD or described up to three approaches to account for missing IPD. Therefore total number of reasons / approaches is greater than 571.
- Corresponds to the proportion of 571 IPDMAs; total percentages sum to greater than 100 as multiple reasons / approaches could be reported for an IPDMA.
- The reason “data not available” corresponds to a statement in the review that IPD was not available for a proportion of studies without any specific reason given.
- Reason applicable only in a small number of IPDMAs where IPD were extracted from publications rather than requested.

Figure titles and footnotes

Figure 1: Study Flow Diagram of identification of eligible Individual Participant Data Meta Analyses (IPDMA)

* two full text articles each reported two individual participant data meta-analyses

Figure 2: Number of distinct systematic individual participant data meta-analyses published to August 2015.

1. See Table 1 for proportion of systematic IPD meta-analyses providing 100%, 80-99% and less than 80% of IPD.
2. Six IPDMA were published from 1987 to 1993; three were provided with less than 80% of IPD and three were provided with 80 – 99% of IPD

Figure 3: Duration and outcome of data requests for 39 randomised controlled trials of anti-epileptic drugs

Figure 4: Plots of studies providing IPD and not providing IPD for a network meta-analysis of 10 anti-epileptic drugs (See Supplementary Table 1 for numbers of studies and participants providing and not providing IPD).

Abbreviations: Carbamazepine (CBZ), Phenobarbitone (PB), Oxcarbazepine (OXC), Phenytoin (PHT), Valproate (VPA), Lamotrigine (LTG), Gabapentin (GBP), Topiramate (TPM), Levetiracetam (LEV), Zonisamide (ZNS)




Figure 1: Study Flow Diagram of identification of eligible Individual Participant Data Meta Analyses (IPDMA)
* two full text articles each reported two individual participant data meta-analyses

Figure 1
232x301mm (72 x 72 DPI)






Figure 2: Number of distinct systematic individual participant data meta-analyses published to August 2015.
 1. See Table 1 for proportion of systematic IPD meta-analyses providing 100%, 80-99% and less than 80% of IPD.
 2. Six IPDMA were published from 1987 to 1993; three were provided with less than 80% of IPD and three were provided with 80 – 99% of IPD

Figure 2
 455x294mm (72 x 72 DPI)

Review Only




Figure 3: Duration and outcome of data requests for 39 randomised controlled trials of anti-epileptic drugs

Figure 3
 368x307mm (72 x 72 DPI)

Review Only




Figure 4: Plots of studies providing IPD and not providing IPD for a network meta-analysis of 10 anti-epileptic drugs (See Supplementary Table 1 for numbers of studies and participants providing and not providing IPD).

Abbreviations: Carbamazepine (CBZ), Phenobarbitone (PB), Oxcarbazepine (OXC) , Phenytoin (PHT), Valproate (VPA), Lamotrigine (LTG), Gabapentin (GBP), Topiramate (TPM), Levetiracetam (LEV), Zonisamide (ZNS)

Figure 4
442x139mm (72 x 72 DPI)

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Number of studies and participants requested ¹	Original requests (approx. 1995 – 2005) by type of study				New requests (2012-2015) by type of study				All requests (approx. 1995-2015) by type of study			
	Ac	Go	Ph	Total	Ac	Go	Ph	Total	Ac	Go	Ph	Total
Eligible studies	15	4	10	29	24	1	14	39	39	5	24	68
Studies providing IPD (n (%))	6 (40%)	3 (75%)	9 (90%)	18 (62%)	7 (29%)	0 (0%)	8 (57%)	15 (38%)	13 (33%)	3 (60%)	17 (71%)	33 (49%)
Eligible participants	1803	1178	2906	5887	1897	593	5771	8261	3700	1771	8677	14148
Participants IPD is provided for (n (%))	1008 (56%)	1091 (93%)	2604 (90%)	4703 (80%)	801 (42%)	0 (0%)	4534 (79%)	5335 (65%)	1809 (49%)	1091 (62%)	7138 (82%)	10038 (71%)
Reason data was not available: Number of studies (n (%))												
Data lost	5 (33%)	1 (25%)	0 (0%)	6 (21%)	3 (13%)	0 (0%)	0 (0%)	3 (8%)	8 (21%)	1 (20%)	0 (0%)	9 (13%)
Relevant data not recorded	2 (13%)	0 (0%)	0 (0%)	2 (7%)	1 (4%)	0 (0%)	0 (0%)	1 (3%)	3 (8%)	0 (0%)	0 (0%)	3 (4%)
Unable to make contact with an author / sponsor	1 (7%)	0 (0%)	0 (0%)	1 (3%)	11 (46%)	0 (0%)	0 (0%)	11 (28%)	12 (31%)	0 (0%)	0 (0%)	12 (18%)
Positive response but no data received	1 (7%)	0 (0%)	0 (0%)	1 (3%)	1 (4%)	1 (100%)	0 (0%)	2 (5%)	2 (5%)	1 (20%)	0 (0%)	3 (4%)
Incomplete dataset provided which could not be used	0 (0%)	0 (0%)	1 (10%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	1 (1%)
Local authority / ethical restrictions	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4%)	0 (0%)	0 (0%)	1 (3%)	1 (3%)	0 (0%)	0 (0%)	1 (1%)
“Data not available” ²	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (21%)	3 (8%)	0 (0%)	0 (0%)	3 (13%)	3 (4%)
Costs of providing data are prohibitive	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (14%)	2 (5%)	0 (0%)	0 (0%)	2 (8%)	2 (3%)
Country specific restrictions	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (7%)	1 (3%)	0 (0%)	0 (0%)	1 (4%)	1 (1%)
Total	9 (60%)	1 (25%)	1 (10%)	11 (38%)	17 (61%)	1 (100%)	6 (43%)	24 (62%)	26 (67%)	2 (40%)	7 (29%)	35 (51%)

Supplementary Table 1: Outcome of individual participant data requests conducted between approx. 1995 to 2005 and 2012 to 2015.

Abbreviations: Ac: Academic studies, Go: Government Studies, Ph: Pharmaceutical Studies

Footnotes

1. In addition, we had IPD available from our own ‘SANAD’ trial,^{50 51} the largest ever in epilepsy at the time, which randomised 2437 participants
2. Refers to a non-specific reason (data not available for secondary analysis with no further reason provided).

1
2
3 **Individual Participant Data Meta-Analyses: Data Extraction Form**
4
5
6

7 **Date of Extraction:**

8
9 **Name of data extractor:**

10
11 **Meta-analysis First Author:**

12
13 **Meta-analysis Year:**

14
15 **Meta-analysis Title:**

16
17 **Journal or Source:**

18
19 **Authorship policy (individual authorship, collaborative group, none):**

20
21 **Source of funding:**

22
23 **Clinical area (lung cancer, breast cancer, epilepsy, diabetes etc.):**

24
25 **Design of studies included (Randomised / Non-randomised/ both / Other (diagnostic test
26 accuracy etc.):**

27
28 **Type of studies included (Drug / Device / Observational / Other (diagnostic test accuracy
29 etc.):**

30
31 **Type of pooled analysis: Systematic search performed or existing database of studies
32 pooled/ collaboration?**

33
34 **Number of studies eligible for meta-analysis:**

35
36 **Number of participants in all eligible studies:**

37
38 **Year range of eligible studies:**

39
40 **Number of studies providing IPD:**

41
42 **Number of participants IPD is provided for:**

43
44 **Number of studies providing aggregate data (AD):**

45
46 **Number of participants AD is provided for:**

1
2
3 **Number of studies excluded due to no IPD or AD available:**
4

5 **Number of patients excluded due to no IPD or AD available:**
6

7
8 **Year range of studies IPD is not available for:**
9

10
11 **Any reported reasons that IPD was not provided (data no longer available, authors**
12 **unwilling to collaborate)?**
13

14
15
16
17
18 **Were any adjustments/ sensitivity analyses performed to account for missing IPD? Or do**
19 **meta-analysis authors note the limitation of missing IPD?**
20

21
22
23 **Additional notes:**
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Footnotes:**

- 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Reasons for IPD not being provided and sensitivity analyses recorded as free text and later classified into broad categories.
 2. Source of funding recorded as free text and later classified as Commercial, Non-Commercial, Mixed (Commercial and Non-Commercial), No funding, Not stated.
 3. Clinical area was also recorded as free text and later classified in broad categories based on the clinical areas covered by the review groups of the Cochrane Collaboration

Appendix 2: Statistical Analysis

1. Characteristics associated with a high success rate of IPD retrieval

Proportion of IPD retrieved (dependent variable of interest) was highly skewed, despite attempts at transformation, as few IPDMAs retrieved a very small proportion of data. It was therefore deemed most appropriate to dichotomise this variable to:

a) Complete IPD retrieval rate (100% compared to less than 100% or unknown proportion of IPD provided)

b) High IPD retrieval rate (at least 80% compared to less than 80% or unknown proportion of IPD provided)

Multivariable logistic regression was performed to examine associations between individual participant data meta-analyses (IPDMA) characteristics and a high or complete retrieval rate of IPD.

A total of 503 IPDMAs were included in this analysis for which we could calculate the proportion of IPD retrieved (i.e. the number of participant eligible for analysis and the number of participants data was provided for was reported).

The following variables were included in the model and results for all variables included in the model are presented regardless of statistical significance; no model selection techniques were used:

- Age of publication (calculated as years before 2016, log transformed due to skew)
- Number of participants eligible for inclusion in IPDMA (log transformed due to skew)
- Inclusion of randomised studies only in IPDMA compared to IPDMAs including non-randomised studies, diagnostic test accuracy studies or a combination of randomised and non-randomised studies
- IPDMA performed as a Cochrane Review compared to non-Cochrane IPDMAs
- IPDMAs with an authorship policy (individual authorship or collaborative group) compared to no authorship policy
- IPDMAs with a commercial source of funding (pharmaceutical or manufacturer) compared to non-commercial sources of funding only, no funding or no information regarding funding provided.

Sensitivity analyses (Results of the primary analysis presented in Table 2)

1. Type of study (drug or device (interventional), non-drug (interventional), diagnostic test accuracy or epidemiological study) was not included in the model due to correlation between this variable and type of study (interventional studies were significantly more likely to be randomised, chi-squared $p < 0.001$) and source of funding (drug or device studies were significantly more likely to be commercially funded, chi-squared $p < 0.001$).

Sensitivity analysis was conducted adding an additional variable to this model of IPDMAs of drug or device studies compared to non-drug or device interventions, diagnostic test accuracy studies or epidemiological studies added to the model. Results showed that this

characteristic was not statistically significant, other numerical results were similar and conclusions were unchanged (results available on request from corresponding author).

2. A sensitivity analysis was conducted excluding 128 IPD-MAs with no information regarding funding. Numerical results were similar and conclusions were unchanged (results available on request from corresponding author).
3. A sensitivity analysis was conducted including all 760 IPDMAs, assuming the following scenarios for the 257 IPDMAs for which the proportion of IPD retrieved could not be calculated:
 - a. Less than 80% of IPD was retrieved
 - b. 80% or more IPD was retrieved
 - c. 100% of IPD was retrieved

The multivariable regression was run under each scenario including the above variables except for number of eligible participants (not available for the 257 additional IPDMAs).

- a) Assuming less than 80% of IPD was retrieved for 257 IPDMAs where proportion of IPD retrieved could not be calculated

IPD MA Characteristic	100% of IPD retrieved compared to less than 100% of IPD			At least 80% of IPD retrieved compared to less than 80% of IPD		
	Odds Ratio	95% Confidence Interval	P value	Odds Ratio	95% Confidence Interval	P value
Age of publication (log scale)	0.641	0.554 to 0.739	<0.001	0.713	0.624 to 0.816	<0.001
Includes randomised studies only	1.667	1.160 to 2.393	0.006	2.906	2.076 to 4.067	<0.001
Cochrane IPD-MA	0.334	0.161 to 0.701	0.004	0.489	0.278 to 0.861	0.013
Authorship Policy	0.505	0.372 to 0.685	<0.001	0.842	0.635 to 1.115	0.230
Commercial source of funding	1.102	0.687 to 1.767	0.687	0.994	0.642 to 1.541	0.980

- b) Assuming 80% or more of IPD was retrieved for 257 IPDMAs where proportion of IPD retrieved could not be calculated

IPD MA Characteristic	100% of IPD retrieved compared to less than 100% of IPD			At least 80% of IPD retrieved compared to less than 80% of IPD		
	Odds Ratio	95% Confidence Interval	P value	Odds Ratio	95% Confidence Interval	P value
Age of publication (log scale)	0.641	0.554 to 0.739	<0.001	1.206	1.046 to 1.392	0.010
Includes randomised studies only	1.667	1.160 to 2.393	0.006	1.479	0.999 to 2.190	0.051
Cochrane IPD-MA	0.334	0.161 to 0.701	0.004	0.428	0.233 to 0.784	0.006
Authorship Policy	0.505	0.372 to 0.685	<0.001	3.222	2.340 to 4.439	<0.001
Commercial source of funding	1.102	0.687 to 1.767	0.687	1.002	0.577 to 1.743	0.993

- c) Assuming 100% of IPD was retrieved for 257 IPDMAs where proportion of IPD retrieved could not be calculated

IPD MA Characteristic	100% of IPD retrieved compared to less than 100% of IPD			At least 80% of IPD retrieved compared to less than 80% of IPD		
	Odds Ratio	95% Confidence Interval	P value	Odds Ratio	95% Confidence Interval	P value
Age of publication (log scale)	1.109	0.975 to 1.392	0.114	1.206	1.046 to 1.392	0.010
Includes randomised studies only	0.682	0.492 to 0.947	0.022	1.479	0.999 to 2.190	0.051
Cochrane IPD-MA	0.477	0.269 to 0.846	0.011	0.428	0.233 to 0.784	0.006
Authorship Policy	1.762	1.331 to 2.332	<0.001	3.222	2.340 to 4.439	<0.001
Commercial source of funding	1.092	0.704 to 1.693	0.993	1.002	0.577 to 1.743	0.993

Results of these sensitivity analyses are varied compared to those reported in Table 2 – for example scenario a) and scenario b) contradict Table 2 and suggest that use of an authorship policy is negatively associated with a high or complete retrieval rate of IPD. These sensitivity analyses highlight the importance of a clear statement of the proportion of IPD retrieved in IPDMA.

4. Multivariable logistic regression was also performed to examine associations between the IPDMA characteristics defined above and the proportion of study data retrieved.

A total of 744 IPDMAs were included in this analysis for which we could calculate the proportion of study data retrieved (i.e. the number of studies eligible for analysis and the number of studies data was provided for was reported).

IPD MA Characteristic	100% of study data retrieved compared to less than 100% of study data			At least 80% of study data retrieved compared to less than 80% of study data		
	Odds Ratio	95% Confidence Interval	P value	Odds Ratio	95% Confidence Interval	P value
Age of publication (log scale)	1.172	0.961 to 1.431	0.116	1.235	1.050 to 1.454	0.011
Number of eligible studies (log scale)	0.498	0.428 to 0.576	<0.001	0.681	0.610 to 0.759	<0.001
Includes randomised studies only	1.555	1.050 to 2.304	0.028	1.301	0.936 to 1.807	0.117
Cochrane IPD-MA	0.441	0.207 to 0.937	0.033	0.664	0.373 to 1.181	0.163
Authorship Policy	1.078	0.739 to 1.573	0.695	1.851	1.355 to 2.529	<0.001
Commercial source of funding	1.339	0.819 to 2.187	0.244	1.227	0.781 to 1.927	0.375

Results of this sensitivity analysis are mostly similar to those reported in Table 2, however these results suggest that older publications may be more likely to retrieve a high proportion (at least 80%) of study data; suggesting that IPD retrieval rate on a study level has got worse over time.

2. Non-linear modelling of publication rates of IPDMA

From previous work conducted by Riley *et al*,¹ it was hypothesised that the number of IPDMAs published each year would be non-linear. This hypothesis was confirmed by visual inspection of Figure 2. Exponential (asymptotic), Logistic and Gompertz non-linear regression models built into the 'nl' command of Stata Version 14 were investigated to model the relationship. Modelling of this relationship was intended only for illustrative purposes, therefore development of user written non-linear models was deemed to be out of the scope of this analysis.

Model Type	Algebraic Model	Adjusted R ²	Residual Deviance
Linear	$y_i = b_0 + b_1 x_i$	0.839	192.95
Exponential (2 parameter)	$y_i = b_1 (b_2)^{x_i}$	0.964	174.80
Exponential (3 parameter)	$y_i = b_0 + b_1 (b_2)^{x_i}$	0.837	193.28
Logistic (4 parameter)	$y_i = b_0 + b_1 / (1 + e^{-b_2(x_i - b_3)})$	0.924	171.01
Logistic (3 parameter)	$y_i = b_1 / (1 + e^{-b_2(x_i - b_3)})$	0.968	171.06
Gompertz (4 parameter)	$y_i = b_0 + b_1 e^{-e^{-b_2(x_i - b_3)}}$	0.922	171.88
Gompertz (3 parameter)	$y_i = b_1 e^{-e^{-b_2(x_i - b_3)}}$	0.966	171.89

Where $i = 1$ to 26 corresponding to the number of years between 1987 and 2015 that at least one IPDMA was published

y_i = Number of systematic IPD meta-analyses

x_i = Years since first published IPD meta-analysis in 1987

According to Adjusted R² and Residual Deviance, it was deemed that the three parameter logistic model was the best fit to the publication rate of IPDMAs:

$$y_i = 142.69 / (1 + e^{-0.1652(x_i - 26.24)})$$

1. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010;**340**:c221.

1. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. *Advanced Ovarian Cancer Trialists' Group. Br J Cancer* 1998;**78**(11):1479-87.
2. Abdulla J, Pogue J, Abildstrom SZ, et al. Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction--a meta-analysis. *Eur J Heart Fail* 2006;**8**(1):90-6.
3. Abe R, Enomoto K, Koyama H, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. *Lancet* 2005;**366**(9503):2087-106.
4. Abrishamchian R, Kanhai D, Zwets E, et al. Low birth weight or diagnosis, which is a higher risk? - a meta-analysis of observational studies. *Eur J Cardiothorac Surg* 2006;**30**(5):700-05.
5. ACE Inhibitors in Diabetic Nephropathy Trialist G. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.[see comment]. *Ann Intern Med* 2001;**134**(5):370-9.
6. Achan J, Adam I, Arinaitwe E, et al. The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data. *PLoS Med* 2013;**10**(12):Article number e1001564.
7. Adachi JD, Rizzoli R, Boonen S, et al. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: A meta-analysis of individual patient data. *Aging Clin Exp Res* 2005;**17**(2):150-56.
8. Adachi JD, Roux C, Pitt PI, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. *J Rheumatol* 2000;**27**(10):2424-31.
9. Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis.[see comment]. *Lancet* 2004;**363**(9402):9-17.
10. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). [Review] [25 refs]. *Cochrane Database Syst Rev* 2006(2):CD006018-.
11. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. *Lancet* 2003;**361**(9373):1927-34.
12. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant cisplatin for advanced bladder cancer. *Cochrane Database Syst Rev* 2000:Issue 2.
13. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. *J Clin Oncol* 1992;**10**(6):896-903.
14. Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. *Cochrane Database Syst Rev* 2000(2):CD001418.
15. Ahlbom A, Day N, Feychting M, et al. A pooled analysis of magnetic fields and childhood leukaemia. *Br J Cancer* 2000;**83**(5):692.
16. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. *PLoS Medicine / Public Library of Science* 2012;**9**(8):e1001300.
17. Alberti W, Anderson G, Bartolucci A, et al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. *Br Med J* 1995;**311**(7010):899.
18. Alessio L, Apostoli P, Braga M, et al. Estimation of pooled reference values for cadmium in blood using meta-analysis and TRACY criteria. *Sci Total Environ* 1994;**152**(2):169-77.
19. Alexopoulos D, Xanthopoulou I, Storey RF, et al. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. *Am Heart J* 2014;**168**(4):530-6.
20. Alfredsson J, Clayton T, Damman P, et al. Impact of an invasive strategy on 5 years outcome in men and women with non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2014;**168**(4):522-9.
21. Alghamdi AA, McCrindle BW, Van Arsdell GS. Physiologic versus anatomic repair of congenitally corrected transposition of the great arteries: Meta-analysis of individual patient data. *Ann Thorac Surg* 2006;**81**(4):1529-35.
22. Ali AMG, Schmidt MK, Bolla MK, et al. Alcohol consumption and survival after a breast cancer diagnosis: A literature-based meta-analysis and collaborative analysis of data for 29,239 cases. *Cancer Epidemiology Biomarkers and Prevention* 2014;**23**(6):934-45.
23. Al-Jurf M, Aranha F, Annasetti C, et al. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials. *J Clin Oncol* 2005;**23**(22):5074-87.
24. Allgulander C, Hartford J, Russell J, et al. Pharmacotherapy of generalized anxiety disorder: Results of duloxetine treatment from a pooled analysis of three clinical trials. *Curr Med Res Opin* 2007;**23**(6):1245-52.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
25. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. *Lancet* 1997;**350**(9089):1417-24.
26. Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. *Cancer Treat Rev* 2012;**38**(6):708-14.
27. AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. *Br J Haematol* 1998;**103**(1):100-9.
28. Anderson JJ, Wells G, Verhoeven AC, et al. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. *Arthritis Rheum* 2000;**43**(1):22-9.
29. Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. *Clin Infect Dis* 2012;**54**(8):1110-22.
30. Andreoli MT, Itani KMF. Malignant eccrine spiradenoma: a meta-analysis of reported cases. *Am J Surg* 2011;**201**(5):695-9.
31. Andrews C, Aviles-Olmos I, Hariz M, et al. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. *Journal of Neurology, Neurosurgery and Psychiatry* 2010;**81**(12):1383-9.
32. Annane D, Chevrolat J, Chevret S, et al. Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders. *Cochrane Database Syst Rev* 2000.
33. Anonymous. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.[erratum appears in *Arch Intern Med* 1994 Oct 10;154(19):2254]. *Arch Intern Med* 1994;**154**(13):1449-57.
34. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994;**308**(6921):81-106.
35. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009;**373**(9678):1849-60.
36. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002;**324**(7329):71-86.
37. Appleby P, Beral V, Berrington de Gonzalez A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. *Int J Cancer* 2006;**118**(6):1481-95.
38. Ara RM, Reynolds AV, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. *Rheumatology* 2007;**46**(8):1338-44.
39. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.[see comment]. *J Natl Cancer Inst* 2007;**99**(11):847-57.
40. Arendts G, Dickson C, Howard K, et al. Transfer from residential aged care to emergency departments: an analysis of patient outcomes. *Intern Med J* 2012;**42**(1):75-82.
41. Arentz M, Pavlinac P, Kimerling ME, et al. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. *PLoS ONE [Electronic Resource]* 2012;**7**(11):e47370.
42. Ariesen MJ, Algra A, Koudstaal PJ, et al. Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. [Review] [10 refs]. *Stroke* 2004;**35**(3):710-4.
43. Arima H, Murakami Y, Lam TH, et al. Effects of prehypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific Region. *Hypertension* 2012;**59**(6):1118-23.
44. Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. *Pacing Clin Electrophysiol* 2012;**35**(2):131-4.
45. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. *Aliment Pharmacol Ther* 2013;**37**(2):234-42.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
46. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. *Autoimmun Rev* 2015;**14**(3):192-200.
47. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma.[update of Cochrane Database Syst Rev. 2000;(2):CD001799; PMID: 10796823]. [Review] [24 refs]. *Cochrane Database Syst Rev* 2000(4):CD001799.
48. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma.[update of Cochrane Database Syst Rev. 2000;(4):CD001799; PMID: 11034728]. [Review] [35 refs]. *Cochrane Database Syst Rev* 2005(4):CD001799-.
49. Arrich J, Holzer M, Havel C, et al. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. *Cochrane Database Syst Rev* 2012;**9**:CD004128.
50. Artemether-Quinine Meta-analysis Study G. A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. *Trans R Soc Trop Med Hyg* 2001;**95**(6):637-50.
51. Asherson P, Bushe C, Saylor K, et al. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. *J Psychopharmacol* 2014;**28**(9):837-46.
52. Asherson P, Stes S, Markhed MN, et al. The effects of atomoxetine on emotional control in adults with ADHD: An integrated analysis of multicenter studies. *Eur Psychiatry* 2015;**30**(4):511-20.
53. Ashworth AB, Senan S, Palma DA, et al. An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer. *Clin Lung Cancer* 2014.
54. Asia Pacific Cohort Studies Collaboration. An evaluation of metabolic risks for coronary death in the Asia Pacific region. *Diabetes Res Clin Pract* 2006;**74**(3):274-81.
55. Asia Pacific Cohort Studies Collaboration. Coronary risk prediction for those with and without diabetes. *Eur J Cardiovasc Prev Rehabil* 2006;**13**(1):30-6.
56. Asia Pacific Cohort Studies Collaboration. Impact of cigarette smoking on the relationship between body mass index and coronary heart disease: a pooled analysis of 3264 stroke and 2706 CHD events in 378579 individuals in the Asia Pacific region. *BMC Public Health* 2009;**9**:294.
57. Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. *Pediatrics* 2011;**128**(4):729-39.
58. Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.[see comment]. [Review] [59 refs]. *Lancet* 2007;**369**(9575):1791-98.
59. Askling J, Fahrback K, Nordstrom B, et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. *Pharmacoepidemiol Drug Saf* 2011;**20**(2):119-30.
60. Astrup A, Gotzsche PC, van de Werken K, et al. Meta-analysis of resting metabolic rate in formerly obese subjects.[see comment]. *Am J Clin Nutr* 1999;**69**(6):1117-22.
61. Asvold BO, Vatten LJ, Bjoro T, et al. Thyroid function within the normal range and risk of coronary heart disease: an individual participant data analysis of 14 cohorts. *JAMA Intern Med* 2015;**175**(6):1037-47.
62. Athappan G, Habib M, Ponniah T, et al. Multi-detector computerized tomography angiography for evaluation of acute chest pain--a meta analysis and systematic review of literature. *Int J Cardiol* 2010;**141**(2):132-40.
63. Atherton PJ, Burger KN, Loprinzi CL, et al. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). *Support Care Cancer* 2012;**20**(8):1729-35.
64. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. *Arch Intern Med* 1997;**157**(11):1237-40.
65. Auperin A, Le PC, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. *Ann Oncol* 2006;**17**(3):473-83.
66. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol* 2010;**28**(13):2181-90.
67. Bacci S, Di Paola R, Menzaghi C, et al. ENPP1 Q121 variant, increased pulse pressure and reduced insulin signaling, and nitric oxide synthase activity in endothelial cells. *Arteriosclerosis, Thrombosis and Vascular Biology* 2009;**29**(10):1678-83.
68. Badhiwala JH, Farrokhvar F, Alhazzani W, et al. Surgical outcomes and natural history of intramedullary spinal cord cavernous malformations: a single-center series and meta-analysis of individual patient data: Clinica article. *Journal of Neurosurgery Spine* 2014;**21**(4):662-76.

69. Bae EH, Theodore WH, Fregni F, et al. An estimate of placebo effect of repetitive transcranial magnetic stimulation in epilepsy. *Epilepsy and Behavior* 2011;**20**(2):355-9.
70. Bae JM, Choi YY, Kim H, et al. Mohs micrographic surgery for extramammary Paget disease: a pooled analysis of individual patient data. *J Am Acad Dermatol* 2013;**68**(4):632-7.
71. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. *J Thromb Haemost* 2010;**8**(11):2436-42.
72. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;**366**(9493):1267-78.
73. Bailey M, McGuinness S, Haase M, et al. Sodium bicarbonate and renal function after cardiac surgery: a prospectively planned individual patient meta-analysis. *Anesthesiology* 2015;**122**(2):294-306.
74. Bakker JP, Edwards BA, Gautam SP, et al. Blood pressure improvement with continuous positive airway pressure is independent of obstructive sleep apnea severity. *J Clin Sleep Med* 2014;**10**(4):365-69.
75. Bakker NA, Veeger NJGM, Vergeer RA, et al. Prognosis after spinal cord and cauda compression in spontaneous spinal epidural hematomas. *Neurology* 2015;**84**(18):1894-903.
76. Bakker OJ, van Brunschot S, Farre A, et al. Timing of enteral nutrition in acute pancreatitis: meta-analysis of individuals using a single-arm of randomised trials. *Pancreatology* 2014;**14**(5):340-6.
77. Balachandra S, Siriwardena AK. Systematic appraisal of the management of the major vascular complications of pancreatitis. *Am J Surg* 2005;**190**(3):489-95.
78. Baman TS, Meier P, Romero J, et al. Safety of pacemaker reuse: a meta-analysis with implications for underserved nations. *Circulation: Arrhythmia and Electrophysiology* 2011;**4**(3):318-23.
79. Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. *Rheumatology* 2006;**45**(8):1029-38.
80. Barnett GC, Elliott RM, Alsner J, et al. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. *Radiother Oncol* 2012;**105**(3):289-95.
81. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. *Addiction* 2001;**96**(5):683-90.
82. Barshes NR, Horwitz IB, Franzini L, et al. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. *Am J Transplant* 2007;**7**(5):1265-70.
83. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. *Blood* 2013;**122**(19):3251-62.
84. Bartlett JMS, McConkey CC, Munro AF, et al. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. *J Clin Oncol* 2015;**33**(15):1680-7.
85. Barton I. The relationship between osteoporotic fracture risk and a surrogate: Apparent discrepancies between analyses based on individual patient data and summary statistics. *Pharm Stat* 2004;**3**(3):205-12.
86. Barzi F, Patel A, Woodward M, et al. A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region. *Ann Epidemiol* 2005;**15**(5):405-13.
87. Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. *Clin Infect Dis* 2014;**59**(10):1364-74.
88. Bauer TM, El-Rayes BF, Li X, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. *Cancer* 2013;**119**(2):285-92.
89. Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. *International Journal of Radiation Oncology Biology Physics* 2006;**64**(1):47-56.
90. Baujat B, Bourhis J, Blanchard P, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. *Cochrane Database Syst Rev* 2010(12):CD002026.
91. Bazelier MT, de Vries F, Vestergaard P, et al. Risk of fracture with thiazolidinediones: An individual patient data meta-analysis. *Front Endocrinol (Lausanne)* 2013;**4**(FEB).
92. Becquet R, Marston M, Dabis F, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. *PLoS One* 2012;**7**(2):e28510.
93. Bedaiwy MA, El-Nashar SA, El Saman AM, et al. Reproductive outcome after transplantation of ovarian tissue: A systematic review. *Hum Reprod* 2008;**23**(12):2709-17.
94. Beer TM, Berry W, Wersinger EM, et al. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. *Clin Prostate Cancer* 2003;**2**(3):167-72.

- 1
- 2
- 3 95. Bell KJL, Hayen A, Macaskill P, et al. Monitoring initial response to Angiotensin-converting enzyme inhibitor-
- 4 based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials.
- 5 Hypertension 2010;**56**(3):533-9.
- 6 96. Bendtsen F, D'Amico G, Rusch E, et al. Effect of recombinant Factor VIIa on outcome of acute variceal
- 7 bleeding: An individual patient based meta-analysis of two controlled trials. J Hepatol 2014.
- 8 97. Benhamou S, Lee WJ, Alexandrie AK, et al. Meta- and pooled analyses of the effects of glutathione S-
- 9 transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002;**23**(8):1343-50.
- 10 98. Benner A, Mansouri L, Rossi D, et al. MDM2 promotor polymorphism and disease characteristics in chronic
- 11 lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica
- 12 2014;**99**(8):1285-91.
- 13 99. Bennett K, Manassis K, Walter SD, et al. Cognitive behavioral therapy age effects in child and adolescent
- 14 anxiety: an individual patient data metaanalysis. *Depress Anxiety* 2013;**30**(9):829-41.
- 15 100. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event
- 16 prediction: an individual participant meta-analysis of prospective observational data from 17,635
- 17 subjects. *J Am Coll Cardiol* 2014;**63**(7):636-46.
- 18 101. Bensinger WI, Al-Jurf M, Annasetti C, et al. Individual patient data meta-analysis of allogeneic peripheral
- 19 blood stem cell transplant vs bone marrow transplant in the management of hematological
- 20 malignancies: Indirect assessment of the effect of day 11 methotrexate administration. *Bone Marrow*
- 21 *Transplant* 2006;**38**(8):539-46.
- 22 102. Beral V, Bull D, Doll R, et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data
- 23 from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without
- 24 breast cancer. *Lancet* 1997;**350**(9084):1047-59.
- 25 103. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from
- 26 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet*
- 27 2008;**371**(9609):303-14.
- 28 104. Berghella V, Odibo AO, To MS, et al. Cerclage for short cervix on ultrasonography: Meta-analysis of trials
- 29 using individual patient-level data. *Obstet Gynecol* 2005;**106**(1):181-89.
- 30 105. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support as
- 31 adjuvant therapy in breast cancer: overview of 15 randomized trials. *J Clin Oncol* 2011;**29**(24):3214-23.
- 32 106. Berry SM, Broglio K, Bunker M, et al. A patient-level meta-analysis of studies evaluating vagus nerve
- 33 stimulation therapy for treatment-resistant depression. *Medical Devices: Evidence and Research*
- 34 2013;**6**(1):17-35.
- 35 107. Best L, Simmonds P, Baughan C, et al. Palliative chemotherapy for advanced or metastatic colorectal cancer.
- 36 *Cochrane Database Syst Rev* 2000;**2**.
- 37 108. Beveridge LA, Struthers AD, Khan F, et al. Effect of Vitamin D Supplementation on Blood Pressure: A
- 38 Systematic Review and Meta-analysis Incorporating Individual Patient Data. *JAMA Intern Med*
- 39 2015;**175**(5):745-54.
- 40 109. Beyerlein A, Hadders-Algra M, Kennedy K, et al. Infant formula supplementation with long-chain
- 41 polyunsaturated fatty acids has no effect on Bayley developmental scores at 18 months of age--IPD
- 42 meta-analysis of 4 large clinical trials. *J Pediatr Gastroenterol Nutr* 2010;**50**(1):79-84.
- 43 110. Bhutta ZA, Bird SM, Black RE, et al. Therapeutic effects of oral zinc in acute and persistent diarrhea in children
- 44 in developing countries: pooled analysis of randomized controlled trials. *The American journal of clinical*
- 45 *nutrition* 2000;**72**(6):1516-22.
- 46 111. Biau DJ, Katsahian S, Kartus J, et al. Patellar tendon versus hamstring tendon autografts for reconstructing
- 47 the anterior cruciate ligament: a meta-analysis based on individual patient data. *Am J Sports Med*
- 48 2009;**37**(12):2470-8.
- 49 112. Bidard F-C, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic
- 50 breast cancer: a pooled analysis of individual patient data. *Lancet Oncol* 2014;**15**(4):406-14.
- 51 113. Bingham CO, 3rd, Smugar SS, Wang H, et al. Early response to COX-2 inhibitors as a predictor of overall
- 52 response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and
- 53 placebo. *Rheumatology (Oxford)* 2009;**48**(9):1122-7.
- 54 114. Birks J, Flicker L. Selegiline for Alzheimer's disease. *Cochrane Database Syst Rev* 2003(1):Issue 1.
- 55 115. Biros E, Norman PE, Jones GT, et al. Meta-analysis of the association between single nucleotide
- 56 polymorphisms in TGF-beta receptor genes and abdominal aortic aneurysm. *Atherosclerosis*
- 57 2011;**219**(1):218-23.
- 58 116. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture
- 59 prevention. *N Engl J Med* 2012;**367**(1):40-9.
- 60

117. Bisset L, Smidt N, Van der Windt DA, et al. Conservative treatments for tennis elbow - Do subgroups of patients respond differently? *Rheumatology* 2007;**46**(10):1601-05.
118. Blacher J, Staessen JA, Girerd X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. *Arch Intern Med* 2000;**160**(8):1085-9.
119. Black JA, Herbison GP, Lyons RA, et al. Recovery after injury: an individual patient data meta-analysis of general health status using the EQ-5D. *Journal of Trauma-Injury Infection and Critical Care* 2011;**71**(4):1003-10.
120. Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. *J Clin Oncol* 2013;**31**(23):2854-60.
121. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *Lancet Oncol* 2015;**16**(6):645-55.
122. Blanke CD, Bot BM, Thomas DM, et al. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. *J Clin Oncol* 2011;**29**(20):2781-6.
123. Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). *Int J Cancer* 1995;**62**(4):367-76.
124. Blood Pressure Lowering Treatment Trialists Collaboration, Ninomiya T, Perkovic V, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. *BMJ* 2013;**347**:f5680.
125. Blood Pressure Lowering Treatment Trialists Collaboration, Sundstrom J, Arima H, et al. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. *Lancet* 2014;**384**(9943):591-8.
126. Blood Pressure Lowering Treatment Trialists Collaboration, Ying A, Arima H, et al. Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. *Lancet* 2015;**385**(9971):867-74.
127. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Med* 2010;**7**(5):e1000279.
128. Blum JL, Barrios CH, Feldman N, et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. *Breast Cancer Res Treat* 2012;**136**(3):777-88.
129. Blum MR, Bauer DC, Collet T-H, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. *JAMA* 2015;**313**(20):2055-65.
130. Boccia S, Hung R, Ricciardi G, et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. *Am J Epidemiol* 2008;**167**(5):505-16.
131. Boeker EB, Ram K, Klopotoska JE, et al. An individual patient data meta-analysis on factors associated with adverse drug events in surgical and non-surgical inpatients. *Br J Clin Pharmacol* 2015;**79**(4):548-57.
132. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.[Erratum appears in *JAMA*. 2012 Apr 25;307(16):1694], [Erratum appears in *JAMA*. 2012 May 9;307(18):1915]. *JAMA* 2012;**307**(12):1302-9.
133. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol* 2014;**64**(5):485-94.
134. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: Individual patient meta-analysis of 13 677 subjects. *Circulation* 2005;**111**(3):278-87.
135. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. *Eur Heart J* 2006;**27**(7):779-88.
136. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.[see comment][erratum appears in *Lancet* 2002 Jun 15;359(9323):2120]. *Lancet* 2002;**359**(9302):189-98.
137. Bogaerts J, Ford R, Sargent D, et al. Individual patient data analysis to assess modifications to the RECIST criteria. *Eur J Cancer* 2009;**45**(2):248-60.

138. Boghani Z, Husain Q, Kanumuri VV, et al. Juvenile nasopharyngeal angiofibroma: a systematic review and comparison of endoscopic, endoscopic-assisted, and open resection in 1047 cases. *Laryngoscope* 2013;**123**(4):859-69.
139. Bohlus J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. *Cochrane Database Syst Rev* 2009(3):CD007303.
140. Bokemeyer C, Kollmannsberger C, Stenning S, et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. *Br J Cancer* 2004;**91**(4):683-7.
141. Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. *Eur J Cancer* 2012;**48**(10):1466-75.
142. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ* 2010;**341**:c3691.
143. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012;**307**(4):382-90.
144. Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2009;**68**(7):1177-83.
145. Bonnetain F, Bosset JF, Gerard JP, et al. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? *Eur J Cancer* 2012;**48**(12):1781-90.
146. Booij L, Van der Does W, Benkelfat C, et al. Predictors of mood response to acute tryptophan depletion. A reanalysis. *Neuropsychopharmacology* 2002;**27**(5):852-61.
147. Boonacker CW, Rovers MM, Browning GG, et al. Adenoidectomy with or without grommets for children with otitis media: an individual patient data meta-analysis. *Health Technol Assess* 2014;**18**(5):1-118.
148. Boonstra N, Klaassen R, Sytema S, et al. Duration of untreated psychosis and negative symptoms--a systematic review and meta-analysis of individual patient data. *Schizophr Res* 2012;**142**(1-3):12-9.
149. Bosetti C, Negri E, Kolonel L, et al. A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (International). *Cancer Causes Control* 2002;**13**(8):765-75.
150. Bossie CA, Turkoz I, Lindenmayer J-P, et al. Paliperidone ER and oral risperidone in patients with schizophrenia: A comparative database analysis. *BMC Psychiatry* 2011;**11**.
151. Bourhis J, Blanchard P, Maillard E, et al. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. *J Clin Oncol* 2011;**29**(18):2590-7.
152. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet* 2006;**368**(9538):843-54.
153. Bourne C, Aydemir O, Balanza-Martinez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. *Acta Psychiatr Scand* 2013;**128**(3):149-62.
154. Boutitie F, Gueyffier F, Pocock S, et al. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta-analysis of individual-patient data.[see comment][summary for patients in *Ann Intern Med*. 2002 Mar 19;136(6):I49; PMID: 11900515]. *Ann Intern Med* 2002;**136**(6):438-48.
155. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. *BMJ* 2011;**342**:d3036.
156. Bova C, Sanchez O, Prandoni P, et al. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. *Eur Respir J* 2014;**44**(3):694-703.
157. Bower P, Byford S, Barber J, et al. Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses.[see comment]. *BMJ* 2003;**326**(7401):1247-50.
158. Bower P, Kontopantelis E, Sutton A, et al. Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. *BMJ* 2013;**346**:f540.
159. Brand JS, Rovers MM, Yeap BB, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: An individual participant data meta-analysis of observational studies. *PLoS One* 2014;**9**(7).
160. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. *J Am Coll Cardiol* 2011;**58**(19):1945-54.

161. Bratton DJ, Stradling JR, Barbe F, et al. Effect of CPAP on blood pressure in patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis using individual patient data from four randomised controlled trials. *Thorax* 2014;**69**(12):1128-35.
162. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. *N Engl J Med* 2005;**353**(8):793-802.
163. Breugom AJ, Swets M, Bosset J-F, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol* 2015;**16**(2):200-7.
164. Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. *JAMA* 2010;**303**(9):865-73.
165. Brin MF, Boodhoo TI, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. *J Am Acad Dermatol* 2009;**61**(6):961-70.e1-11.
166. Brinthen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. *Haematologica* 2013;**98**(6):980-7.
167. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: Male breast cancer pooling project results. *J Natl Cancer Inst* 2014;**106**(3).
168. Broer SL, Dolleman M, van Disseldorp J, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. *Fertil Steril* 2013;**100**(2):420-9.e7.
169. Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. *Hum Reprod Update* 2013;**19**(1):26-36.
170. Broeze KA, Opmeer BC, Coppus SFPJ, et al. Chlamydia antibody testing and diagnosing tubal pathology in subfertile women: an individual patient data meta-analysis. *Hum Reprod Update* 2011;**17**(3):301-10.
171. Broeze KA, Opmeer BC, Van Geloven N, et al. Are patient characteristics associated with the accuracy of hysterosalpingography in diagnosing tubal pathology? An individual patient data meta-analysis. *Hum Reprod Update* 2011;**17**(3):293-300.
172. Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. *Aliment Pharmacol Ther* 2003;**17**(1):99-109.
173. Brouwer IA, Raitt MH, Dullemeijer C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. *Eur Heart J* 2009;**30**(7):820-6.
174. Brunotto M, Zarate AM, Bono A, et al. Risk genes in head and neck cancer: A systematic review and meta-analysis of last 5 years. *Oral Oncol* 2014;**50**(3):178-88.
175. Bruzzi P, Del Mastro L, Sormani MP, et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. *J Clin Oncol* 2005;**23**(22):5117-25.
176. Bueters RRG, Van De Kar NCAJ, Schreuder MF. Adult renal size is not a suitable marker for nephron numbers: An individual patient data meta-analysis. *Kidney Blood Press Res* 2013;**37**(6):540-46.
177. Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database Syst Rev* 2015;**3**.
178. Burdett S, Stephens R, Stewart L, et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. *J Clin Oncol* 2008;**26**(28):4617-25.
179. Burdett S, Stewart L, on behalf of the PM-aG. Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. *Lung Cancer* 2005;**47**(1):81-3.
180. Burns A, Yeates A, Akintade L, et al. Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies. *Drugs Aging* 2008;**25**(8):707-14.
181. Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled analysis of 11 trials. *Eur Heart J* 2009;**30**(18):2193-203.
182. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. *J Clin Oncol* 2008;**26**(12):1987-92.
183. Bustamante A, Sobrino T, Giralt D, et al. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis. *J Neuroimmunol* 2014;**274**(1-2):215-24.

184. Butali A, Little J, Chevrier C, et al. Folic acid supplementation use and the MTHFR C677T polymorphism in orofacial clefts etiology: An individual participant data pooled-analysis. *Birth Defects Research* 2013;**97**(8):509-14.
185. Butcher I, Maas AIR, Lu J, et al. Prognostic value of admission blood pressure in traumatic brain injury: Results from the IMPACT study. *J Neurotrauma* 2007;**24**(2):294-302.
186. Butcher I, McHugh GS, Lu J, et al. Prognostic value of cause of injury in traumatic brain injury: results from the IMPACT study. *J Neurotrauma* 2007;**24**(2):281-6.
187. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. *Arch Surg* 2008;**143**(1):75-83; discussion 83.
188. Buyse M. Cyclophosphamide Plus Cisplatin Versus Cyclophosphamide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma-a Metaanalysis. *J Clin Oncol* 1991;**9**(9):1668-74.
189. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. *J Clin Oncol* 2007;**25**(33):5218-24.
190. Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. *Blood* 2011;**117**(26):7007-13.
191. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. *Lancet* 2000;**356**(9227):373-78.
192. C Reactive Protein Coronary Heart Disease Genetics Collaboration, Wensley F, Gao P, et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. *BMJ* 2011;**342**:d548.
193. C. L. L. Trialists' Collaborative Group. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. *Haematologica* 2012;**97**(3):428-36.
194. Calatayud CM, Garcia AM, Aragones AM, et al. Safety and efficacy profile and immunological changes associated with oral immunotherapy for IgE-mediated cow's milk allergy in children: systematic review and meta-analysis. *J Investig Allergol Clin Immunol* 2014;**24**(5):298-307.
195. Caldon LJ, Walters SJ, Reed JA, et al. Case-mix fails to explain variation in mastectomy rates: management of screen-detected breast cancer in a UK region 1997-2003. *Br J Cancer* 2005;**92**(1):55-9.
196. Caleyachetty R, Echouffo-Tcheugui JB, Tait CA, et al. Prevalence of behavioural risk factors for cardiovascular disease in adolescents in low-income and middle-income countries: An individual participant data meta-analysis. *Lancet Diabetes Endocrinol* 2015;**3**(7):535-44.
197. Callan MJ, Shead NW, Olson JM. The relation between personal relative deprivation and the urge to gamble among gamblers is moderated by problem gambling severity: A meta-analysis. *Addict Behav* 2015;**45**:146-49.
198. Camacho M, Teixeira J, Abdullatif J, et al. Maxillomandibular advancement and tracheostomy for morbidly obese obstructive sleep apnea: a systematic review and meta-analysis. *Otolaryngology - Head and Neck Surgery* 2015;**152**(4):619-30.
199. Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. *Gut* 2002;**51**(6):864-9.
200. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. *Hepatology* 2004;**39**(2):333-42.
201. Camma C, Giunta M, Chemello L, et al. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1999;**30**(3):801-7.
202. Canaud L, Karthikesalingam A, Jackson D, et al. Clinical outcomes of single versus staged hybrid repair for thoracoabdominal aortic aneurysm. *J Vasc Surg* 2013;**58**(5):1192-200.
203. Cancer CGoHFIB. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. *Lancet* 1996;**347**(9017):1713-27.
204. Cancer. CGoESoO. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. *PLoS Med* 2012;**9**(4):e1001200.
205. Cardarelli MG, Young AJ, Griffith B. Use of extracorporeal membrane oxygenation for adults in cardiac arrest (E-CPR): a meta-analysis of observational studies. *ASAIO J* 2009;**55**(6):581-6.
206. Cardwell CR, Stene LC, Joner G, et al. Maternal age at birth and childhood type 1 diabetes: a pooled analysis of 30 observational studies. *Diabetes* 2010;**59**(2):486-94.
207. Cardwell CR, Stene LC, Joner G, et al. Birth order and childhood type 1 diabetes risk: a pooled analysis of 31 observational studies. *Int J Epidemiol* 2011;**40**(2):363-74.

- 1
2
3 208. Cardwell CR, Stene LC, Joner G, et al. Birthweight and the risk of childhood-onset type 1 diabetes: a meta-
4 analysis of observational studies using individual patient data. *Diabetologia* 2010;**53**(4):641-51.
- 5 209. Cardwell CR, Stene LC, Ludvigsson J, et al. Breast-feeding and childhood-onset type 1 diabetes: a pooled
6 analysis of individual participant data from 43 observational studies. *Diabetes Care* 2012;**35**(11):2215-25.
- 7 210. Carnero-Pardo C, Lopez-Alcalde S, Allegri RF, et al. A systematic review and meta-analysis of the diagnostic
8 accuracy of the phototest for cognitive impairment and dementia. *Dementia e Neuropsychologia*
9 2014;**8**(2):141-47.
- 10 211. Caro JJ, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with
11 subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: A systematic review.
12 *BMC Blood Disord* 2002;**2**(4).
- 13 212. Carotid Stenting Trialists Collaboration, Bonati LH, Dobson J, et al. Short-term outcome after stenting versus
14 endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data.
15 *Lancet* 2010;**376**(9746):1062-73.
- 16 213. Cassese S, Desch S, Kastrati A, et al. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting
17 stents: An individual patient data analysis of randomized trials. *Revista Espanola de Cardiologia*
18 2013;**66**(6):435-42.
- 19 214. Cassidy J, Saltz L, Twelves C, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric
20 cancers: a meta-analysis of individual data from 6171 patients. *Ann Oncol* 2011;**22**(12):2604-9.
- 21 215. Castellsague X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human
22 papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. *Lancet Oncol*
23 2011;**12**(11):1023-31.
- 24 216. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: Serious adverse events. *Cochrane*
25 *Database Syst Rev* 2008(3):-.
- 26 217. Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive
27 bronchitis: a meta-analysis of individual patient data. *Pulm Pharmacol Ther* 2010;**23**(2):135-44.
- 28 218. Celio L, Bonizzoni E, Bajetta E, et al. Palonosetron plus single-dose dexamethasone for the prevention of
29 nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy:
30 meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
31 *Support Care Cancer* 2013;**21**(2):565-73.
- 32 219. Chaker L, Baumgartner C, Den Elzen WPJ, et al. Subclinical hypothyroidism and the risk of stroke events and
33 fatal stroke: An individual participant data analysis. *J Clin Endocrinol Metab* 2015;**100**(6):2181-91.
- 34 220. Chalidis B, Stengel D, Giannoudis PV. Early excision and late excision of heterotopic ossification after
35 traumatic brain injury are equivalent: A systematic review of the literature. *J Neurotrauma*
36 2007;**24**(11):1675-86.
- 37 221. Chambrone L, Pannuti CM, Tu Y-K, et al. Evidence-based periodontal plastic surgery. II. An individual data
38 meta-analysis for evaluating factors in achieving complete root coverage. *J Periodontol* 2012;**83**(4):477-
39 90.
- 40 222. Chambrone L, Preshaw PM, Rosa EF, et al. Effects of smoking cessation on the outcomes of non-surgical
41 periodontal therapy: a systematic review and individual patient data meta-analysis. *J Clin Periodontol*
42 2013;**40**(6):607-15.
- 43 223. Chang K-C, Yew W-W, Tam C-M, et al. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a
44 systematic review with cohort analysis and meta-analysis. *Antimicrob Agents Chemother*
45 2013;**57**(9):4097-104.
- 46 224. Chappell FM, Wardlaw JM, Young GR, et al. Carotid artery stenosis: accuracy of noninvasive tests--individual
47 patient data meta-analysis. *Radiology* 2009;**251**(2):493-502.
- 48 225. Chau I, Norman AR, Cunningham D, et al. The impact of primary tumour origins in patients with advanced
49 oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from
50 1775 patients in four randomised controlled trials. *Ann Oncol* 2009;**20**(5):885-91.
- 51 226. Chau I, Norman AR, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and
52 metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled
53 trials using individual patient data. *J Clin Oncol* 2004;**22**(12):2395-403.
- 54 227. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration. Reducing uncertainties about the
55 effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. *Cochrane*
56 *Database Syst Rev* 2010(1):CD008285.
- 57 228. Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : A combined
58 analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke
59 trial. On behalf of the CAST and IST collaborative groups. *Stroke* 2000;**31**(6):1240-9.
- 60

- 1
2
3 229. Cheung WY, Shi Q, O'Connell M, et al. The predictive and prognostic value of sex in early-stage colon cancer:
4 a pooled analysis of 33,345 patients from the ACCENT database. *Clin Colorectal Cancer* 2013;**12**(3):179-
5 87.
- 6 230. Chiappini E, Galli L, Giaquinto C, et al. Use of combination neonatal prophylaxis for the prevention of
7 mother-to-child transmission of HIV infection in European high-risk infants. *AIDS* 2013;**27**(6):991-1000.
- 8 231. Chierakul W, Anunnatsiri S, Short JM, et al. Two randomized controlled trials of ceftazidime alone versus
9 ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis.
10 *Clin Infect Dis* 2005;**41**(8):1105-13.
- 11 232. Childhood Acute Lymphoblastic Leukaemia Collaborative Group. Beneficial and harmful effects of
12 anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and
13 meta-analysis. *Br J Haematol* 2009;**145**(3):376-88.
- 14 233. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute
15 lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. . *Lancet*
16 1996;**347**(9018):1783-8.
- 17 234. Cho JK, Woo S-H, Park J, et al. Primary squamous cell carcinomas in the thyroid gland: an individual
18 participant data meta-analysis. *Cancer Medicine* 2014;**3**(5):1396-403.
- 19 235. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more
20 intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26
21 randomised trials. *Lancet* 2010;**376**(9753):1670-81.
- 22 236. Cholesterol Treatment Trialists Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL
23 cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data
24 from 27 randomised trials. *Lancet* 2012;**380**(9841):581-90.
- 25 237. Chowdhury N, Sapru S. Association of prot1ein translation and extracellular matrix gene sets with breast
26 cancer metastasis: Findings uncovered on analysis of multiple publicly available datasets using individual
27 patient data approach. *PLoS One* 2015;**10**(6).
- 28 238. Choy Pui Yee G, Bissett Ian P, Docherty James G, et al. Stapled versus handsewn methods for ileocolic
29 anastomoses. *Cochrane Database Syst Rev* 2007.
- 30 239. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alfa versus chemotherapy for chronic
31 myeloid leukemia: a meta-analysis of seven randomized trials. *J Natl Cancer Inst* 1997;**89**(21):1616-20.
- 32 240. Chronic myeloid leukemia trialists' collaborative group. Hydroxyurea versus busulphan for chronic myeloid
33 leukaemia: an individual patient data meta-analysis of three randomized trials. . *Br J Haematol*
34 2000;**110**(3):573-6.
- 35 241. Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and
36 radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. *J Clin Oncol*
37 2005;**23**(6):1118-24.
- 38 242. Cil AP, Bang H, Oktay K. Age-specific probability of live birth with oocyte cryopreservation: an individual
39 patient data meta-analysis. *Fertil Steril* 2013;**100**(2):492-9.e3.
- 40 243. Clahsen PC, van de Velde CJ, Goldhirsch A, et al. Overview of randomized perioperative polychemotherapy
41 trials in women with early-stage breast cancer. *J Clin Oncol* 1997;**15**(7):2526-35.
- 42 244. Clark IA, Mackay CE, Holmes EA. Low emotional response to traumatic footage is associated with an absence
43 of analogue flashbacks: An individual participant data meta-analysis of 16 trauma film paradigm
44 experiments. *Cognition and Emotion* 2015;**29**(4):702-13.
- 45 245. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia:
46 Childhood ALL Collaborative Group overview of 43 randomized trials. *J Clin Oncol* 2003;**21**(9):1798-809.
- 47 246. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on
48 cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials
49 involving 37 485 individuals. *Arch Intern Med* 2010;**170**(18):1622-31.
- 50 247. Clouser C, Nieri M, Franceschi D, et al. Evidence-based mucogingival therapy. Part 2: Ordinary and individual
51 patient data meta-analyses of surgical treatment of recession using complete root coverage as the
52 outcome variable. *J Periodontol* 2003;**74**(5):741-56.
- 53 248. Clauss W, Dinger J, Meissner C. Renal tolerance of iotrolan 280—a meta-analysis of 14 double-blind studies.
54 *Eur Radiol* 1995;**5**(2):S79-S84.
- 55 249. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials
56 assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with
57 symptomatic heart failure. *Eur Heart J* 2013;**34**(46):3547-56.
- 58 250. Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran:
59 comprehensive analysis of individual subject data by treatment. *Vascular Health and Risk Management*
60 2013;**9**:599-615.

- 1
2
3 251. Cohen EEW, Halpern AB, Kasza K, et al. Factors associated with clinical benefit from epidermal growth factor
4 receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. *Oral*
5 *Oncol* 2009;**45**(10):e155-60.
- 6 252. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, et al. Ovarian cancer
7 and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51
8 epidemiological studies. *Lancet Oncol* 2012;**13**(9):946-56.
- 9 253. Collet T-H, Bauer DC, Cappola AR, et al. Thyroid antibody status, subclinical hypothyroidism, and the risk of
10 coronary heart disease: an individual participant data analysis. *J Clin Endocrinol Metab* 2014;**99**(9):3353-
11 62.
- 12 254. Collette L, Burzykowski T, Carroll KJ, et al. Is prostate-specific antigen a valid surrogate end point for survival
13 in hormonally treated patients with metastatic prostate cancer? Joint research of the European
14 Organisation for Research and treatment of cancer, the Limburgs Universitair Centrum, and AstraZeneca
15 Pharmaceuticals. *J Clin Oncol* 2005;**23**(25):6139-48.
- 16 255. Collins M, Wilhelm M, Conyers R, et al. Benefits and adverse events in younger versus older patients
17 receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. *J Clin Oncol*
18 2013;**31**(18):2303-12.
- 19 256. Colorectal Cancer Collaborative G. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507
20 patients from 22 randomised trials.[see comment]. *Lancet* 2001;**358**(9290):1291-304.
- 21 257. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator
22 secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator
23 study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. *Eur Heart J*
24 2000;**21**(24):2071-8.
- 25 258. Conway DI, Brenner DR, McMahon AD, et al. Estimating and explaining the effect of education and income
26 on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27
27 countries. *Int J Cancer* 2015;**136**(5):1125-39.
- 28 259. Cook MB, Guénel P, Gapstur SM, et al. Tobacco and alcohol in relation to male breast cancer: An analysis of
29 the male breast cancer pooling project consortium. *Cancer Epidemiology Biomarkers and Prevention*
30 2015;**24**(3):520-31.
- 31 260. Cools F, Askie LM, Offringa M, et al. Elective high-frequency oscillatory versus conventional ventilation in
32 preterm infants: a systematic review and meta-analysis of individual patients' data. *Lancet*
33 2010;**375**(9731):2082-91.
- 34 261. Cooper BC, Mullins PR, Jones MR, et al. Clinical efficacy of roxithromycin in the treatment of adults with
35 upper and lower respiratory tract infection due to *Haemophilus influenzae*: A meta-analysis of 12 clinical
36 studies. *Drug Investigation* 1994;**7**(6):299-314.
- 37 262. Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: a systematic review
38 and meta-analysis with synthetic cohort. *AIDS* 2011;**25**(6):777-86.
- 39 263. Cooper ME, Perkovic V, McGill JB, et al. Kidney Disease End Points in a Pooled Analysis of Individual Patient-
40 Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type
41 2 Diabetes. *Am J Kidney Dis* 2015.
- 42 264. Cope S, Zhang J, Williams J, et al. Efficacy of once-daily indacaterol 75 mug relative to alternative
43 bronchodilators in COPD: a study level and a patient level network meta-analysis. *BMC Pulm Med*
44 2012;**12**:29.
- 45 265. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of
46 end-stage renal disease and mortality. *JAMA* 2014;**311**(24):2518-31.
- 47 266. Cornu C, Boutitie F, Candelise L, et al. Streptokinase in acute ischemic stroke: an individual patient data meta-
48 analysis : The Thrombolysis in Acute Stroke Pooling Project. *Stroke* 2000;**31**(7):1555-60.
- 49 267. Costantino G, Casazza G, Reed M, et al. Syncope risk stratification tools vs clinical judgment: an individual
50 patient data meta-analysis. *Am J Med* 2014;**127**(11):1126.e13-25.
- 51 268. Coutinho T, Goel K, Correa de Sa D, et al. Central obesity and survival in subjects with coronary artery
52 disease: a systematic review of the literature and collaborative analysis with individual subject data. *J Am*
53 *Coll Cardiol* 2011;**57**(19):1877-86.
- 54 269. Coutsoudis A, Dabis F, Fawzi W, et al. Late postnatal transmission of HIV-1 in breast-fed children: an
55 individual patient data meta-analysis.[see comment]. *J Infect Dis* 2004;**189**(12):2154-66.
- 56 270. Couture F, Turner AR, Melosky B, et al. Prior red blood cell transfusions in cancer patients increase the risk of
57 subsequent transfusions with or without recombinant human erythropoietin management. *Oncologist*
58 2005;**10**(1):63-71.
- 59 271. Cowling BJ, Shaw JEH, Hutton JL, et al. New statistical method for analyzing time to first seizure: Example
60 using data comparing carbamazepine and valproate monotherapy. *Epilepsia* 2007;**48**(6):1173-78.

- 1
2
3 272. Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper
4 gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant
5 data from randomised trials. *Lancet* 2013;**382**(9894):769-79.
- 6 273. Craig JV, Lancaster GA, Taylor S, et al. Infrared ear thermometry compared with rectal thermometry in
7 children: a systematic review.[see comment]. [Review] [48 refs]. *Lancet* 2002;**360**(9333):603-9.
- 8 274. Craig LE, Bernhardt J, Langhorne P, et al. Early mobilization after stroke: an example of an individual patient
9 data meta-analysis of a complex intervention. *Stroke* 2010;**41**(11):2632-6.
- 10 275. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: A pooled
11 analysis of individual patient data. *Osteoporos Int* 2009;**20**(2):291-97.
- 12 276. Crawford MR, Bartlett DJ, Coughlin SR, et al. The effect of continuous positive airway pressure usage on
13 sleepiness in obstructive sleep apnoea: real effects or expectation of benefit? *Thorax* 2012;**67**(10):920-4.
- 14 277. Crowe FL, Appleby PN, Travis RC, et al. Circulating fatty acids and prostate cancer risk: individual participant
15 meta-analysis of prospective studies. *J Natl Cancer Inst* 2014;**106**(9):dju240.
- 16 278. Crump M, Sawka CA, DeBoer G, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian
17 ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. *Breast
18 Cancer Res Treat* 1997;**44**(3):201-10.
- 19 279. Cuijpers P, Weitz E, Twisk J, et al. Gender as predictor and moderator of outcome in cognitive behavior
20 therapy and pharmacotherapy for adult depression: an "individual patient data" meta-analysis. *Depress
21 Anxiety* 2014;**31**(11):941-51.
- 22 280. Cuzick J, Clavel C, Petry K-U, et al. Overview of the European and North American studies on HPV testing in
23 primary cervical cancer screening. *Int J Cancer* 2006;**119**(5):1095-101.
- 24 281. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer:
25 an updated meta-analysis of individual participant data. *Lancet* 2013;**381**(9880):1827-34.
- 26 282. Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials comparing radical mastectomy without
27 radiotherapy against simple mastectomy with radiotherapy in breast cancer. *Cancer Treat Rep*
1987;**71**(1):7-14.
- 28 283. Czernichow S, Kengne AP, Stamatakis E, et al. Body mass index, waist circumference and waist-hip ratio:
29 which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-
30 participant meta-analysis of 82 864 participants from nine cohort studies. *Obes Rev* 2011;**12**(9):680-7.
- 31 284. Czobor P, Van Dorn RA, Citrome L, et al. Treatment adherence in schizophrenia: A patient-level meta-analysis
32 of combined CATIE and EUFEST studies. *Eur Neuropsychopharmacol* 2015.
- 33 285. Daemen J, Boersma E, Flather M, et al. Long-term safety and efficacy of percutaneous coronary intervention
34 with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis
35 with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials. *Circulation*
36 2008;**118**(11):1146-54.
- 37 286. Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. *Breast
38 Cancer Res Treat* 2010;**119**(3):621-31.
- 39 287. Dahlof CG, Pascual J, Dodick DW, et al. Efficacy, speed of action and tolerability of almotriptan in the acute
40 treatment of migraine: Pooled individual patient data from four randomized, double-blind, placebo-
41 controlled clinical trials. *Cephalalgia* 2006;**26**(4):400-08.
- 42 288. D'Amico R, Pifferi S, Leonetti C, et al. Effectiveness of antibiotic prophylaxis in critically ill adult patients:
43 systematic review of randomised controlled trials.[see comment]. *BMJ* 1998;**316**(7140):1275-85.
- 44 289. Damman P, Wallentin L, Fox KAA, et al. Long-term cardiovascular mortality after procedure-related or
45 spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome:
46 a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR).
47 *Circulation* 2012;**125**(4):568-76.
- 48 290. Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular
49 diseases and nonvascular mortality: An individual participant meta-analysis. *J Am Med Assoc*
2005;**294**(14):1799-809.
- 50 291. Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting
51 stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical
52 Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With
53 De Novo Native Coronary Artery Lesions). *JACC Cardiovasc Interv* 2013;**6**(9):914-22.
- 54 292. Dangour AD, Watson L, Cumming O, et al. Interventions to improve water quality and supply, sanitation and
55 hygiene practices, and their effects on the nutritional status of children. *Cochrane Database Syst Rev*
56 2013;**8**:CD009382.
- 57
58
59
60

- 1
2
3 293. Daniels JP, Middleton L, Xiong T, et al. Individual patient data meta-analysis of randomized evidence to
4 assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic pain. *Hum Reprod*
5 *Update* 2010;**16**(6):568-76.
- 6 294. Darby S, Hill D, Deo H, et al. Residential radon and lung cancer--detailed results of a collaborative analysis of
7 individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13
8 epidemiologic studies in Europe. *Scand J Work Environ Health* 2006;**32** Suppl 1:1-83.
- 9 295. Darbyshire J, Foulkes M, Peto R, et al. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus
10 zalcitabine (ddC) in HIV infected adults.[update in *Cochrane Database Syst Rev*. 2000;(3):CD002038;
11 PMID: 10908523]. [Review] [26 refs]. *Cochrane Database Syst Rev* 2000(2):CD002038.
- 12 296. Darbyshire J, Foulkes M, Peto R, et al. Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly
13 symptomatic HIV infected adults.[update of *Cochrane Database Syst Rev*. 2000;(2):CD002039; PMID:
14 10796852]. [Review] [30 refs]. *Cochrane Database Syst Rev* 2000(3):CD002039.
- 15 297. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data
16 pooling analysis of clinical trials. *Stroke* 2002;**33**(12):2850-7.
- 17 298. Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30
18 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. *Clin*
19 *Ther* 2009;**31**(8):1641-51.
- 20 299. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis:
21 combined results of the North American and international trials. *J Clin Psychiatry* 2001;**62**(10):757-71.
- 22 300. Davison BA, Metra M, Cotter G, et al. Worsening heart failure following admission for acute heart failure. A
23 pooled analysis of the PROTECT and RELAX-AHF Studies. *JACC Heart Fail* 2015;**3**(5):395-403.
- 24 301. Dawson SJ, Makretsov N, Blows FM, et al. BCL2 in breast cancer: a favourable prognostic marker across
25 molecular subtypes and independent of adjuvant therapy received.[Erratum appears in *Br J Cancer*. 2010
26 Sep 28;103(7):1137]. *Br J Cancer* 2010;**103**(5):668-75.
- 27 302. Daya S, Gunby J. The effectiveness of allogeneic leukocyte immunization in unexplained primary recurrent
28 spontaneous abortion. *Am J Reprod Immunol* 1994;**32**(4):294-302.
- 29 303. Daya S, Gunby J, Porter F, et al. Critical analysis of intravenous immunoglobulin therapy for recurrent
30 miscarriage. *Hum Reprod Update* 1999;**5**(5):475-82.
- 31 304. de Backer Tine LM, Vander Stichele R, Lehert P, et al. Naftidrofuryl for intermittent claudication. *Cochrane*
32 *Database Syst Rev* 2008(2).
- 33 305. de Backer TLM, Vander Stichele R, Lehert P, et al. Naftidrofuryl for intermittent claudication. *Cochrane*
34 *Database Syst Rev* 2012;**12**:CD001368.
- 35 306. de Boer SPM, Barnes EH, Westerhout CM, et al. High-risk patients with ST-elevation myocardial infarction
36 derive greatest absolute benefit from primary percutaneous coronary intervention: results from the
37 Primary Coronary Angioplasty Trialist versus thrombolysis (PCAT)-2 collaboration. *Am Heart J*
38 2011;**161**(3):500-07.e1.
- 39 307. de Haas S, Delmar P, Bansal AT, et al. Genetic variability of VEGF pathway genes in six randomized phase III
40 trials assessing the addition of bevacizumab to standard therapy. *Angiogenesis* 2014;**17**(4):909-20.
- 41 308. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: A meta-analysis.
42 *Osteoporos Int* 2005;**16**(11):1330-38.
- 43 309. De LG, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT)
44 cooperation: An individual patient data meta-analysis. *Heart* 2008;**94**(12):1548-58.
- 45 310. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab
46 long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. *J Thromb Haemost*
47 2011;**9**(12):2361-70.
- 48 311. De Luca G, Dirksen MT, Kelbæk H, et al. Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled
49 patient-level meta-analysis of randomized trials. *J Thromb Thrombolysis* 2014.
- 50 312. De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled
51 patient-level meta-analysis of randomized trials. *Arch Intern Med* 2012;**172**(8):611-21; discussion 21-2.
- 52 313. De Luca G, Michael Gibson C, Bellandi F, et al. Benefits of pharmacological facilitation with glycoprotein IIb-
53 IIIa inhibitors in diabetic patients undergoing primary angioplasty for STEMI. A subanalysis of the EGYPT
54 cooperation. *J Thromb Thrombolysis* 2009;**28**(3):288-98.
- 55 314. De Luca G, Wirianta J, Lee JH, et al. Sirolimus-eluting versus paclitaxel-eluting stent in primary angioplasty: a
56 pooled patient-level meta-analysis of randomized trials. *J Thromb Thrombolysis* 2014.
- 57 315. De Morton NA, Jones CT, Keating JL, et al. The effect of exercise on outcomes for hospitalised older acute
58 medical patients: An individual patient data meta-analysis [1]. *Age Ageing* 2007;**36**(2):219-22.
- 59 316. de Oliveira IR, de Sena EP, Pereira EL, et al. Haloperidol blood levels and clinical outcome: a meta-analysis of
60 studies relevant to testing the therapeutic window hypothesis. *J Clin Pharm Ther* 1996;**21**(4):229-36.

- 1
2
3 317. de Waha A, Dibra A, Kufner S, et al. Long-term outcome after sirolimus-eluting stents versus bare metal
4 stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials.[Erratum
5 appears in Clin Res Cardiol. 2011 Sep;100(9):811-3]. Clin Res Cardiol 2011;**100**(7):561-70.
- 6 318. De Waha A, Stefanini GG, King LA, et al. Long-term outcomes of biodegradable polymer versus durable
7 polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3
8 randomized trials. Int J Cardiol 2013;**168**(6):5162-66.
- 9 319. de Weerd M, Greving JP, Hedblad B, et al. Prevalence of asymptomatic carotid artery stenosis in the general
10 population: an individual participant data meta-analysis. Stroke 2010;**41**(6):1294-7.
- 11 320. Degraeuwe PLJ, Beld MPA, Ashorn M, et al. Faecal calprotectin in suspected paediatric inflammatory bowel
12 disease. J Pediatr Gastroenterol Nutr 2015;**60**(3):339-46.
- 13 321. Dehghan N, McKee MD, Nauth A, et al. Surgical fixation of vancouver type B1 periprosthetic femur fractures:
14 A systematic review. J Orthop Trauma 2014.
- 15 322. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, The
16 Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997;**15**(15):1624-
17 30.
- 18 323. Delaney B, Ford AC, Forman D, et al. Initial management strategies for dyspepsia.[update of Cochrane
19 Database Syst Rev. 2003;(2):CD001961; PMID: 12804417]. [Review] [90 refs]. Cochrane Database Syst Rev
20 2005(4):CD001961-.
- 21 324. Delfino A, Petrelli N. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by
22 methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;**12**(5):960-69.
- 23 325. Demonty I, Ras RT, van der Knaap HCM, et al. The effect of plant sterols on serum triglyceride concentrations
24 is dependent on baseline concentrations: a pooled analysis of 12 randomised controlled trials. Eur J Nutr
25 2013;**52**(1):153-60.
- 26 326. Den Ruijter HM, Peters SAE, Anderson TJ, et al. Common carotid intima-media thickness measurements in
27 cardiovascular risk prediction: a meta-analysis.[Erratum appears in JAMA. 2013 Oct 23;310(16):1739].
28 JAMA 2012;**308**(8):796-803.
- 29 327. Denhaerynck K, Abraham I, Gourley G, et al. Validity testing of the Long-Term Medication Behavior Self-
30 Efficacy Scale. J Nurs Meas 2003;**11**(3):267-82.
- 31 328. Depla AL, Scharloo-Karels CH, de Jong MAA, et al. Treatment and prognostic factors of radiation-associated
32 angiosarcoma (RAAS) after primary breast cancer: A systematic review. Eur J Cancer 2014.
- 33 329. Desjardins PJ, Mehlich DR, Chang DJ, et al. The time to onset and overall analgesic efficacy of rofecoxib 50
34 mg: a meta-analysis of 13 randomized clinical trials. Clin J Pain 2005;**21**(3):241-50.
- 35 330. Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients.
36 Laryngoscope 2009;**119**(7):1412-6.
- 37 331. Devaiah AK, Andreoli S. Postmaneuver restrictions in benign paroxysmal positional vertigo: an individual
38 patient data meta-analysis. Otolaryngology - Head and Neck Surgery 2010;**142**(2):155-9.
- 39 332. Di Leo A, Desmedt C, Bartlett JMS, et al. HER2 and TOP2A as predictive markers for anthracycline-containing
40 chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient
41 data. Lancet Oncol 2011;**12**(12):1134-42.
- 42 333. Di Maio M, Chiodini P, Georgoulas V, et al. Meta-analysis of single-agent chemotherapy compared with
43 combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin
44 Oncol 2009;**27**(11):1836-43.
- 45 334. Di Maio M, Lama N, Morabito A, et al. Clinical assessment of patients with advanced non-small-cell lung
46 cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine
47 randomised trials. Eur J Cancer 2010;**46**(4):735-43.
- 48 335. Di MM, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once
49 every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung
50 cancer. J Clin Oncol 2007;**25**(11):1377-82.
- 51 336. Diener HC, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I
52 and II Trials. Stroke 2008;**39**(6):1751-8.
- 53 337. DiGiuro G, Ignjatovic D, Brogger J, et al. How accurate are published recurrence rates after rectal prolapse
54 surgery? A meta-analysis of individual patient data. Am J Surg 2006;**191**(6):773-78.
- 55 338. Diletti R, Garcia-Garcia HM, Bourantas C, et al. Impact of body mass index on long-term clinical outcomes
56 after second-generation drug eluting stent implantation: Insights from the international global
57 RESOLUTE program. Catheter Cardiovasc Interv 2015;**85**(6):952-58.
- 58 339. Dillon DG, Gurdasani D, Riha J, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan
59 Africa: A systematic review and meta-analysis. Int J Epidemiol 2013;**42**(6):1754-71.
- 60

- 1
2
3 340. Ding J, Wai KL, McGeechan K, et al. Retinal vascular caliber and the development of hypertension: a meta-
4 analysis of individual participant data. *Journal of Hypertension* 2014;**32**(2):207-15.
- 5 341. Dipart Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US
6 and Europe. *BMJ* 2010;**340**:b5463.
- 7 342. Direct Thrombin Inhibitor Trialists' Collaborative G. Direct thrombin inhibitors in acute coronary syndromes:
8 principal results of a meta-analysis based on individual patients' data.[see comment]. *Lancet*
9 2002;**359**(9303):294-302.
- 10 343. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of
11 randomised controlled trials. *Lancet* 2015;**385**(9979):1729-37.
- 12 344. Donadini MP, Ageno W, Antonucci E, et al. Prognostic significance of residual venous obstruction in patients
13 with treated unprovoked deep vein thrombosis: A patient-level meta-analysis. *Thromb Haemost*
14 2013;**111**(1):172-79.
- 15 345. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and
16 women: patient level meta-analysis. *BMJ* 2011;**342**:d813.
- 17 346. Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold,
18 and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous
19 thromboembolism. *Ann Intern Med* 2010;**153**(8):523-31.
- 20 347. Downing M, Lau F, Lesperance M, et al. Meta-analysis of survival prediction with Palliative Performance Scale.
21 *J Palliat Care* 2007;**23**(4):245-52.
- 22 348. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase
23 inhibitors versus tamoxifen. *J Clin Oncol* 2010;**28**(3):509-18.
- 24 349. Draube A, Klein-Gonzalez N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal
25 cell cancer: a systematic review and meta-analysis. *PLoS ONE [Electronic Resource]* 2011;**6**(4):e18801.
- 26 350. Dubreuil M, Greger S, LaValley M, et al. Improvement in wrist pain with ultrasound-guided glucocorticoid
27 injections: a meta-analysis of individual patient data. *Semin Arthritis Rheum* 2013;**42**(5):492-7.
- 28 351. Duparc S, Borghini-Fuhrer I, Craft CJ, et al. Safety and efficacy of pyronaridine-artesunate in uncomplicated
29 acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. *Malaria*
30 *Journal* 2013;**12**:70.
- 31 352. Durier C, Launay O, Meiffredy V, et al. Clinical safety of HIV lipopeptides used as vaccines in healthy
32 volunteers and HIV-infected adults. *AIDS* 2006;**20**(7):1039-49.
- 33 353. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the
34 randomised trials. *Lancet* 1996;**348**(9036):1189-96.
- 35 354. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the
36 randomised trials. *Lancet* 1998;**351**(9114):1451.
- 37 355. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of
38 the randomised trials. *Lancet* 1998;**352**(9132):930-42.
- 39 356. Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival
40 of radiotherapy for early breast cancer: an overview of the randomised trials. *Lancet*
41 2000;**355**(9217):1757-70.
- 42 357. Early Breast Cancer Trialists' Collaborative Group. Adjuvant chemotherapy in oestrogen-receptor-poor breast
43 cancer: patient-level meta-analysis of randomised trials. *Lancet* 2008;**371**(9606):29-40.
- 44 358. Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after mastectomy and axillary
45 surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient
46 data for 8135 women in 22 randomised trials. *Lancet* 2014.
- 47 359. Early Breast Cancer Trialists' Collaborative Group, Correa C, McGale P, et al. Overview of the randomized trials
48 of radiotherapy in ductal carcinoma in situ of the breast. *J Natl Cancer Inst Monogr* 2010;**2010**(41):162-
49 77.
- 50 360. Early Breast Cancer Trialists' Collaborative Group, Darby S, McGale P, et al. Effect of radiotherapy after breast-
51 conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual
52 patient data for 10,801 women in 17 randomised trials. *Lancet* 2011;**378**(9804):1707-16.
- 53 361. Early Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer
54 hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis
55 of randomised trials. *Lancet* 2011;**378**(9793):771-84.
- 56 362. Early Breast Cancer Trialists' Collaborative Group, Peto R, Davies C, et al. Comparisons between different
57 polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among
58 100,000 women in 123 randomised trials. *Lancet* 2012;**379**(9814):432-44.
- 59
60

- 1
2
3 363. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy
4 for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet*
5 2005;**365**(9472):1687-717.
- 6 364. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early
7 breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet* 2015.
- 8 365. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP. Systemic treatment of early breast cancer by
9 hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000
10 deaths among 75 000 women. *Lancet* 1992;**339**(8784):1-15.
- 11 366. Early Supported Discharge T. Services for reducing duration of hospital care for acute stroke patients.
12 *Cochrane Database Syst Rev* 2005(2).
- 13 367. Ebbing M, Bonna KH, Arnesen E, et al. Combined analyses and extended follow-up of two randomized
14 controlled homocysteine-lowering B-vitamin trials. *J Intern Med* 2010;**268**(4):367-82.
- 15 368. Ebrahim S, Montoya L, Truong W, et al. Effectiveness of cognitive behavioral therapy for depression in
16 patients receiving disability benefits: a systematic review and individual patient data meta-analysis. *PLoS*
17 *ONE [Electronic Resource]* 2012;**7**(11):e50202.
- 18 369. Eckmann C, Montravers P, Bassetti M, et al. Efficacy of tigecycline for the treatment of complicated intra-
19 abdominal infections in real-life clinical practice from five European observational studies. *J Antimicrob*
20 *Chemother* 2013;**68 Suppl 2**:ii25-35.
- 21 370. Edwards JE, McQuay HJ, Moore RA. Combination analgesic efficacy: individual patient data meta-analysis of
22 single-dose oral tramadol plus acetaminophen in acute postoperative pain.[see comment]. *J Pain*
23 *Symptom Manage* 2002;**23**(2):121-30.
- 24 371. Edwards JE, Moore RA, McQuay HJ. Rofecoxib for dysmenorrhoea: Meta-analysis using individual patient
25 data. *BMC Womens Health* 2004;**4**(5).
- 26 372. Egberts J, Brand R, Walti H, et al. Mortality, severe respiratory distress syndrome, and chronic lung disease of
27 the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant
28 Curosurf. *Pediatrics* 1997;**100**(1):e4-e4.
- 29 373. Eggeling T, Regitz-Zagrosek V, Zimmermann A, et al. Baseline severity but not gender modulates quantified
30 Crataegus extract effects in early heart failure--a pooled analysis of clinical trials. *Phytomedicine*
31 2011;**18**(14):1214-9.
- 32 374. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous
33 thromboembolism prevention trials. *Circulation* 2009;**120**(20):2006-11.
- 34 375. Eikendal ALM, Groenewegen KA, Anderson TJ, et al. Common carotid intima-media thickness relates to
35 cardiovascular events in adults aged <45 years. *Hypertension* 2015;**65**(4):707-13.
- 36 376. Eisen DP, Dean MM, Boermeester MA, et al. Low serum mannose-binding lectin level increases the risk of
37 death due to pneumococcal infection. *Clin Infect Dis* 2008;**47**(4):510-6.
- 38 377. Elkayam LU, Koehler JL, Sheldon TJ, et al. The influence of atrial and ventricular pacing on the incidence of
39 atrial fibrillation: a meta-analysis. *Pacing Clin Electrophysiol* 2011;**34**(12):1593-9.
- 40 378. Ellis AG, Reginster JY, Luo X, et al. Bazedoxifene versus Oral Bisphosphonates for the Prevention of
41 Nonvertebral Fractures in Postmenopausal Women with Osteoporosis at Higher Risk of Fracture: A
42 Network Meta-Analysis. *Value Health* 2014.
- 43 379. Ellis AG, Reginster J-Y, Luo X, et al. Indirect comparison of bazedoxifene vs oral bisphosphonates for the
44 prevention of vertebral fractures in postmenopausal osteoporotic women. *Curr Med Res Opin*
45 2014;**30**(8):1617-26.
- 46 380. Ellis G, Mant J, Langhorne P, et al. Stroke liaison workers for stroke patients and carers: an individual patient
47 data meta-analysis. *Cochrane Database Syst Rev* 2010(5):CD005066.
- 48 381. Elsayed EF, Sarnak MJ, Tighiouart H, et al. Waist-to-Hip Ratio, Body Mass Index, and Subsequent Kidney
49 Disease and Death. *Am J Kidney Dis* 2008;**52**(1):29-38.
- 50 382. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. *Arch Intern*
51 *Med* 2007;**167**(11):1130-36.
- 52 383. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of
53 intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient
54 data from randomised trials. *Lancet* 2014;**384**(9958):1929-35.
- 55 384. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-
56 analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One*
57 2012;**7**(1):e29849.
- 58 385. Emerging Risk Factors Collaboration. Adult height and the risk of cause-specific death and vascular morbidity
59 in 1 million people: individual participant meta-analysis. *Int J Epidemiol* 2012;**41**(5):1419-33.
- 60

- 1
2
3 386. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, et al. Glycated hemoglobin measurement
4 and prediction of cardiovascular disease. *JAMA* 2014;**311**(12):1225-33.
- 5 387. Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, et al. Association of Cardiometabolic
6 Multimorbidity With Mortality. *JAMA* 2015;**314**(1):52-60.
- 7 388. Emerging Risk Factors Collaboration, Seshasai SRK, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and
8 risk of cause-specific death.[Erratum appears in *N Engl J Med*. 2011 Mar 31;364(13):1281]. *N Engl J Med*
9 2011;**364**(9):829-41.
- 10 389. Empana JP, Tafflet M, Escolano S, et al. Predicting CHD risk in France: a pooled analysis of the D.E.S.I.R., Three
11 City, PRIME, and SU.VI.MAX studies. *Eur J Cardiovasc Prev Rehabil* 2011;**18**(2):175-85.
- 12 390. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, et al. Sex hormones and
13 risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data
14 from seven prospective studies. *Lancet Oncol* 2013;**14**(10):1009-19.
- 15 391. Engel LS, Taioli E, Pfeiffer R, et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and
16 bladder cancer: a HuGE review. *Am J Epidemiol* 2002;**156**(2):95-109.
- 17 392. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major
18 depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. *J Clin*
19 *Psychiatry* 2001;**62**(11):869-77.
- 20 393. Ervasti J, Kivimäki M, Dray-Spira R, et al. Psychosocial factors associated with work disability in men and
21 women with diabetes: A pooled analysis of three occupational cohort studies. *Diabet Med* 2015.
- 22 394. Escherich G, Richards S, Stork LC, et al. Meta-analysis of randomised trials comparing thiopurines in
23 childhood acute lymphoblastic leukaemia. *Leukemia* 2011;**25**(6):953-9.
- 24 395. EU Hernia Trialists Collaboration. Repair of groin hernia with synthetic mesh: meta-analysis of randomized
25 controlled trials. *Ann Surg* 2002;**235**(3):322-32.
- 26 396. Fabbri A, Magrini N, Bianchi G, et al. Overview of randomized clinical trials of oral branched-chain amino acid
27 treatment in chronic hepatic encephalopathy. *JPEN J Parenter Enteral Nutr* 1996;**20**(2):159-64.
- 28 397. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-
29 specific cardiovascular events in hypertension. *Hypertension* 2008;**51**(1):55-61.
- 30 398. Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: A systematic
31 review of the published evidence. *J Antimicrob Chemother* 2006;**58**(2):273-80.
- 32 399. Fallah A, Guyatt GH, Snead OC, 3rd, et al. Predictors of seizure outcomes in children with tuberous sclerosis
33 complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data
34 meta-analysis. *PLoS ONE [Electronic Resource]* 2013;**8**(2):e53565.
- 35 400. Farmer AJ, Perera R, Ward A, et al. Meta-analysis of individual patient data in randomised trials of self
36 monitoring of blood glucose in people with non-insulin treated type 2 diabetes. *BMJ* 2012;**344**:e486.
- 37 401. Fayad ZY, Semaan E, Fahoum B, et al. Aortic mural thrombus in the normal or minimally atherosclerotic aorta.
38 *Ann Vasc Surg* 2013;**27**(3):282-90.
- 39 402. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple
40 myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. *Blood*
41 2011;**118**(5):1239-47.
- 42 403. Fearon P, Langhorne P, Early Supported Discharge T. Services for reducing duration of hospital care for acute
43 stroke patients. *Cochrane Database Syst Rev* 2012;**9**:CD000443.
- 44 404. Feigin V, Parag V, Lawes CMM, et al. Smoking and elevated blood pressure are the most important risk
45 factors for subarachnoid hemorrhage in the Asia-Pacific region: An overview of 26 cohorts involving 306
46 620 participants. *Stroke* 2005;**36**(7):1360-65.
- 47 405. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT_{1B/1D} agonists) in migraine: detailed results
48 and methods of a meta-analysis of 53 trials. *Cephalalgia* 2002;**22**(8):633-58.
- 49 406. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT_{1B/1D} agonists) in acute migraine
50 treatment: a meta-analysis of 53 trials. *Lancet* 2001;**358**(9294):1668-75.
- 51 407. Ferreira ML, Ferreira PH, Henschke N, et al. Age does not modify the effects of treatment on pain in patients
52 with low back pain: Secondary analyses of randomized clinical trials. *European Journal of Pain (United*
53 *Kingdom)* 2014;**18**(7):932-38.
- 54 408. Feuer D, Broadley K. Systematic review and meta-analysis of corticosteroids for the resolution of malignant
55 bowel obstruction in advanced gynaecological and gastrointestinal cancers. *Ann Oncol* 1999;**10**(9):1035-
56 41.
- 57 409. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced
58 gynaecological and gastrointestinal cancer. [Review] [10 refs]. *Cochrane Database Syst Rev*
59 2000(2):CD001219.
60

- 1
2
3 410. Fillmore KM, Golding JM, Leino EV, et al. Relationships of measures of alcohol consumption with alcohol-
4 related problems in multiple studies: a research synthesis from the collaborative alcohol-related
5 longitudinal project. *Addiction* 1994;**89**(9):1143-56.
- 6 411. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european
7 countries: a systematic review and individual patient data meta-analysis. *Inflamm Bowel Dis*
8 2014;**20**(5):936-45.
- 9 412. Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery:
10 pooled analysis of two studies. *Thromb Haemost* 2007;**97**(6):931-7.
- 11 413. Fizazi K, Le MA, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with
12 castration-refractory prostate cancer: a meta-analysis of individual patient data. *Lancet Oncol*
13 2007;**8**(11):994-1000.
- 14 414. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-
15 ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial
16 Infarction Collaborative Group.[see comment]. *Lancet* 2000;**355**(9215):1575-81.
- 17 415. Flint A, Gregersen NT, Gluud LL, et al. Associations between postprandial insulin and blood glucose
18 responses, appetite sensations and energy intake in normal weight and overweight individuals: A meta-
19 analysis of test meal studies. *Br J Nutr* 2007;**98**(1):17-25.
- 20 416. Flossmann E, Rothwell PM. Prognosis of vertebrobasilar transient ischaemic attack and minor stroke. *Brain*
21 2003;**126**(Pt 9):1940-54.
- 22 417. Flynn JT, Schiffman J, Feuer W, et al. The therapy of amblyopia: an analysis of the results of amblyopia
23 therapy utilizing the pooled data of published studies. *Trans Am Ophthalmol Soc* 1998;**96**:431-53.
- 24 418. Foerster BR, Dwamena BA, Petrou M, et al. Diagnostic accuracy of diffusion tensor imaging in amyotrophic
25 lateral sclerosis: a systematic review and individual patient data meta-analysis. *Acad Radiol*
26 2013;**20**(9):1099-106.
- 27 419. Fokkema M, Vrijenhoek JEP, Den Ruijter HM, et al. Stenting versus endarterectomy for restenosis following
28 prior ipsilateral carotid endarterectomy: an individual patient data meta-analysis. *Ann Surg*
29 2015;**261**(3):598-604.
- 30 420. Fokkema ML, van der Meer P, Rao SV, et al. Safety and clinical outcome of erythropoiesis-stimulating agents
31 in patients with ST-elevation myocardial infarction: a meta-analysis of individual patient data. *Am Heart J*
32 2014;**168**(3):354-62.e2.
- 33 421. Fonseca V, Davidson J, Home P, et al. Starting insulin therapy with basal insulin analog or premix insulin
34 analog in T2DM: a pooled analysis of treat-to-target trials. *Curr Med Res Opin* 2010;**26**(7):1621-8.
- 35 422. Ford AC, Moayyedi P, Jarbol DE, et al. Meta-analysis: Helicobacter pylori 'test and treat' compared with
36 empirical acid suppression for managing dyspepsia. *Aliment Pharmacol Ther* 2008;**28**(5):534-44.
- 37 423. Ford AC, Qume M, Moayyedi P, et al. Helicobacter pylori "test and treat" or endoscopy for managing
38 dyspepsia: An individual patient data meta-analysis. *Gastroenterology* 2005;**128**(7):1838-44.
- 39 424. Forrester LT, Maayan N, Orrell M, et al. Aromatherapy for dementia. *Cochrane Database Syst Rev* 2014(2).
- 40 425. Foster NR, Renfro LA, Schild SE, et al. Multitrial Evaluation of Progression-Free Survival as a Surrogate End
41 Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. *J Thorac Oncol*
42 2015;**10**(7):1099-106.
- 43 426. Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-
44 level meta-analysis. *JAMA* 2010;**303**(1):47-53.
- 45 427. Fowkes G, Fowkes FGR, Murray GD, et al. Ankle brachial index combined with Framingham risk score to
46 predict cardiovascular events and mortality: A meta-analysis. *JAMA* 2008;**300**(2):197-208.
- 47 428. Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a
48 pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. *Eur Heart J*
49 2013;**34**(29):2263-70.
- 50 429. Franchini M, Mengoli C, Lippi G, et al. Immune tolerance with rituximab in congenital haemophilia with
51 inhibitors: a systematic literature review based on individual patients' analysis. [Review] [39 refs].
52 *Haemophilia* 2008;**14**(5):903-12.
- 53 430. Francis HP, Wade DT, Turner-Stokes L, et al. Does reducing spasticity translate into functional benefit? An
54 exploratory meta-analysis. *J Neurol Neurosurg Psychiatry* 2004;**75**(11):1547-51.
- 55 431. Franklin J, Paus Marcus D, Pluetschow A, et al. Chemotherapy, radiotherapy and combined modality for
56 Hodgkin's disease, with emphasis on second cancer risk. *Cochrane Database Syst Rev* 2005(4).
- 57 432. Fransson EI, Heikkila K, Nyberg ST, et al. Job strain as a risk factor for leisure-time physical inactivity: an
58 individual-participant meta-analysis of up to 170,000 men and women: the IPD-Work Consortium. *Am J*
59 *Epidemiol* 2012;**176**(12):1078-89.
- 60

- 1
2
3 433. Fransson EI, Nyberg ST, Heikkila K, et al. Comparison of alternative versions of the job demand-control scales
4 in 17 European cohort studies: the IPD-Work consortium. *BMC Public Health* 2012;**12**:62.
- 5 434. Fransson EI, Nyberg ST, Heikkila K, et al. Job strain and the risk of stroke: an individual-participant data meta-
6 analysis. *Stroke* 2015;**46**(2):557-9.
- 7 435. Franzosi M, Santoro E, Zuanetti G, et al. Indications for ACE inhibitors in the early treatment of acute
8 myocardial infarction-Systematic overview of individual data from 100,000 patients in randomized trials.
9 *Circulation* 1998;**97**(22):2202-12.
- 10 436. Freeman R, Emir B, Parsons B. Predictors of placebo response in peripheral neuropathic pain: Insights from
11 pregabalin clinical trials. *J Pain Res* 2015;**8**:257-68.
- 12 437. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis.
13 *Kidney Int* 2001;**59**(1):260-9.
- 14 438. Frosch K-H, Preiss A, Heider S, et al. Primary ligament sutures as a treatment option of knee dislocations: a
15 meta-analysis. *Knee Surgery, Sports Traumatology, Arthroscopy* 2013;**21**(7):1502-9.
- 16 439. Fruh M, Rolland E, Pignon J-P, et al. Pooled analysis of the effect of age on adjuvant cisplatin-based
17 chemotherapy for completely resected non-small-cell lung cancer. *J Clin Oncol* 2008;**26**(21):3573-81.
- 18 440. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic
19 protein-2 in spine fusion: a systematic review and meta-analysis. *Ann Intern Med* 2013;**158**(12):890-902.
- 20 441. Furst DE, Anderson W. Differential effects of diclofenac and aspirin on serum glutamic oxaloacetic
21 transaminase elevations in patients with rheumatoid arthritis and osteoarthritis. *Arthritis Rheum*
22 1993;**36**(6):804-10.
- 23 442. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke
24 risk stratification in patients taking aspirin. *Circulation* 2004;**110**(16):2287-92.
- 25 443. Galiatsatos P, Shrier I, Lamoureux E, et al. Meta-analysis of outcome of cytomegalovirus colitis in
26 immunocompetent hosts. [Review] [41 refs]. *Dig Dis Sci* 2005;**50**(4):609-16.
- 27 444. Galsky MD, Krege S, Lin CC, et al. Cisplatin-based combination chemotherapy in septuagenarians with
28 metastatic urothelial cancer. *Urologic Oncology: Seminars and Original Investigations* 2014;**32**(1):30.e15-
29 30.e21.
- 30 445. Gamble C, Williamson PR, Chadwick DW, et al. A meta-analysis of individual patient responses to lamotrigine
31 or carbamazepine monotherapy. *Neurology* 2006;**66**(9):1310-17.
- 32 446. Gans SL, Ateama JJ, Stoker J, et al. C-reactive protein and white blood cell count as triage test between urgent
33 and nonurgent conditions in 2961 patients with acute abdominal pain. *Medicine* 2015;**94**(9):e569.
- 34 447. Garcia-Berrococo T, Giralt D, Bustamante A, et al. B-type natriuretic peptides and mortality after stroke: a
35 systematic review and meta-analysis. *Neurology* 2013;**81**(23):1976-85.
- 36 448. Gardner MP, Lightman S, Sayer AA, et al. Dysregulation of the hypothalamic pituitary adrenal (HPA) axis and
37 physical performance at older ages: an individual participant meta-analysis. *Psychoneuroendocrinology*
38 2013;**38**(1):40-9.
- 39 449. Gasowski J, Fagard RH, Staessen JA, et al. Pulsatile blood pressure component as predictor of mortality in
40 hypertension: a meta-analysis of clinical trial control groups. *Journal of Hypertension* 2002;**20**(1):145-51.
- 41 450. Gasowski J, Wilkins A, Drzewoski J, et al. Short-term antihypertensive efficacy of perindopril according to
42 clinical profile of 3,188 patients: A meta-analysis. *Cardiol J* 2010;**17**(3):259-66.
- 43 451. Gastric Group, Oba K, Paoletti X, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an
44 individual-patient-data meta-analysis. *Eur J Cancer* 2013;**49**(7):1565-77.
- 45 452. Gastric Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a
46 meta-analysis. *JAMA* 2010;**303**(17):1729-37.
- 47 453. Gauthier S, Proaño JV, Jia J, et al. Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of
48 Randomized Controlled Clinical Trials. *Dement Geriatr Cogn Disord* 2015;**39**(5/6):332-47.
- 49 454. Gaynor JW, Stopp C, Wypij D, et al. Neurodevelopmental outcomes after cardiac surgery in infancy. *Pediatrics*
50 2015;**135**(5):816-25.
- 51 455. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-
52 analysis and meta-regression of individual patient data from five randomised trials. [Review] [27 refs]. *Br*
53 *J Psychiatry* 2009;**194**(1):4-9.
- 54 456. Geddes JR, Verdoux H, Takei N, et al. Schizophrenia and complications of pregnancy and labor: an individual
55 patient data meta-analysis. *Schizophr Bull* 1999;**25**(3):413-23.
- 56 457. Geersing GJ, Zuithoff NPA, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically
57 important subgroups: individual patient data meta-analysis. *BMJ* 2014;**348**:g1340.
- 58 458. Gencer B, Collet T-H, Virgini V, et al. Subclinical thyroid dysfunction and cardiovascular outcomes among
59 prospective cohort studies. *Endocrine, Metabolic and Immune Disorders Drug Targets* 2013;**13**(1):4-12.
- 60

- 1
2
3 459. Gencer B, Collet T-H, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an
4 individual participant data analysis from 6 prospective cohorts. *Circulation* 2012;**126**(9):1040-9.
- 5 460. Genders TSS, Steyerberg EW, Hunink MGM, et al. Prediction model to estimate presence of coronary artery
6 disease: retrospective pooled analysis of existing cohorts. *BMJ* 2012;**344**:e3485.
- 7 461. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: A
8 retrospective analysis based on individual patient data from six consecutive studies. *Cancer*
9 2005;**104**(8):1742-50.
- 10 462. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in
11 people living with HIV in resource-constrained settings: individual participant data meta-analysis of
12 observational studies. *PLoS Medicine / Public Library of Science* 2011;**8**(1):e1000391.
- 13 463. Gevers TJG, Inthout J, Caroli A, et al. Young women with polycystic liver disease respond best to somatostatin
14 analogues: a pooled analysis of individual patient data. *Gastroenterology* 2013;**145**(2):357-65.e1-2.
- 15 464. Ghio S, Temporelli PL, Marsan NA, et al. Prognostic implications of left ventricular dilation in patients with
16 nonischemic heart failure: interactions with restrictive filling pattern and mitral regurgitation. *Congest*
17 *Heart Fail* 2012;**18**(4):198-204.
- 18 465. Giallauria F, Vigorito C, Piepoli MF, et al. Effects of cardiac contractility modulation by non-excitatory
19 electrical stimulation on exercise capacity and quality of life: an individual patient's data meta-analysis of
20 randomized controlled trials. *Int J Cardiol* 2014;**175**(2):352-7.
- 21 466. Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level
22 outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. *Arch*
23 *Gen Psychiatry* 2012;**69**(6):572-9.
- 24 467. Gidal BE, Baltes E, Otoul C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic
25 drugs: a pooled analysis of data from randomized clinical trials. *Epilepsy Res* 2005;**64**(1-2):1-11.
- 26 468. Giebel S, Thomas X, Hallbook H, et al. The prophylactic use of granulocyte-colony stimulating factor during
27 remission induction is associated with increased leukaemia-free survival of adults with acute
28 lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. *Eur J Cancer*
29 2012;**48**(3):360-7.
- 30 469. Gill PJ, Ashdown HF, Wang K, et al. Identification of children at risk of influenza-related complications in
31 primary and ambulatory care: A systematic review and meta-analysis. *Lancet Respir Med* 2015;**3**(2):139-
32 49.
- 33 470. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III
34 colon cancer: who benefits and by how much? *J Clin Oncol* 2004;**22**(10):1797-806.
- 35 471. Giorgino FL, Egan CG. Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm
36 labour: a systematic review of previous literature. *Arzneimittelforschung* 2010;**60**(7):415-20.
- 37 472. Giovanni B, Michelle E, Letizia C, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-
38 analysis of individual patient data from five studies. *Leuk Lymphoma* 2002;**43**(12):2301-7.
- 39 473. Gluud LL, Dam G, Borre M, et al. Oral branched-chain amino acids have a beneficial effect on manifestations
40 of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. *J*
41 *Nutr* 2013;**143**(8):1263-8.
- 42 474. Gluud LL, Knop FK, Vilsboll T. Effects of lixisenatide on elevated liver transaminases: systematic review with
43 individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes.
44 *BMJ Open* 2014;**4**(12):e005325.
- 45 475. Gnanenthiran SR, Adie S, Harris IA. Nonoperative versus operative treatment for thoracolumbar burst
46 fractures without neurologic deficit: a meta-analysis. *Clin Orthop Relat Res* 2012;**470**(2):567-77.
- 47 476. Goetz CG, Wu J, McDermott MP, et al. Placebo response in Parkinson's disease: Comparisons among 11
48 trials covering medical and surgical interventions. *Mov Disord* 2008;**23**(5):690-99.
- 49 477. Gomes M, Ribeiro I, Warsame M, et al. Rectal artemisinins for malaria: A review of efficacy and safety from
50 individual patient data in clinical studies. *BMC Infect Dis* 2008;**8**(39):-.
- 51 478. Gonik NJ, Cheng J, Lesser M, et al. Patient selection in congenital pyriform aperture stenosis repair - 14 year
52 experience and systematic review of literature. *Int J Pediatr Otorhinolaryngol* 2015;**79**(2):235-39.
- 53 479. Goodacre S, Stevens JW, Pandor A, et al. Prehospital noninvasive ventilation for acute respiratory failure:
54 systematic review, network meta-analysis, and individual patient data meta-analysis. *Acad Emerg Med*
55 2014;**21**(9):960-70.
- 56 480. Gordon CE, Uhlig K, Lau J, et al. Interferon for hepatitis C virus in hemodialysis--an individual patient meta-
57 analysis of factors associated with sustained virological response. *Clinical Journal of The American*
58 *Society of Nephrology: CJASN* 2009;**4**(9):1449-58.
- 59 481. Gorman JD, David-Vaudey E, Pai M, et al. Particular HLA-DRB1 shared epitope genotypes are strongly
60 associated with rheumatoid vasculitis. *Arthritis Rheum* 2004;**50**(11):3476-84.

- 1
- 2
- 3 482. Gorman JD, David-Vaudey E, Pai M, et al. Lack of association of the HLA-DRB1 shared epitope with
- 4 rheumatoid nodules: an individual patient data meta-analysis of 3,272 Caucasian patients with
- 5 rheumatoid arthritis. *Arthritis Rheum* 2004;**50**(3):753-62.
- 6 483. Gorman JD, Lum RF, Chen JJ, et al. Impact of shared epitope genotype and ethnicity on erosive disease: a
- 7 meta-analysis of 3,240 rheumatoid arthritis patients. *Arthritis Rheum* 2004;**50**(2):400-12.
- 8 484. Gouw SC, Van Den Berg HM, Le CS, et al. Treatment characteristics and the risk of inhibitor development: A
- 9 multicenter cohort study among previously untreated patients with severe hemophilia A. *J Thromb*
- 10 *Haemost* 2007;**5**(7):1383-90.
- 11 485. Grant AM, Collaboration EHT. Laparoscopic versus open groin hernia repair: meta-analysis of randomised
- 12 trials based on individual patient data. *Hernia* 2002;**6**(1):2-10.
- 13 486. Greb A, Bohlius J, Schiefer D, et al. High-dose chemotherapy with autologous stem cell transplantation in the
- 14 first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. *Cochrane Database Syst Rev*
- 15 2008(1):-.
- 16 487. Green SM, Roback MG, Krauss B, et al. Predictors of emesis and recovery agitation with emergency
- 17 department ketamine sedation: an individual-patient data meta-analysis of 8,282 children. *Ann Emerg*
- 18 *Med* 2009;**54**(2):171-80.e1-4.
- 19 488. Green SM, Roback MG, Krauss B, et al. Predictors of airway and respiratory adverse events with ketamine
- 20 sedation in the emergency department: an individual-patient data meta-analysis of 8,282 children. *Ann*
- 21 *Emerg Med* 2009;**54**(2):158-68.e1-4.
- 22 489. Greenland S, Sheppard AR, Kaune WT, et al. A pooled analysis of magnetic fields, wire codes, and childhood
- 23 leukemia. *Epidemiology* 2000;**11**(6):624-34.
- 24 490. Gregson BA, Broderick JP, Auer LM, et al. Individual patient data subgroup meta-analysis of surgery for
- 25 spontaneous supratentorial intracerebral hemorrhage.[Erratum appears in *Stroke*. 2013 Jul;44(7):e82].
- 26 *Stroke* 2012;**43**(6):1496-504.
- 27 491. Greving JP, Wermer MJH, Brown RD, Jr., et al. Development of the PHASES score for prediction of risk of
- 28 rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. *Lancet Neurol*
- 29 2014;**13**(1):59-66.
- 30 492. Griffith LE, Shannon HS, Wells RP, et al. Individual participant data meta-analysis of mechanical workplace
- 31 risk factors and low back pain. *Am J Public Health* 2012;**102**(2):309-18.
- 32 493. Grines C, Patel A, Zijlstra F, et al. Primary coronary angioplasty compared with intravenous thrombolytic
- 33 therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from
- 34 randomized trials. [Review] [35 refs]. *Am Heart J* 2003;**145**(1):47-57.
- 35 494. Groen RJM, Middel B, Meilof JF, et al. Operative treatment of anterior thoracic spinal cord herniation: three
- 36 new cases and an individual patient data meta-analysis of 126 case reports. *Neurosurgery* 2009;**64**(3
- 37 *Suppl*):ons145-59; discussion ons59-60.
- 38 495. Groeneveld E, Broeze KA, Lambers MJ, et al. Is aspirin effective in women undergoing in vitro fertilization
- 39 (IVF)? Results from an individual patient data meta-analysis (IPD MA). *Hum Reprod Update*
- 40 2011;**17**(4):501-9.
- 41 496. Groeneveld E, Lambers MJ, Lambalk CB, et al. Preconceptional low-dose aspirin for the prevention of
- 42 hypertensive pregnancy complications and preterm delivery after IVF: a meta-analysis with individual
- 43 patient data. *Hum Reprod* 2013;**28**(6):1480-8.
- 44 497. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled,
- 45 double-blind, comparative studies with baclofen and diazepam. *Adv Ther* 1998;**15**(4):241-51.
- 46 498. Gruss HJ, Pediconi C, Jacobs A. Meta-analysis for cardiovascular effects of NRL001 after rectal application in
- 47 healthy volunteers. *Colorectal Dis* 2014;**16**(S1):51-58.
- 48 499. Gueyffier F, Boissel J-P, Pocock S, et al. Identification of risk factors in hypertensive patients contribution of
- 49 randomized controlled trials through an individual patient database. *Circulation* 1999;**100**(18):e88-e94.
- 50 500. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes
- 51 in women and men. A meta-analysis of individual patient data from randomized, controlled trials. *The*
- 52 *INDANA Investigators*. *Ann Intern Med* 1997;**126**(10):761-7.
- 53 501. Guirao X, Sanchez Garcia M, Bassetti M, et al. Safety and tolerability of tigecycline for the treatment of
- 54 complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European
- 55 observational studies. *J Antimicrob Chemother* 2013;**68** *Suppl 2*:ii37-44.
- 56 502. Gulli G, Marquardt L, Rothwell PM, et al. Stroke risk after posterior circulation stroke/transient ischemic attack
- 57 and its relationship to site of vertebrobasilar stenosis: pooled data analysis from prospective studies.
- 58 *Stroke* 2013;**44**(3):598-604.
- 59
- 60

- 1
2
3 503. Gupta V, Richards S, Rowe J, et al. Allogeneic, but not autologous, hematopoietic cell transplantation
4 improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an
5 individual patient data meta-analysis. *Blood* 2013;**121**(2):339-50.
- 6 504. Guthmann J-P, Pinoges L, Checchi F, et al. Methodological issues in the assessment of antimalarial drug
7 treatment: Analysis of 13 studies in eight African countries from 2001 to 2004. *Antimicrob Agents*
8 *Chemother* 2006;**50**(11):3734-39.
- 9 505. Gyongyosi M, Wojakowski W, Lemarchand P, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in
10 patients with acute myocardial infarction based on individual patient data. *Circ Res* 2015;**116**(8):1346-60.
- 11 506. Ha TC, Spreafico F, Graf N, et al. An international strategy to determine the role of high dose therapy in
12 recurrent Wilms' tumour. *Eur J Cancer* 2013;**49**(1):194-210.
- 13 507. Haasova M, Warren FC, Ussher M, et al. The acute effects of physical activity on cigarette cravings: systematic
14 review and meta-analysis with individual participant data. *Addiction* 2013;**108**(1):26-37.
- 15 508. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of
16 ATLANTIS, ECASS, and NINDS rt-PA stroke trials. *Lancet* 2004;**363**(9411):768-74.
- 17 509. Halkes PHA, Gray LJ, Bath PMW, et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention
18 after TIA or stroke: A meta-analysis by risk. *Journal of Neurology, Neurosurgery and Psychiatry*
19 2008;**79**(11):1218-23.
- 20 510. Hallahan B, Newell J, Soares JC, et al. Structural magnetic resonance imaging in bipolar disorder: an
21 international collaborative mega-analysis of individual adult patient data. *Biol Psychiatry* 2011;**69**(4):326-
22 35.
- 23 511. Haller DG, O'Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant treatment
24 outcomes for stage III colon cancer: A pooled analysis of individual patient data from four randomized,
25 controlled trials. *Ann Oncol* 2015;**26**(4):715-24.
- 26 512. Halpin D, Menjoge S, Viel K. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations
27 and related hospitalisations. *Prim Care Respir J* 2009;**18**(2):106-13.
- 28 513. Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-
29 uracil in non-small-cell lung cancer. *J Clin Oncol* 2005;**23**(22):4999-5006.
- 30 514. Hamajima N, Hirose K, Tajima K, et al. Alcohol, tobacco and breast cancer--collaborative reanalysis of
31 individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067
32 women without the disease. *Br J Cancer* 2002;**87**(11):1234-45.
- 33 515. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. *Arch*
34 *Gen Psychiatry* 2006;**63**(3):332-39.
- 35 516. Hansen RA, Song L, Moore CG, et al. Effect of ropinirole on sleep outcomes in patients with restless legs
36 syndrome: meta-analysis of pooled individual patient data from randomized controlled trials.
37 *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* 2009;**29**(3):255-62.
- 38 517. Harada E, Schacht A, Koyama T, et al. Efficacy comparison of duloxetine and SSRIs at doses approved in
39 Japan. *Neuropsychiatr Dis Treat* 2015;**11**:115-23.
- 40 518. Harris R, Whittemore AS, Itnyre J. Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12
41 US Case-Control Studies III. Epithelial Tumors of Low Malignant Potential in White Women. *Am J*
42 *Epidemiol* 1992;**136**(10):1204-11.
- 43 519. Harris R, Wilson-Barnett J, Griffiths P. Effectiveness of nursing-led inpatient care for patients with post-acute
44 health care needs: Secondary data analysis from a programme of randomized controlled trials. *J Eval Clin*
45 *Pract* 2007;**13**(2):198-205.
- 46 520. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in
47 women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. *Curr Med Res*
48 *Opin* 2008;**24**(1):237-45.
- 49 521. Hasan B, Greillier L, Pallis A, et al. Progression free survival rate at 9 and 18 weeks predict overall survival in
50 patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European
51 Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent
52 study validation. *Eur J Cancer* 2014;**50**(16):2771-82.
- 53 522. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic
54 myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic
55 Factors Project Group. *Journal of the National Cancer Institute: JNCI* 1998;**90**(11):850-58.
- 56 523. Hasford J, Pfirrmann M, Shepherd P, et al. The impact of the combination of baseline risk group and
57 cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon-
58 alpha. *Haematologica* 2005;**90**(3):335-40.
- 59 524. Hassan C, Zullo A, De F, V, et al. Systematic review: Endoscopic dilatation in Crohn's disease. *Aliment*
60 *Pharmacol Ther* 2007;**26**(11-12):1457-64.

- 1
2
3 525. Hassell MECJ, Hildick-Smith D, Durand E, et al. Antiplatelet therapy following transcatheter aortic valve
4 implantation. *Heart* 2015;**101**(14):1118-25.
- 5 526. He W, Chen F, Dalm B, et al. Metastatic involvement of the pituitary gland: a systematic review with pooled
6 individual patient data analysis. *Pituitary* 2014:1-10.
- 7 527. He W, Gandhi CD, Quinn J, et al. True aneurysms of the posterior communicating artery: a systematic review
8 and meta-analysis of individual patient data. *World Neurosurg* 2011;**75**(1):64-72; discussion 49.
- 9 528. Healey JS, Hallstrom AP, Kuck K-H, et al. Role of the implantable defibrillator among elderly patients with a
10 history of life-threatening ventricular arrhythmias. *Eur Heart J* 2007;**28**(14):1746-49.
- 11 529. Healey JS, Toff WD, Lamas GA, et al. Cardiovascular outcomes with atrial-based pacing compared with
12 ventricular pacing: Meta-analysis of randomized trials, using individual patient data. *Circulation*
13 2006;**114**(1):11-17.
- 14 530. Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary
15 data. *Chest* 2000;**117**(1):87-95.
- 16 531. Heffner JE, Sahn SA, Brown LK. Multilevel likelihood ratios for identifying exudative pleural effusions(*). *Chest*
17 2002;**121**(6):1916-20.
- 18 532. Heikkilä K, Fransson EI, Nyberg ST, et al. Job strain and health-related lifestyle: Findings from an individual-
19 participant meta-analysis of 118,000 working adults. *Am J Public Health* 2013;**103**(11):2090-97.
- 20 533. Heikkilä K, Madsen IEH, Nyberg ST, et al. Job strain and the risk of inflammatory bowel diseases: Individual-
21 participant meta-analysis of 95 000 men and women. *PLoS ONE [Electronic Resource]* 2014;**9**(2).
- 22 534. Heikkilä K, Madsen IEH, Nyberg ST, et al. Job strain and the risk of severe asthma exacerbations: A meta-
23 analysis of individual-participant data from 100 000 European men and women. *Allergy: European*
24 *Journal of Allergy and Clinical Immunology* 2014;**69**(6):775-83.
- 25 535. Heikkilä K, Nyberg ST, Fransson EI, et al. Job strain and alcohol intake: a collaborative meta-analysis of
26 individual-participant data from 140,000 men and women. *PLoS ONE [Electronic Resource]*
27 2012;**7**(7):e40101.
- 28 536. Heikkilä K, Nyberg ST, Fransson EI, et al. Job strain and tobacco smoking: an individual-participant data
29 meta-analysis of 166,130 adults in 15 European studies. *PLoS ONE [Electronic Resource]*
30 2012;**7**(7):e35463.
- 31 537. Heikkilä K, Nyberg ST, Theorell T, et al. Work stress and risk of cancer: meta-analysis of 5700 incident cancer
32 events in 116,000 European men and women. *BMJ* 2013;**346**:f165.
- 33 538. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from
34 gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. *BMC Cancer*
35 2008;**8**:82.
- 36 539. Heinemann V, Labianca R, Hinke A, et al. Increased survival using platinum analog combined with
37 gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of
38 two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. *Ann*
39 *Oncol* 2007;**18**(10):1652-59.
- 40 540. Helicobacter and Cancer Collaborative G. Gastric cancer and Helicobacter pylori: a combined analysis of 12
41 case control studies nested within prospective cohorts. [Review] [36 refs]. *Gut* 2001;**49**(3):347-53.
- 42 541. Heller S, Bode B, Kozlovski P, et al. Meta-analysis of insulin aspart versus regular human insulin used in a
43 basal-bolus regimen for the treatment of diabetes mellitus. *J Diabetes* 2013;**5**(4):482-91.
- 44 542. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-
45 analysis of individual patient data. *Lancet* 2012;**379**(9813):322-34.
- 46 543. Hicks LK, Cheung MC, Ding K, et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled
47 analysis of National Cancer Institute of Canada Clinical Trials Group trials. *Cancer* 2009;**115**(23):5516-25.
- 48 544. Higgins TS, Thorp B, Rawlings BA, et al. Outcome results of endoscopic vs craniofacial resection of sinonasal
49 malignancies: a systematic review and pooled-data analysis. *Int Forum Allergy Rhinol* 2011;**1**(4):255-61.
- 50 545. Hill CJ, Maxwell AP, Cardwell CR, et al. Glycated hemoglobin and risk of death in diabetic patients treated
51 with hemodialysis: a meta-analysis. *Am J Kidney Dis* 2014;**63**(1):84-94.
- 52 546. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy
53 in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from
54 randomised controlled trials. *Lancet Oncol* 2014;**15**(9):986-96.
- 55 547. HIV SURROGATE MARKER COLLABORATIVE GROUP. Human immunodeficiency virus type 1 RNA level and
56 CD4 count as prognostic markers and surrogate end points: A meta-analysis. *AIDS Res Hum Retroviruses*
57 2000;**16**(12):1123-33.
- 58 548. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous
59 coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten
60 randomised trials. *Lancet* 2009;**373**(9670):1190-7.

- 1
2
3 549. Hollaar G, Gooszen H, Post S, et al. Perioperative Blood Transfusion Does Not Prevent Recurrence in Crohn's
4 Disease: A Pooled Analysis. *J Clin Gastroenterol* 1995;**21**(2):134-38.
- 5 550. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma:
6 an individual patient data meta-analysis. *J Clin Oncol* 2012;**30**(13):1541-9.
- 7 551. Holloway KL, Baron MS, Brown R, et al. Deep brain stimulation for dystonia: a meta-analysis.
8 *Neuromodulation* 2006;**9**(4):253-61.
- 9 552. Holmes JM, Lazar EL, Melia BM, et al. Effect of age on response to amblyopia treatment in children. *Arch*
10 *Ophthalmol* 2011;**129**(11):1451-7.
- 11 553. Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian
12 randomisation analysis based on individual participant data. *BMJ* 2014;**349**:g4164.
- 13 554. Holmes MV, Frikke-Schmidt R, Melis D, et al. A systematic review and meta-analysis of 130,000 individuals
14 shows smoking does not modify the association of APOE genotype on risk of coronary heart disease.
15 *Atherosclerosis* 2014;**237**(1):5-12.
- 16 555. Holty JE, Guilleminault C. Maxillomandibular advancement for the treatment of obstructive sleep apnea: a
17 systematic review and meta-analysis. *Sleep Med Rev* 2010;**14**(5):287-97.
- 18 556. Holty J-EC, Gould MK, Meinke L, et al. Tuberculosis in liver transplant recipients: a systematic review and
19 meta-analysis of individual patient data. *Liver Transpl* 2009;**15**(8):894-906.
- 20 557. Holzer M, Bernard SA, Hachimi-Idrissi S, et al. Hypothermia for neuroprotection after cardiac arrest:
21 systematic review and individual patient data meta-analysis. [Review] [53 refs]. *Crit Care Med*
22 2005;**33**(2):414-8.
- 23 558. Home PD, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of
24 hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. *Diabetes, Obesity*
25 *and Metabolism* 2010;**12**(9):772-9.
- 26 559. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based
27 supplements: meta-analysis of randomised trials. *BMJ* 1998;**316**(7135):894-98.
- 28 560. Homocysteine Studies C. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.[see
29 comment]. *JAMA* 2002;**288**(16):2015-22.
- 30 561. Horn J, Naylor AR, Laman DM, et al. Identification of patients at risk for ischaemic cerebral complications
31 after carotid endarterectomy with TCD monitoring. *Eur J Vasc Endovasc Surg* 2005;**30**(3):270-74.
- 32 562. Houben RMGJ, Crampin AC, Ndhlovu R, et al. Human immunodeficiency virus associated tuberculosis more
33 often due to recent infection than reactivation of latent infection. *Int J Tuberc Lung Dis* 2011;**15**(1):24-31.
- 34 563. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of preoperative magnetic
35 resonance imaging and breast cancer recurrence. *J Clin Oncol* 2014;**32**(5):392-401.
- 36 564. Howell A, Ribeiro G, Swindell R. Effects of radiotherapy and surgery in early breast cancer. An overview of the
37 randomized trials. Early Breast Cancer Trialists' Collaborative Group. *N Engl J Med* 1995.
- 38 565. Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric
39 junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. *Int J Epidemiol*
40 2012;**41**(6):1706-18.
- 41 566. Huang J, van Gelder JM. The probability of sudden death from rupture of intracranial aneurysms: a meta-
42 analysis. *Neurosurgery* 2002;**51**(5):1101-5; discussion 05-7.
- 43 567. Hubbard J, Thomas DM, Yothers G, et al. Benefits and adverse events in younger versus older patients
44 receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints
45 data set. *J Clin Oncol* 2012;**30**(19):2334-9.
- 46 568. Hughes MD, Daniels MJ, Fischl MA, et al. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-
47 analysis of studies of the AIDS Clinical Trials Group. *AIDS* 1998;**12**(14):1823-32.
- 48 569. Huh D, Mun EY, Larimer ME, et al. Brief motivational interventions for college student drinking may not be as
49 powerful as we think: An individual participant-level data meta-analysis. *Alcoholism: Clinical and*
50 *Experimental Research* 2015;**39**(5):919-31.
- 51 570. Hukkelhoven CW, Steyerberg EW, Rampen AJ, et al. Patient age and outcome following severe traumatic
52 brain injury: an analysis of 5600 patients. *J Neurosurg* 2003;**99**(4):666-73.
- 53 571. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus
54 bevacizumab: a pooled analysis of patients in randomized phase II and III studies. *J Clin Oncol*
55 2011;**29**(13):1757-64.
- 56 572. Hurwitz HI, Tebbutt NC, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal
57 cancer: Pooled analysis from seven randomized controlled trials. *Oncologist* 2013;**18**(9):1004-12.
- 58 573. Husain Q, Kanumuri VV, Svider PF, et al. Sinonasal adenoid cystic carcinoma: systematic review of survival
59 and treatment strategies. *Otolaryngology - Head and Neck Surgery* 2013;**148**(1):29-39.
- 60

- 1
2
3 574. Huth C, Heid IM, Vollmert C, et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of
4 individual participants' data from 21 studies. *Diabetes* 2006;**55**(10):2915-21.
- 5 575. Huth C, Illig T, Herder C, et al. Joint analysis of individual participants' data from 17 studies on the association
6 of the IL6 variant -174G>C with circulating glucose levels, interleukin-6 levels, and body mass index. *Ann*
7 *Med* 2009;**41**(2):128-38.
- 8 576. Huxley R. The impact of cardiovascular risk factors on the age-related excess risk of coronary heart disease.
9 *Int J Epidemiol* 2006;**35**(4):1025-33.
- 10 577. Huxley R, Collaboration APCS. The impact of modifiable risk factors on mortality from prostate cancer in
11 populations of the Asia-Pacific region. *Asian Pac J Cancer Prev* 2007;**8**(2):199-205.
- 12 578. Huxley R, Okayama A, Ueshima H, et al. Does sex matter in the associations between classic risk factors and
13 fatal coronary heart disease in populations from the Asia-Pacific region? *J Womens Health*
14 2005;**14**(9):820-27.
- 15 579. Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of high-density lipoprotein cholesterol are associated
16 with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23
17 studies in the Asia-Pacific region. *Circulation* 2011;**124**(19):2056-64.
- 18 580. Huxley RR, Barzi F, Woo J, et al. A comparison of risk factors for mortality from heart failure in Asian and non-
19 Asian populations: an overview of individual participant data from 32 prospective cohorts from the Asia-
20 Pacific Region. *BMC Cardiovasc Disord* 2014;**14**:61.
- 21 581. Hyun KK, Huxley RR, Arima H, et al. A comparative analysis of risk factors and stroke risk for Asian and non-
22 Asian men: The Asia Pacific Cohort Studies Collaboration. *Int J Stroke* 2013;**8**(8):606-11.
- 23 582. Iijima R, Byrne RA, Dibra A, et al. Drug-eluting stents versus bare-metal stents in diabetic patients with ST-
24 segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven
25 randomized trials. *Revista Espanola de Cardiologia* 2009;**62**(4):354-64.
- 26 583. Inglis SC, Bebbchuk J, Al-Suhaim SA, et al. Peripheral artery disease and outcomes after myocardial infarction:
27 an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and
28 VALIANT. *Int J Cardiol* 2013;**168**(2):1094-101.
- 29 584. Inker LA, Levey AS, Pandya K, et al. Early Change in Proteinuria as a Surrogate End Point for Kidney Disease
30 Progression: An Individual Patient Meta-analysis. *Am J Kidney Dis* 2014.
- 31 585. International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and
32 reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma
33 and 33,542 women without cervical carcinoma from 25 epidemiological studies. *Int J Cancer*
34 2006;**119**(5):1108-24.
- 35 586. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for
36 invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of
37 individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma
38 from 12 epidemiological studies. *Int J Cancer* 2007;**120**(4):885-91.
- 39 587. International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human
40 immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies. *N Engl J Med*
41 1999;**340**(13):977-87.
- 42 588. International Perinatal HIVG. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-
43 analysis from 15 prospective cohort studies. *AIDS* 2001;**15**(3):357-68.
- 44 589. Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human
45 immunodeficiency virus infection: a meta-analysis of randomized individual patient data. *J Infect Dis*
46 1998;**178**(2):349-59.
- 47 590. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on
48 HIV-1 disease progression: An international meta-analysis of individual-patient data. *Ann Intern Med*
49 2001;**135**(9):782-95.
- 50 591. Ioannidis JP, Tektonidou MG, Vlachoyiannopoulos PG, et al. HLA associations of anti-beta2 glycoprotein I
51 response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groups.
52 *Hum Immunol* 1999;**60**(12):1274-80.
- 53 592. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-
54 analysis of individual patient data. *Am J Med* 2005;**118**(1):2-10.
- 55 593. Iorio A, Marcucci M, Cheng J, et al. Patient data meta-analysis of Post-Authorization Safety Surveillance
56 (PASS) studies of haemophilia A patients treated with rAHF-PFM. *Haemophilia* 2014;**20**(6):777-83.
- 57 594. Jackson CA, Hutchison A, Dennis MS, et al. Differing risk factor profiles of ischemic stroke subtypes: evidence
58 for a distinct lacunar arteriopathy? *Stroke* 2010;**41**(4):624-9.
- 59 595. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of
60 nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern Med* 2001;**135**(2):73-87.

- 1
2
3 596. Jafar TH, Schmid CH, Stark PC, et al. The rate of progression of renal disease may not be slower in women
4 compared with men: a patient-level meta-analysis. *Nephrol Dial Transplant* 2003;**18**(10):2047-53.
- 5 597. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure
6 control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. *Ann
7 Intern Med* 2003;**139**(4):244-52.
- 8 598. Jaja BNR, Lingsma H, Schweizer TA, et al. Prognostic value of premonitory hypertension and neurological
9 status in aneurysmal subarachnoid hemorrhage: pooled analyses of individual patient data in the SAHIT
10 repository. *J Neurosurg* 2015;**122**(3):644-52.
- 11 599. Janni W, Vogl FD, Wiedswang G, et al. Persistence of disseminated tumor cells in the bone marrow of breast
12 cancer patients predicts increased risk for relapse--a European pooled analysis. *Clin Cancer Res*
13 2011;**17**(9):2967-76.
- 14 600. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without
15 dementia: a meta-analysis. *JAMA* 2015;**313**(19):1924-38.
- 16 601. Jauch A, Fsadni M, Gamba G. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye
17 drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. *Graefes's
18 archive for clinical and experimental ophthalmology* 1999;**237**(9):705-13.
- 19 602. Jefferis J, Perera R, Everitt H, et al. Acute infective conjunctivitis in primary care: who needs antibiotics? An
20 individual patient data meta-analysis. *Br J Gen Pract* 2011;**61**(590):e542-8.
- 21 603. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in
22 healthy adults and children. *Cochrane Database Syst Rev* 2012;**1**:CD008965.
- 23 604. Jeger RV, Urban P, Harkness SM, et al. Early revascularization is beneficial across all ages and a wide
24 spectrum of cardiogenic shock severity: A pooled analysis of trials. *Acute Card Care* 2011;**13**(1):14-20.
- 25 605. Jiang W, Yao J, He Y, et al. The timing of surgical treatment of knee dislocations: a systematic review. *Knee
26 Surgery, Sports Traumatology, Arthroscopy* 2014.
- 27 606. Jokela M, Hintsanen M, Hakulinen C, et al. Association of personality with the development and persistence
28 of obesity: a meta-analysis based on individual-participant data. *Obes Rev* 2013;**14**(4):315-23.
- 29 607. Jones PW, Mahler DA, Gale R, et al. Profiling the effects of indacaterol on dyspnoea and health status in
30 patients with COPD. *Respir Med* 2011;**105**(6):892-9.
- 31 608. Jones RW, Schwam E, Wilkinson D, et al. Rates of cognitive change in Alzheimer disease: observations across
32 a decade of placebo-controlled clinical trials with donepezil. *Alzheimer Dis Assoc Disord* 2009;**23**(4):357-
33 64.
- 34 609. Jorgensen AL, Alfievic Z, Tudur SC, et al. Cervical stitch (cerclage) for preventing pregnancy loss: individual
35 patient data meta-analysis.[see comment]. [Review] [29 refs]. *BJOG* 2007;**114**(12):1460-76.
- 36 610. Joye I, Deroose CM, Vandecaveye V, et al. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the
37 prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic
38 review. *Radiother Oncol* 2014;**113**(2):158-65.
- 39 611. Jumaily JS, Noordzij JP, Dukas AG, et al. Prediction of hypocalcemia after using 1- to 6-hour postoperative
40 parathyroid hormone and calcium levels: an analysis of pooled individual patient data from 3
41 observational studies. *Head Neck* 2010;**32**(4):427-34.
- 42 612. Kahi CJ, Jensen DM, Sung JY, et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with
43 adherent clot: A meta-analysis. (vol 129, pg 855, 2005). *Gastroenterology* 2006;**131**(3):980-81.
- 44 613. Kaiser R, Barton JL, Chang M, et al. Factor V Leiden and thrombosis in patients with systemic lupus
45 erythematosus: a meta-analysis. *Genes Immun* 2009;**10**(5):495-502.
- 46 614. Kanda J, Ichinohe T, Matsuo K, et al. Impact of ABO mismatching on the outcomes of allogeneic related and
47 unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-
48 analysis of cohort studies. *Transfusion (Paris)* 2009;**49**(4):624-35.
- 49 615. Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of
50 prior vertebral fracture. *Osteoporos Int* 2005;**16**(5):475-82.
- 51 616. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart
52 disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010;**375**(9709):132-40.
- 53 617. Karlson BW, Barter PJ, Palmer MK, et al. Comparison of the effects of different statins and doses on lipid
54 levels in patients with diabetes: results from VOYAGER. *Nutrition Metabolism and Cardiovascular
55 Diseases* 2012;**22**(9):697-703.
- 56 618. Karyotaki A, Kleiboer A, Smit F, et al. Predictors of treatment dropout in self-guided web-based interventions
57 for depression: an 'individual patient data' meta-analysis. *Psychol Med* 2015.
- 58 619. Kasper S, Corruble E, Hale A, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a
59 pooled analysis of head-to-head studies without a placebo control. *Int Clin Psychopharmacol*
60 2013;**28**(1):12-9.

- 1
2
3 620. Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in
4 mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-
5 controlled trials. *Psychopharmacology (Berl)* 2002;**164**(3):301-8.
- 6 621. Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: A systematic review and a meta-
7 analysis of individual patient data. *Epilepsia* 2008;**49**(2):343-48.
- 8 622. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-
9 metal stents in patients with acute myocardial infarction. *Eur Heart J* 2007;**28**(22):2706-13.
- 10 623. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal
11 stents. *N Engl J Med* 2007;**356**(10):1030-9.
- 12 624. Kasturi KS, Chennareddygar S, Mummadi RR. Effect of bisphosphonates on bone mineral density in liver
13 transplant patients: a meta-analysis and systematic review of randomized controlled trials. *Transpl Int*
14 2010;**23**(2):200-7.
- 15 625. Katanoda K, Marugame T, Saika K, et al. Population attributable fraction of mortality associated with tobacco
16 smoking in Japan: a pooled analysis of three large-scale cohort studies. *J Epidemiol* 2008;**18**(6):251-64.
- 17 626. Kazlauskaitė R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary- adrenal
18 insufficiency: a metaanalysis. *J Clin Endocrinol Metab* 2008;**93**(11):4245-53.
- 19 627. Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in
20 general practice: an individual patient data meta-analysis. *Heart* 2011;**97**(12):959-63.
- 21 628. Kelley GA, Kelley KS. Efficacy of resistance exercise on lumbar spine and femoral neck bone mineral density in
22 premenopausal women: a meta-analysis of individual patient data. *J Womens Health* 2004;**13**(3):293-
23 300.
- 24 629. Kelley GA, Kelley KS. Exercise and bone mineral density at the femoral neck in postmenopausal women: A
25 meta-analysis of controlled clinical trials with individual patient data. *Am J Obstet Gynecol*
26 2006;**194**(3):760-67.
- 27 630. Kelley GA, Kelley KS, Tran ZV. Exercise and lumbar spine bone mineral density in postmenopausal women: a
28 meta-analysis of individual patient data. *Journals of Gerontology Series A-Biological Sciences and
29 Medical Sciences* 2002;**57**(9):M599-604.
- 30 631. Kendrick D, Smith S, Sutton A, et al. Effect of education and safety equipment on poisoning-prevention
31 practices and poisoning: Systematic review, meta-analysis and meta-regression. *Arch Dis Child*
32 2008;**93**(7):599-608.
- 33 632. Kendrick D, Smith S, Sutton AJ, et al. The effect of education and home safety equipment on childhood
34 thermal injury prevention: meta-analysis and meta-regression. *Inj Prev* 2009;**15**(3):197-204.
- 35 633. Kendrick D, Watson MC, Mulvaney CA, et al. Preventing Childhood Falls at Home. Meta-Analysis and Meta-
36 Regression. *Am J Prev Med* 2008;**35**(4):370-79.
- 37 634. Kendrick D, Young B, Mason-Jones AJ, et al. Home safety education and provision of safety equipment for
38 injury prevention. *Cochrane Database Syst Rev* 2012;**9**:CD005014.
- 39 635. Kengne AP, Nakamura K, Barzi F, et al. Smoking, diabetes and cardiovascular diseases in men in the Asia
40 Pacific region. *J Diabetes* 2009;**1**(3):173-81.
- 41 636. Kengne AP, Patel A, Barzi F, et al. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in
42 the Asia-Pacific region. *Journal of Hypertension* 2007;**25**(6):1205-13.
- 43 637. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-
44 analysis. *Curr Med Res Opin* 2009;**25**(1):161-75.
- 45 638. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women:
46 reanalysis of nine prospective studies. *J Natl Cancer Inst* 2002;**94**(8):606-16.
- 47 639. Key TJ, Appleby PN, Reeves GK, et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and
48 breast cancer risk: pooled individual data analysis of 17 prospective studies. *Lancet Oncol*
49 2010;**11**(6):530-42.
- 50 640. Key TJ, Fraser GE, Thorogood M, et al. Mortality in vegetarians and non-vegetarians: a collaborative analysis
51 of 8300 deaths among 76,000 men and women in five prospective studies. *Public Health Nutr*
52 1998;**1**(01):33-41.
- 53 641. Khalil AA, Bentzen SM, Bernier J, et al. Compliance to the prescribed dose and overall treatment time in five
54 randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas.
55 *International Journal of Radiation Oncology, Biology, Physics* 2003;**55**(3):568-75.
- 56 642. Khedmat H, Amini M, Ghamar-Chehreh ME. Colorectal involvement by post-transplant lymphoproliferative
57 disorders: a review of 81 cases. *Saudi J Kidney Dis Transpl* 2014;**25**(3):597-604.
- 58 643. Kheifets L, Ahlbom A, Crespi CM, et al. Pooled analysis of recent studies on magnetic fields and childhood
59 leukaemia. *Br J Cancer* 2010;**103**(7):1128-35.
- 60

- 1
2
3 644. Kheifets L, Ahlbom A, Crespi CM, et al. A pooled analysis of extremely low-frequency magnetic fields and
4 childhood brain tumors. *Am J Epidemiol* 2010;**172**(7):752-61.
- 5 645. KIDS-ART-LINC Collaboration. Low risk of death, but substantial program attrition, in pediatric HIV treatment
6 cohorts in Sub-Saharan Africa. *J Acquir Immune Defic Syndr* 2008;**49**(5):523-31.
- 7 646. Kim H, Al-Shahi Salman R, McCulloch CE, et al. Untreated brain arteriovenous malformation: patient-level
8 meta-analysis of hemorrhage predictors. *Neurology* 2014;**83**(7):590-7.
- 9 647. Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with
10 cefepime use. *Clin Infect Dis* 2010;**51**(4):381-9.
- 11 648. Kirtane AJ, Ellis SG, Dawkins KD, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus:
12 pooled analysis from 5 randomized trials. *J Am Coll Cardiol* 2008;**51**(7):708-15.
- 13 649. Kishi T, Hirota T, Iwata N. Add-on fluvoxamine treatment for schizophrenia: An updated meta-analysis of
14 randomized controlled trials. *Eur Arch Psychiatry Clin Neurosci* 2013;**263**(8):633-41.
- 15 650. Kishi T, Matsuda Y, Nakamura H, et al. Blonanserin for schizophrenia: systematic review and meta-analysis of
16 double-blind, randomized, controlled trials. *J Psychiatr Res* 2013;**47**(2):149-54.
- 17 651. Kishi T, Mukai T, Matsuda Y, et al. Selective serotonin 3 receptor antagonist treatment for schizophrenia:
18 Meta-analysis and systematic review. *Neuromolecular Med* 2014;**16**(1):61-69.
- 19 652. Kishi T, Mukai T, Matsuda Y, et al. Efficacy and safety of noradrenalin reuptake inhibitor augmentation
20 therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. *J*
21 *Psychiatr Res* 2013;**47**(11):1557-63.
- 22 653. Kivimäki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for coronary heart disease: a collaborative
23 meta-analysis of individual participant data. *Lancet* 2012;**380**(9852):1491-7.
- 24 654. Kivimäki M, Virtanen M, Kawachi I, et al. Long working hours, socioeconomic status, and the risk of incident
25 type 2 diabetes: A meta-analysis of published and unpublished data from 222120 individuals. *Lancet*
26 *Diabetes Endocrinol* 2015;**3**(1):27-34.
- 27 655. Kleinrouweler CE, Bossuyt PMM, Thilaganathan B, et al. Value of adding second-trimester uterine artery
28 Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-
29 eclampsia: an individual patient data meta-analysis. *Ultrasound Obstet Gynecol* 2013;**42**(3):257-67.
- 30 656. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a
31 meta-analysis.[see comment]. *JAMA* 2002;**288**(16):2023-31.
- 32 657. Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone
33 (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of
34 four randomized trials.[see comment]. *J Clin Oncol* 2001;**19**(2):343-53.
- 35 658. Klotz L, Miller K, Crawford ED, et al. Disease Control Outcomes from Analysis of Pooled Individual Patient
36 Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-
37 releasing Hormone Agonists. *Eur Urol* 2014.
- 38 659. Klug SJ, Rensing M, Koenig J, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of
39 individual data from 49 studies. *Lancet Oncol* 2009;**10**(8):772-84.
- 40 660. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney
41 transplantation: systematic review and meta-analysis of individual patient data. *BMJ* 2014;**349**:g6679.
- 42 661. Koch A, Ziegler S, Breitschwerdt H, et al. Low molecular weight heparin and unfractionated heparin in
43 thrombosis prophylaxis: meta-analysis based on original patient data. *Thromb Res* 2001;**102**(4):295-309.
- 44 662. Koeter MWJ, van den Brink W, Lehert P. Effect of early and late compliance on the effectiveness of
45 acamprosate in the treatment of alcohol dependence. *J Subst Abuse Treat* 2010;**39**(3):218-26.
- 46 663. Kolli KK, Arif I, Peelukhana SV, et al. Diagnostic performance of pressure drop coefficient in relation to
47 fractional flow reserve and coronary flow reserve. *J Invasive Cardiol* 2014;**26**(5):188-95.
- 48 664. Koopman L, Hoes AW, Glasziou PP, et al. Antibiotic therapy to prevent the development of asymptomatic
49 middle ear effusion in children with acute otitis media: A meta-analysis of individual patient data. *Arch*
50 *Otolaryngol Head Neck Surg* 2008;**134**(2):128-32.
- 51 665. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial
52 fibrillation: an individual-patient data meta-analysis. *Lancet* 2014;**384**(9961):2235-43.
- 53 666. Kotecha RS, Jacoby P, Cole CH, et al. Morbidity in survivors of child and adolescent meningioma. *Cancer*
54 2013;**119**(24):4350-7.
- 55 667. Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a meta-analysis of
56 individual patient data. *Lancet Oncol* 2011;**12**(13):1229-39.
- 57 668. Kovalchik SA. Mother's CD4+ count moderates the risk associated with higher parity for late postnatal HIV-
58 free survival of breastfed children: an individual patient data meta-analysis of randomized controlled
59 trials. *AIDS Behav* 2012;**16**(1):79-85.
- 60

- 1
2
3 669. Krauter J, Wagner K, Schafer I, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid
4 leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of
5 the German Acute Myeloid Leukemia Intergroup. *J Clin Oncol* 2009;**27**(18):3000-6.
- 6 670. Kricger A, Armstrong BK, Hughes AM, et al. Personal sun exposure and risk of non Hodgkin lymphoma: a
7 pooled analysis from the Interlymph Consortium. *Int J Cancer* 2008;**122**(1):144-54.
- 8 671. Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha interferon in chronic hepatitis B
9 is independent of pre-treatment variables. Results based on individual patient data from 10 clinical
10 controlled trials. *European Concerted Action on Viral Hepatitis (Eurohep)*. *J Hepatol* 1994;**21**(4):646-55.
- 11 672. Krogsgaard K, Christensen E, Bindslev N, et al. Relation between treatment efficacy and cumulative dose of
12 alpha interferon in chronic hepatitis B. *European Concerted Action on Viral Hepatitis (Eurohep)*. *J*
13 *Hepatol* 1996;**25**(6):795-802.
- 14 673. Kubo A, Cook MB, Shaheen NJ, et al. Sex-specific associations between body mass index, waist circumference
15 and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. *Gut*
16 2013;**62**(12):1684-91.
- 17 674. Kufner S, de Waha A, Tomai F, et al. A meta-analysis of specifically designed randomized trials of sirolimus-
18 eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. *Am Heart J*
19 2011;**162**(4):740-7.
- 20 675. Kumagai K, Rouvelas I, Tsai JA, et al. Survival benefit and additional value of preoperative chemoradiotherapy
21 in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison
22 meta-analysis. *Eur J Surg Oncol* 2015;**41**(3):282-94.
- 23 676. La Vecchia C, Ron E, Franceschi S, et al. A pooled analysis of case-control studies of thyroid cancer[†] III. Oral
24 contraceptives, menopausal replacement therapy and other female hormones. *Cancer Causes Control*
25 1999;**10**(2):157-66.
- 26 677. Lam TH, Barzi F, Patel A, et al. Smoking, quitting, and the risk of cardiovascular disease among women and
27 men in the Asia-Pacific region. *Int J Epidemiol* 2005;**34**(5):1036-45.
- 28 678. Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate
29 end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
30 *Gastroenterology* 2014;**147**(6):1338-49.e5; quiz e15.
- 31 679. Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: Individual patient data
32 meta-analysis of three trials in migraine headache and migraine accompanying symptoms. *J Neurol*
33 2007;**254**(6):705-12.
- 34 680. Lampl C, Voelker M, Steiner TJ. Aspirin is first-line treatment for migraine and episodic tension-type
35 headache regardless of headache intensity. *Headache* 2012;**52**(1):48-56.
- 36 681. Lanan A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds -
37 gastrointestinal adverse effects: a meta-analysis of randomized clinical trials. *Drugs R D* 2011;**11**(3):277-
38 88.
- 39 682. Landman GWD, van Hateren KJJ, van Dijk PR, et al. Efficacy of device-guided breathing for hypertension in
40 blinded, randomized, active-controlled trials: a meta-analysis of individual patient data. *JAMA Intern*
41 *Med* 2014;**174**(11):1815-21.
- 42 683. Lane SD, Yechiam E, Busemeyer JR. Application of a computational decision model to examine acute drug
43 effects on human risk taking. *Exp Clin Psychopharmacol* 2006;**14**(2):254-64.
- 44 684. Lange N, Swearer S, Sturmer WQ. Human postmortem interval estimation from vitreous potassium: an
45 analysis of original data from six different studies. *Forensic Sci Int* 1994;**66**(3):159-74.
- 46 685. Langhorne P, Taylor G, Murray G, et al. Early supported discharge services for stroke patients: a meta-analysis
47 of individual patients' data.[see comment]. *Lancet* 2005;**365**(9458):501-6.
- 48 686. Lanterna LA, Ruigrok Y, Alexander S, et al. Meta-analysis of APOE genotype and subarachnoid hemorrhage:
49 Clinical outcome and delayed ischemia. *Neurology* 2007;**69**(8):766-75.
- 50 687. Laporte S, Liotier J, Bertolotti L, et al. Individual patient data meta-analysis of enoxaparin vs. unfractionated
51 heparin for venous thromboembolism prevention in medical patients. *J Thromb Haemost* 2011;**9**(3):464-
52 72.
- 53 688. Laporte S, Squifflet P, Baroux N, et al. Prediction of survival benefits from progression-free survival benefits in
54 advanced non-small-cell lung cancer: Evidence from a meta-analysis of 2334 patients from 5 randomised
55 trials. *BMJ Open* 2013;**3**(3).
- 56 689. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality
57 prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute
58 Heart Failure (MOCA) study. *Int J Cardiol* 2013;**168**(3):2186-94.
- 59 690. Latini R, Tognoni G, Maggioni AP, et al. Clinical effects of early angiotensin-converting enzyme inhibitor
60 treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic

- overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group.[see comment]. *J Am Coll Cardiol* 2000;**35**(7):1801-7.
691. Lawes CM, Parag V, Bennett DA, et al. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. *Diabetes Care* 2004;**27**(12):2836-42.
692. Lawes CM, Rodgers A, Bennett DA, et al. Blood pressure and cardiovascular disease in the Asia Pacific region.[see comment]. *Journal of Hypertension* 2003;**21**(4):707-16.
693. Le Cesne A, Ouali M, Leahy MG, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. *Ann Oncol* 2014;**25**(12):2425-32.
694. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology* 2006;**130**(6):1636-42.
695. Lee CH, Chung CK, Jahng TA, et al. Which one is a valuable surrogate for predicting survival between Tomita and Tokuhashi scores in patients with spinal metastases? A meta-analysis for diagnostic test accuracy and individual participant data analysis. *J Neurooncol* 2015;**123**(2):267-75.
696. Lee N, Leo YS, Cao B, et al. Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients. *Eur Respir J* 2015;**45**(6):1642-52.
697. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. *Lancet* 2010;**375**(9727):1695-703.
698. Leheret P, Cheron G, Calatayud GA, et al. Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis. *Dig Liver Dis* 2011;**43**(9):707-13.
699. Lehrke M, Marx N, Patel S, et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: A comprehensive pooled analysis of 22 placebo-controlled studies. *Clin Ther* 2014;**36**(8):1130-46.
700. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. *Cardiac Insufficiency Bisoprolol Study*. *Am Heart J* 2002;**143**(2):301-7.
701. Lejoyeux M, Leheret P. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. *Alcohol Alcohol* 2011;**46**(1):61-7.
702. Lemmens R, Christensen S, Straka M, et al. Patients with single distal MCA perfusion lesions have a high rate of good outcome with or without reperfusion. *Int J Stroke* 2014;**9**(2):156-9.
703. Leonardi-Bee J, Bath PMW, Bousser M-G, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: A meta-analysis of individual patient data from randomized controlled trials. *Stroke* 2005;**36**(1):162-68.
704. Leonardi-Bee J, Steiner T, Bath-Hextall F. Naftidrofuryl for acute stroke. *Cochrane Database Syst Rev* 2007(2):CD005478.
705. Leppik I, Morrell M, Godfroid P, et al. Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy. *Epilepsia* 2003;**44**(10):1350-2.
706. Leroy S, Fernandez-Lopez A, Nikfar R, et al. Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI. *Pediatrics* 2013;**131**(5):870-9.
707. Leroy S, Romanello C, Galetto-Lacour A, et al. Procalcitonin is a predictor for high-grade vesicoureteral reflux in children: meta-analysis of individual patient data. *J Pediatr* 2011;**159**(4):644-51.e4.
708. Leroy V, Halfon P, Bacq Y, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. *Clin Biochem* 2008;**41**(16-17):1368-76.
709. Leroy V, Newell M-L, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. *Lancet* 1998;**352**(9128):597-600.
710. Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. *Biol Psychiatry* 2005;**57**(12):1543-49.
711. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. *J Clin Psychiatry* 2007;**68**(3):352-60.
712. Levy E, Piedbois P, Buyse M, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 1998;**16**(11):3537-41.
713. Levy V, Katsahian S, Ferman JP, et al. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. *Medicine* 2005;**8**(4):250-60.
714. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.[see comment][erratum appears in *Lancet*. 2003 Mar 22;361(9362):1060]. *Lancet* 2002;**360**(9349):1903-13.

- 1
2
3 715. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood
4 pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.
5 *Lancet* 2007;**370**(9602):1829-39.
- 6 716. Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin
7 nonsteroidal anti-inflammatory drugs (NNSAIDs) and serious upper gastrointestinal bleeding: a meta-
8 analysis based on individual patient data. *Br J Clin Pharmacol* 2002;**54**(3):320-6.
- 9 717. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone
10 agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast
11 cancer: a meta-analysis of individual patient data from randomised adjuvant trials. *Lancet*
12 2007;**369**(9574):1711-23.
- 13 718. Li JZ, Paredes R, Ribaldo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based
14 antiretroviral treatment failure: a systematic review and pooled analysis. *JAMA* 2011;**305**(13):1327-35.
- 15 719. Li W, Gueyffier F, Liu G, et al. The effect of antihypertensive treatment on cardiovascular events--a meta-
16 analysis of four clinical trials in China. *Biomedical and environmental sciences: BES* 2001;**14**(4):341-49.
- 17 720. Li Wan Po A, Petersen B. How high should total pain-relief score be to obviate the need for analgesic
18 remedication in acute pain? Estimation using signal detection theory and individual-patient meta-
19 analysis. *J Clin Pharm Ther* 2006;**31**(2):161-5.
- 20 721. Lievre M, Gueyffier F, Ekblom T, et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients:
21 Results from a meta-analysis. *Diabetes Care* 2000;**23**(SUPPL. 2):B65-B71.
- 22 722. Lim E, Clough R, Goldstraw P, et al. Impact of positive pleural lavage cytology on survival in patients having
23 lung resection for non-small-cell lung cancer: An international individual patient data meta-analysis. *J*
24 *Thorac Cardiovasc Surg* 2010;**139**(6):1441-6.
- 25 723. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2
26 diabetes mellitus: A meta-analysis of randomized trials. *J Am Med Assoc* 2007;**298**(10):1180-88.
- 27 724. Lingsma HF, Roozenbeek B, Li B, et al. Large between-center differences in outcome after moderate and
28 severe traumatic brain injury in the international mission on prognosis and clinical trial design in
29 traumatic brain injury (IMPACT) study. *Neurosurgery* 2011;**68**(3):601-7; discussion 07-8.
- 30 725. Liu PY, Swerdloff RS, Anawalt BD, et al. Determinants of the rate and extent of spermatogenic suppression
31 during hormonal male contraception: An integrated analysis. *J Clin Endocrinol Metab* 2008;**93**(5):1774-
32 83.
- 33 726. Lodrup Carlsen KC, Roll S, Carlsen K-H, et al. Does pet ownership in infancy lead to asthma or allergy at
34 school age? Pooled analysis of individual participant data from 11 European birth cohorts. *PLoS ONE*
35 [Electronic Resource] 2012;**7**(8):e43214.
- 36 727. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality
37 treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study
38 Group.[see comment]. *J Clin Oncol* 1998;**16**(3):818-29.
- 39 728. Loibl S, Jackisch C, Lederer B, et al. Outcome after neoadjuvant chemotherapy in young breast cancer
40 patients: a pooled analysis of individual patient data from eight prospectively randomized controlled
41 trials. *Breast Cancer Res Treat* 2015.
- 42 729. Loibl S, Skacel T, Nekljudova V, et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on
43 patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic
44 breast cancer- a pooled analysis. *BMC Cancer* 2011;**11**:131.
- 45 730. Longnecker MP, Martin-Moreno JM, Knekt P, et al. Serum alpha-tocopherol concentration in relation to
46 subsequent colorectal cancer: pooled data from five cohorts. *J Natl Cancer Inst* 1992;**84**(6):430-5.
- 47 731. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type
48 plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. *J Natl Cancer Inst*
49 2002;**94**(2):116-28.
- 50 732. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual
51 patient pooled analysis. *J Clin Oncol* 2009;**27**(17):2831-7.
- 52 733. Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular
53 events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual
54 participant data.[Erratum appears in *Lancet*. 2012 Aug 4;380(9840):474]. *Lancet* 2012;**379**(9831):2053-62.
- 55 734. Losier BJ, Klein RM. A review of the evidence for a disengage deficit following parietal lobe damage. [Review]
56 [57 refs]. *Neurosci Biobehav Rev* 2001;**25**(1):1-13.
- 57 735. Loverix L, Juvonen T, Biancari F. Prosthetic endocarditis after transcatheter aortic valve implantation: Pooled
58 individual patient outcome. *Int J Cardiol* 2015;**178**:67-68.
- 59
60

- 1
2
3 736. Low N, Chersich MF, Schmidlin K, et al. Intravaginal practices, bacterial vaginosis, and HIV infection in
4 women: individual participant data meta-analysis. *PLoS Medicine / Public Library of Science*
5 2011;**8**(2):e1000416.
- 6 737. Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled
7 analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). *Ann Oncol*
8 2012;**23**(2):374-82.
- 9 738. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized,
10 double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with
11 chemotherapy-induced anemia. *J Clin Oncol* 2009;**27**(17):2838-47.
- 12 739. Maas AIR, Steyerberg EW, Butcher I, et al. Prognostic value of computerized tomography scan characteristics
13 in traumatic brain injury: Results from the IMPACT study. *J Neurotrauma* 2007;**24**(2):303-14.
- 14 740. Maas M, Nelemans PJ, Valentini V, et al. Adjuvant chemotherapy in rectal cancer: defining subgroups who
15 may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. *Int J*
16 *Cancer* 2015;**137**(1):212-20.
- 17 741. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete
18 response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. *Lancet*
19 *Oncol* 2010;**11**(9):835-44.
- 20 742. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with
21 stage III/IV epithelial ovarian cancer. *Int J Gynecol Cancer* 2010;**20**(6):945-52.
- 22 743. MacPherson H, Maschino AC, Lewith G, et al. Characteristics of acupuncture treatment associated with
23 outcome: an individual patient meta-analysis of 17,922 patients with chronic pain in randomised
24 controlled trials.[Erratum appears in *PLoS One*. 2013;8(12). doi:10.1371/annotation/23629d97-3b72-
25 474b-9d89-c7198ba43d60 Note: Witt, Claudia [corrected to Witt, Claudia M]]. *PLoS ONE [Electronic*
26 *Resource]* 2013;**8**(10):e77438.
- 27 744. Mahaffey KW, Van de WF, Shernan SK, et al. Effect of pexelizumab on mortality in patients with acute
28 myocardial infarction or undergoing coronary artery bypass surgery: A systematic overview. *Am Heart J*
29 2006;**152**(2):291-96.
- 30 745. Mahmoodi BK, Gansevoort RT, Naess IA, et al. Association of mild to moderate chronic kidney disease with
31 venous thromboembolism: pooled analysis of five prospective general population cohorts. *Circulation*
32 2012;**126**(16):1964-71.
- 33 746. Mahmoodi BK, Yatsuya H, Matsushita K, et al. Association of kidney disease measures with ischemic versus
34 hemorrhagic strokes: Pooled analyses of 4 prospective community-based cohorts. *Stroke* 2014.
- 35 747. Mahner S, Eulenburg C, Staehle A, et al. Prognostic impact of the time interval between surgery and
36 chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. *Eur J*
37 *Cancer* 2013;**49**(1):142-9.
- 38 748. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual
39 patient data meta-analysis. *Arthritis Rheum* 2007;**56**(8):2789-97.
- 40 749. Maino A, Siegerink B, Lotta LA, et al. Plasma ADAMTS-13 levels and the risk of myocardial infarction: An
41 individual patient data meta-analysis. *J Thromb Haemost* 2015;**13**(8):1396-404.
- 42 750. Makanga M, Premji Z, Falade C, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine
43 in pediatrics with uncomplicated *Plasmodium falciparum* malaria: A pooled analysis of individual patient
44 data. *Am J Trop Med Hyg* 2006;**74**(6):991-98.
- 45 751. Malbrain MLNG, Chiumello D, Cesana BM, et al. A systematic review and individual patient data meta-
46 analysis on intra-abdominal hypertension in critically ill patients: The wake-up project. *World initiative on*
47 *Abdominal Hypertension Epidemiology, a Unifying Project (WAKE-Up!)*. *Minerva Anestesiol*
48 2014;**80**(3):293-306.
- 49 752. Malmstrom P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term
50 outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for
51 non-muscle-invasive bladder cancer. *Eur Urol* 2009;**56**(2):247-56.
- 52 753. Manassis K, Changgun Le T, Bennett K, et al. Types of parental involvement in CBT with anxious youth: A
53 preliminary meta-analysis. *J Consult Clin Psychol* 2015;**82**(6):1163-72.
- 54 754. Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-
55 analysis of the 5 international randomized trials. *The Multicenter Study of Perioperative Ischemia (McSPI)*
56 *Research Group*. *JAMA* 1997;**277**(4):325-32.
- 57 755. Mangia A, Leandro G, Helbling B, et al. Combination therapy with amantadine and interferon in naive
58 patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. *J Hepatol*
59 2004;**40**(3):478-83.
- 60

- 1
2
3 756. Man-Son-Hing M, Wells G. Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in
4 elderly people.[see comment]. *BMJ* 1995;**310**(6971):13-7.
- 5 757. Man-Son-Hing M, Wells G, Lau A. Quinine for nocturnal leg cramps: a meta-analysis including unpublished
6 data. *J Gen Intern Med* 1998;**13**(9):600-6.
- 7 758. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of
8 heart failure, with modelling of implications of different diagnostic strategies in primary care. *Health*
9 *technology assessment* (Winchester, England) 2009;**13**(32):1-207, iii.
- 10 759. Marcucci M, Mancuso ME, Santagostino E, et al. Type and intensity of FVIII exposure on inhibitor
11 development in PUPs with haemophilia A: A patient-level meta-analysis. *Thromb Haemost*
12 2015;**113**(5):1-10.
- 13 760. Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers: a
14 pooled analysis. *Arch Dermatol* 2000;**136**(12):1531-5.
- 15 761. Marmarou A, Lu J, Butcher I, et al. Prognostic value of the Glasgow Coma Scale and pupil reactivity in
16 traumatic brain injury assessed pre-hospital and on enrollment: an IMPACT analysis. *J Neurotrauma*
17 2007;**24**(2):270-80.
- 18 762. Marshall M, Crowther R, Almaraz-Serrano A, et al. Systematic reviews of the effectiveness of day care for
19 people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational
20 rehabilitation; (3) day hospital versus outpatient care. [Review] [66 refs]. *Health Technol Assess*
21 2001;**5**(21):1-75.
- 22 763. Marshall M, Crowther R, Sledge WH, et al. Day hospital versus admission for acute psychiatric disorders.
23 *Cochrane Database Syst Rev* 2011(12):CD004026.
- 24 764. Marson AG, Williamson PR, Clough H, et al. Carbamazepine versus valproate monotherapy for epilepsy: a
25 meta-analysis. *Epilepsia* 2002;**43**(5):505-13.
- 26 765. Martin J, Donaldson AN, Villarroel R, et al. Efficacy of acupuncture in asthma: systematic review and meta-
27 analysis of published data from 11 randomised controlled trials. *Eur Respir J* 2002;**20**(4):846-52.
- 28 766. Mason BJ, Lehart P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual
29 patient data. *Alcoholism: Clinical and Experimental Research* 2012;**36**(3):497-508.
- 30 767. Mason J, Young P, Freemantle N, et al. Safety and costs of initiating angiotensin converting enzyme
31 inhibitors for heart failure in primary care: analysis of individual patient data from studies of left
32 ventricular dysfunction.[see comment]. *BMJ* 2000;**321**(7269):1113-6.
- 33 768. Matafsi A, Haidich A-B, Kokkali S, et al. Postoperative glaucoma following infantile cataract surgery: an
34 individual patient data meta-analysis. *JAMA Ophthalmol* 2014;**132**(9):1059-67.
- 35 769. Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe
36 alcoholic hepatitis: meta-analysis of individual patient data. *Gut* 2011;**60**(2):255-60.
- 37 770. Matsuda Y, Kishi T, Shibayama H, et al. Yokukansan in the treatment of behavioral and psychological
38 symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. *Human*
39 *Psychopharmacology* 2013;**28**(1):80-6.
- 40 771. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of
41 cardiovascular outcomes: A collaborative meta-analysis of individual participant data. *Lancet Diabetes*
42 *Endocrinol* 2015;**3**(7):514-25.
- 43 772. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and
44 albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative
45 meta-analysis. *Lancet* 2010;**375**(9731):2073-81.
- 46 773. Matsushita Y, Sugihara M, Kaburagi J, et al. Pravastatin use and cancer risk: a meta-analysis of individual
47 patient data from long-term prospective controlled trials in Japan. *Pharmacoepidemiol Drug Saf*
48 2010;**19**(2):196-202.
- 49 774. Mattila T, Wohlfarth T, Koeter M, et al. Geographic variation in efficacy of atypical antipsychotics for the
50 acute treatment of schizophrenia - An individual patient data meta-analysis. *Eur Neuropsychopharmacol*
51 2014.
- 52 775. Mauer DK, Nolan J, Plaisance P, et al. Effect of active compression-decompression resuscitation (ACD-CPR)
53 on survival: a combined analysis using individual patient data. *Resuscitation* 1999;**41**(3):249-56.
- 54 776. Mauguen A, Le Pechoux C, Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer:
55 an individual patient data meta-analysis. *J Clin Oncol* 2012;**30**(22):2788-97.
- 56 777. Mavros MN, Mayo SC, Hyder O, et al. A systematic review: treatment and prognosis of patients with
57 fibrolamellar hepatocellular carcinoma. *J Am Coll Surg* 2012;**215**(6):820-30.
- 58 778. Mbuagbaw L, Van Der Kop ML, Lester RT, et al. Mobile phone text messages for improving adherence to
59 antiretroviral therapy (ART): An individual patient data meta-analysis of randomised trials. *BMJ Open*
60 2013;**3**(12).

- 1
2
3 779. McAlister FA. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in
4 normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. *Eur Heart J*
5 2012;**33**(4):505-14.
- 6 780. McAlister FA, Ezekowitz J, Tarantini L, et al. Renal dysfunction in patients with heart failure with preserved
7 versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration
8 Group formula. *Circ Heart Fail* 2012;**5**(3):309-14.
- 9 781. McCormack K, Wake B, Perez J, et al. Laparoscopic surgery for inguinal hernia repair: Systematic review of
10 effectiveness and economic evaluation. *Health Technol Assess* 2005;**9**(14):iii-80.
- 11 782. McCullough PA, Bertrand ME, Brinker JA, et al. A Meta-Analysis of the Renal Safety of Isosmolar Iodixanol
12 Compared With Low-Osmolar Contrast Media. *J Am Coll Cardiol* 2006;**48**(4):692-99.
- 13 783. McGee DL. Body mass index and mortality: a meta-analysis based on person-level data from twenty-six
14 observational studies. *Ann Epidemiol* 2005;**15**(2):87-97.
- 15 784. McGeechan K, Liew G, Macaskill P, et al. Prediction of incident stroke events based on retinal vessel caliber: a
16 systematic review and individual-participant meta-analysis. *Am J Epidemiol* 2009;**170**(11):1323-32.
- 17 785. McGeechan K, Liew G, Macaskill P, et al. Meta-analysis: retinal vessel caliber and risk for coronary heart
18 disease. *Ann Intern Med* 2009;**151**(6):404-13.
- 19 786. McHugh GS, Engel DC, Butcher I, et al. Prognostic value of secondary insults in traumatic brain injury: Results
20 from the IMPACT study. *J Neurotrauma* 2007;**24**(2):287-93.
- 21 787. McLernon DJ, Harrild K, Bergh C, et al. Clinical effectiveness of elective single versus double embryo transfer:
22 meta-analysis of individual patient data from randomised trials. *BMJ* 2010;**341**:c6945.
- 23 788. Mehta SR, Boden WE, Eikelboom JW, et al. Antithrombotic therapy with fondaparinux in relation to
24 interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary
25 syndromes: an individual patient-level combined analysis of the fifth and sixth organization to assess
26 strategies in ischemic syndromes (OASIS 5 and 6) randomized trials. *Circulation* 2008;**118**(20):2038-46.
- 27 789. Meijer A, Conradi HJ, Bos EH, et al. Adjusted prognostic association of depression following myocardial
28 infarction with mortality and cardiovascular events: individual patient data meta-analysis. *Br J Psychiatry*
29 2013;**203**(2):90-102.
- 30 790. Meijer AB, O YL, Geleijns J, et al. Meta-analysis of 40- and 64-MDCT angiography for assessing coronary
31 artery stenosis. *AJR Am J Roentgenol* 2008;**191**(6):1667-75.
- 32 791. Melichar B, Urminska H, Kohlova T, et al. Brain metastases of epithelial ovarian carcinoma responding to
33 cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
34 [Review] [86 refs]. *Gynecol Oncol* 2004;**94**(2):267-76.
- 35 792. Melichar B, Voboril Z, Cerman JJ, et al. Hepatic arterial infusion chemotherapy in gastric cancer: a report of
36 four cases and analysis of the literature. [Review] [41 refs]. *Tumori* 2004;**90**(4):428-34.
- 37 793. Melsen WG, Rovers MM, Groenwold RHH, et al. Attributable mortality of ventilator-associated pneumonia: a
38 meta-analysis of individual patient data from randomised prevention studies. *Lancet Infect Dis*
39 2013;**13**(8):665-71.
- 40 794. Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus
41 percutaneous coronary intervention with multiple stenting for multisystem disease: A meta-analysis of
42 individual patient data from randomized clinical trials. *J Thorac Cardiovasc Surg* 2005;**130**(2):512-19.
- 43 795. Messori A, Vaiani M, Trippoli S, et al. Survival in patients with intermediate or high grade non-Hodgkin's
44 lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. *Br J*
45 *Cancer* 2001;**84**(3):303-7.
- 46 796. Meta-analysis Global Group in Chronic Heart Failure. The survival of patients with heart failure with preserved
47 or reduced left ventricular ejection fraction: an individual patient data meta-analysis. *Eur Heart J*
48 2012;**33**(14):1750-7.
- 49 797. Meta-analysis Research Group, Moller JE, Whalley GA, et al. Independent prognostic importance of a
50 restrictive left ventricular filling pattern after myocardial infarction: an individual patient meta-analysis:
51 Meta-Analysis Research Group in Echocardiography acute myocardial infarction.[see comment].
52 *Circulation* 2008;**117**(20):2591-98.
- 53 798. Meta-analysis Research Group in Echocardiography (MeRGE) Heart Failure Collaborators. Independence of
54 restrictive filling pattern and LV ejection fraction with mortality in heart failure: An individual patient
55 meta-analysis. *Eur J Heart Fail* 2008;**10**(8):786-92.
- 56 799. Meyer-Baron M, Schaper M, Knapp G, et al. The neurobehavioral impact of manganese: results and
57 challenges obtained by a meta-analysis of individual participant data. *Neurotoxicology* 2013;**36**:1-9.
- 58 800. Mhuircheartaigh RJN, Moore RA, McQuay HJ. Analysis of individual patient data from clinical trials: epidural
59 morphine for postoperative pain. *Br J Anaesth* 2009;**103**(6):874-81.
- 60

- 1
2
3 801. Michiels S, Le Maitre A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and
4 neck cancer: meta-analyses of individual patient data. *Lancet Oncol* 2009;**10**(4):341-50.
- 5 802. Middleton LJ, Champaneria R, Daniels JP, et al. Hysterectomy, endometrial destruction, and levonorgestrel
6 releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-
7 analysis of data from individual patients. *BMJ* 2010;**341**:c3929.
- 8 803. Migliori GB, Sotgiu G, Gandhi NR, et al. Drug resistance beyond extensively drug-resistant tuberculosis:
9 individual patient data meta-analysis. *Eur Respir J* 2013;**42**(1):169-79.
- 10 804. Miles DW, Dieras V, Cortes J, et al. First-line bevacizumab in combination with chemotherapy for HER2-
11 negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. *Ann Oncol*
12 2013;**24**(11):2773-80.
- 13 805. Miller PD, Recker RR, Harris S, et al. Long-term fracture rates seen with continued ibandronate treatment:
14 Pooled analysis of DIVA and MOBILE long-term extension studies. *Osteoporos Int* 2014;**25**(1):349-57.
- 15 806. Mills EJ, Lester R, Thorlund K, et al. Interventions to promote adherence to antiretroviral therapy in Africa: A
16 network meta-analysis. *Lancet HIV* 2014;**1**(3):e104-e11.
- 17 807. Mismetti P, Quenet S, Levine M, et al. Enoxaparin in the treatment of deep vein thrombosis with or without
18 pulmonary embolism: An individual patient data meta-analysis. *Chest* 2005;**128**(4):2203-10.
- 19 808. Misra P, Husain Q, Svider PF, et al. Management of sinonasal teratocarcinoma: A systematic review.
20 *American Journal of Otolaryngology - Head and Neck Medicine and Surgery* 2014;**35**(1):5-11.
- 21 809. Mistiaen PJ, Jolley DJ, McGowan S, et al. A multilevel analysis of three randomised controlled trials of the
22 Australian Medical Sheepskin in the prevention of sacral pressure ulcers. *Med J Aust* 2010;**193**(11-
23 12):638-41.
- 24 810. Mitry E, Douillard JY, Van Cutsem E, et al. Predictive factors of survival in patients with advanced colorectal
25 cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. *Ann Oncol*
26 2004;**15**(7):1013-7.
- 27 811. Mizoue T, Inoue M, Wakai K, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of
28 results from five cohort studies. *Am J Epidemiol* 2008;**167**(12):1397-406.
- 29 812. Mongraw-Chaffin ML, Peters SAE, Huxley RR, et al. The sex-specific association between BMI and coronary
30 heart disease: A systematic review and meta-analysis of 95 cohorts with 1.2 million participants. *Lancet*
31 *Diabetes Endocrinol* 2015;**3**(6):437-49.
- 32 813. Mons U, Muezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events
33 and mortality among older adults: meta-analysis of individual participant data from prospective cohort
34 studies of the CHANCES consortium. *BMJ* 2015;**350**:h1551.
- 35 814. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation
36 myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
37 *Eur Heart J* 2007;**28**(4):443-9.
- 38 815. Montravers P, Bassetti M, Dupont H, et al. Efficacy of tigecycline for the treatment of complicated skin and
39 soft-tissue infections in real-life clinical practice from five European observational studies. *J Antimicrob*
40 *Chemother* 2013;**68 Suppl 2**:ii15-24.
- 41 816. Moore RA, Cai N, Skljarevski V, et al. Duloxetine use in chronic painful conditions—Individual patient data
42 responder analysis. *European Journal of Pain* 2014;**18**(1):67-75.
- 43 817. Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of
44 different ways of analysing and presenting results. *Pain* 2005;**116**(3):322-31.
- 45 818. Moore RA, McQuay HJ. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol
46 versus placebo, codeine and combination analgesics. *Pain* 1997;**69**(3):287-94.
- 47 819. Moore RA, Mhuirheartaigh RJN, Derry S, et al. Mean analgesic consumption is inappropriate for testing
48 analgesic efficacy in post-operative pain: analysis and alternative suggestion. *Eur J Anaesthesiol*
49 2011;**28**(6):427-32.
- 50 820. Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a
51 meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice.
52 *Ann Rheum Dis* 2010;**69**(2):374-9.
- 53 821. Moore RA, Straube S, Paine J, et al. Minimum efficacy criteria for comparisons between treatments using
54 individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and
55 ibuprofen/paracetamol combinations after third molar extraction. *Pain* 2011;**152**(5):982-9.
- 56 822. Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib
57 for non-small cell lung cancer with EGFR mutations. *Clin Cancer Res* 2009;**15**(13):4493-8.
- 58 823. Morrison CS, Chen P-L, Kwok C, et al. Hormonal Contraception and the Risk of HIV Acquisition: An Individual
59 Participant Data Meta-analysis. *PLoS Med* 2015;**12**(1):e1001778.
- 60

- 1
2
3 824. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin
4 monotherapy and identification of factors associated with treatment response: a pooled analysis of over
5 21,000 subjects from 27 clinical trials. *Atherosclerosis* 2012;**223**(2):251-61.
- 6 825. Mosges R, Konig V, Koberlein J. The effectiveness of modern antihistamines for treatment of allergic rhinitis -
7 an IPD meta-analysis of 140,853 patients. *Allergy International* 2013;**62**(2):215-22.
- 8 826. Moss A, Nicholas M. Language rehabilitation in chronic aphasia and time postonset: A review of single-
9 subject data. *Stroke* 2006;**37**(12):3043-51.
- 10 827. Moss RL, Dimmitt RA, Henry MC, et al. A meta-analysis of peritoneal drainage versus laparotomy for
11 perforated necrotizing enterocolitis. *J Pediatr Surg* 2001;**36**(8):1210-3.
- 12 828. Mou J, Paillard F, Turnbull B, et al. Qutenza (Capsaicin) 8% patch onset and duration of response and effects
13 of multiple treatments in neuropathic pain patients. *Clin J Pain* 2014;**30**(4):286-94.
- 14 829. Mueller EA, van VM, Kirch W, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine for
15 treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: A pooled analysis
16 of individual patient data from randomized clinical trials. *Acta Trop* 2006;**100**(1-2):41-53.
- 17 830. Mulherin SA, O'Brien TR, Ioannidis JP, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease
18 progression: the protection varies with duration of infection.[see comment]. *AIDS* 2003;**17**(3):377-87.
- 19 831. Muller M, Marson AG, Williamson PR. Oxcarbazepine versus phenytoin monotherapy for epilepsy. [Review]
20 [20 refs]. *Cochrane Database Syst Rev* 2006(2):CD003615-.
- 21 832. Mullins P, Sharplin P, Yki-Jarvinen H, et al. Negative binomial meta-regression analysis of combined
22 glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin
23 glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. *Clin
24 Ther* 2007;**29**(8):1607-19.
- 25 833. Murakami Y. Meta-analyses using individual participant data from cardiovascular cohort studies in Japan:
26 Current status and future directions. *J Epidemiol* 2014;**24**(2):96-101.
- 27 834. Murakami Y, Miura K, Okamura T, et al. Population attributable numbers and fractions of deaths due to
28 smoking: a pooled analysis of 180,000 Japanese. *Prev Med* 2011;**52**(1):60-5.
- 29 835. Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: Results
30 from the IMPACT study. *J Neurotrauma* 2007;**24**(2):329-37.
- 31 836. Mushkudiani NA, Engel DC, Steyerberg EW, et al. Prognostic value of demographic characteristics in
32 traumatic brain injury: Results from the IMPACT study. *J Neurotrauma* 2007;**24**(2):259-69.
- 33 837. Musso G, Gambino R, Tabibian JH, et al. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney
34 Disease: A Systematic Review and Meta-analysis. *PLoS Med* 2014;**11**(7).
- 35 838. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in
36 patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual
37 participant data. *Lancet Respir Med* 2014;**2**(5):395-404.
- 38 839. Myeloma Trialists' Collaborative G. Interferon as therapy for multiple myeloma: an individual patient data
39 overview of 24 randomized trials and 4012 patients. *Br J Haematol* 2001;**113**(4):1020-34.
- 40 840. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as
41 treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. *J Clin Oncol*
42 1998;**16**(12):3832-42.
- 43 841. Naber KG, Niggemann H, Stein G, et al. Review of the literature and individual patients' data meta-analysis
44 on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections. *BMC
45 Infect Dis* 2014;**14**:628.
- 46 842. Naghibi M, Smith TR, Elia M. A systematic review with meta-analysis of survival, quality of life and cost-
47 effectiveness of home parenteral nutrition in patients with inoperable malignant bowel obstruction. *Clin
48 Nutr* 2014.
- 49 843. Nakamura K, Barzi F, Huxley R, et al. Does cigarette smoking exacerbate the effect of total cholesterol and
50 high-density lipoprotein cholesterol on the risk of cardiovascular diseases? *Heart* 2009;**95**(11):909-16.
- 51 844. Nakamura K, Barzi F, Lam TH, et al. Cigarette smoking, systolic blood pressure, and cardiovascular diseases in
52 the Asia-Pacific region. *Stroke* 2008;**39**(6):1694-702.
- 53 845. Nakamura K, Kuwata T, Shimoda T, et al. Determination of the optimal cutoff percentage of residual tumors
54 to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-
55 A). *Gastric Cancer* 2014.
- 56 846. Nan C, Guo B, Warner C, et al. Heritability of body mass index in pre-adolescence, young adulthood and late
57 adulthood. *Eur J Epidemiol* 2012;**27**(4):247-53.
- 58 847. Naumann DN, Bhangu A, Kelly M, et al. Stapled versus handsewn intestinal anastomosis in emergency
59 laparotomy: a systemic review and meta-analysis. *Surgery* 2015;**157**(4):609-18.
- 60

- 1
2
3 848. Neal B, MacMahon S, Chapman N, et al. Effects of ACE inhibitors, calcium antagonists, and other blood-
4 pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *Blood*
5 *Pressure Lowering Treatment Trialists' Collaboration*. *Lancet* 2000;**356**(9246):1955-64.
- 6 849. Negri E, Dal Maso L, Ron E, et al. A pooled analysis of case-control studies of thyroid cancer[†] II. Menstrual
7 and reproductive factors. *Cancer Causes Control* 1999;**10**(2):143-55.
- 8 850. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol
9 inhaled from a single inhaler versus separate inhalers.[see comment]. *J Allergy Clin Immunol*
10 2003;**112**(1):29-36.
- 11 851. Nelson JC. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis
12 of individual patient data from 11 placebo-controlled trials. *Depress Anxiety* 2010;**27**(1):12-8.
- 13 852. Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-
14 analysis. *Am J Psychiatry* 2013;**170**(6):651-9.
- 15 853. Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration NC. Neoadjuvant
16 chemotherapy for locally advanced cervix cancer. [Review] [47 refs]. *Cochrane Database Syst Rev*
17 2004(2):CD001774.
- 18 854. Neuman A, Hohmann C, Orsini N, et al. Maternal smoking in pregnancy and asthma in preschool children: a
19 pooled analysis of eight birth cohorts. *Am J Respir Crit Care Med* 2012;**186**(10):1037-43.
- 20 855. Newman DB, Fidahusein SS, Kashiwagi DT, et al. Reversible cardiac dysfunction associated with
21 hypocalcemia: A systematic review and meta-analysis of individual patient data. *Heart Fail Rev*
22 2014;**19**(2):199-205.
- 23 856. Ni Mhurchu C, Rodgers A, Pan WH, et al. Body mass index and cardiovascular disease in the Asia-Pacific
24 Region: an overview of 33 cohorts involving 310 000 participants. *Int J Epidemiol* 2004;**33**(4):751-8.
- 25 857. Nicolucci A, Carinci F, Graepel JG, et al. The efficacy of tolrestat in the treatment of diabetic peripheral
26 neuropathy. A meta-analysis of individual patient data. *Diabetes Care* 1996;**19**(10):1091-6.
- 27 858. Nieder C, Grosu AL, Andratschke NH, et al. Proposal of human spinal cord reirradiation dose based on
28 collection of data from 40 patients. [Review] [36 refs]. *International Journal of Radiation Oncology,*
29 *Biology, Physics* 2005;**61**(3):851-5.
- 30 859. Nitsch D, Grams M, Sang Y, et al. Associations of estimated glomerular filtration rate and albuminuria with
31 mortality and renal failure by sex: a meta-analysis. *BMJ* 2013;**346**:f324.
- 32 860. Nixon R, Bergvall N, Tomic D, et al. No evidence of disease activity: indirect comparisons of oral therapies for
33 the treatment of relapsing-remitting multiple sclerosis. *Adv Ther* 2014;**31**(11):1134-54.
- 34 861. Nolan SJ, Marson AG, Pulman J, et al. Phenytoin versus valproate monotherapy for partial onset seizures and
35 generalised onset tonic-clonic seizures. *Cochrane Database Syst Rev* 2013;**8**:CD001769.
- 36 862. Nolan SJ, Muller M, Tudur Smith C, et al. Oxcarbazepine versus phenytoin monotherapy for epilepsy.
37 *Cochrane Database Syst Rev* 2013;**5**:CD003615.
- 38 863. Nolan SJ, Tudur Smith C, Pulman J, et al. Phenobarbitone versus phenytoin monotherapy for partial onset
39 seizures and generalised onset tonic-clonic seizures. *Cochrane Database Syst Rev* 2013;**1**:CD002217.
- 40 864. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. . *Cochrane*
41 *Database Syst Rev* 2000(2):CD002139.
- 42 865. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care
43 alone for advanced non-small cell lung cancer. *Cochrane Database Syst Rev* 2010(5):CD007309.
- 44 866. Noordzij JP, Lee SL, Bernet VJ, et al. Early Prediction of Hypocalcemia after Thyroidectomy using Parathyroid
45 Hormone: An Analysis of Pooled Individual Patient Data from Nine Observational Studies. *J Am Coll Surg*
46 2007;**205**(6):748-54.
- 47 867. Norman G, Soares M, Peura P, et al. Capecitabine for the treatment of advanced gastric cancer. *Health*
48 *technology assessment (Winchester, England)* 2010;**14**(Suppl. 2):11-7.
- 49 868. Novara G, Chapple CR, Montorsi F. A pooled analysis of individual patient data from registrational trials of
50 silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of
51 benign prostatic hyperplasia (BPH). *BJU Int* 2014.
- 52 869. Novara G, Chapple CR, Montorsi F. Individual patient data from registrational trials of silodosin in the
53 treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic
54 hyperplasia (BPH): subgroup analyses of efficacy and safety data. *BJU Int* 2015;**115**(5):802-14.
- 55 870. nsary-Moghaddam A, Huxley R, Barzi F, et al. The effect of modifiable risk factors on pancreatic cancer
56 mortality in populations of the Asia-Pacific region. *Cancer Epidemiology Biomarkers and Prevention*
57 2006;**15**(12):2435-40.
- 58 871. NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or
59 without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of
60 individual patient data. *Lancet* 2010;**375**(9722):1267-77.

- 1
2
3 872. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a
4 systematic review and meta-analysis of individual participant data. *Lancet* 2014;**383**(9928):1561-71.
- 5 873. Nyberg ST, Fransson EI, Heikkilä K, et al. Job strain and cardiovascular disease risk factors: meta-analysis of
6 individual-participant data from 47,000 men and women. *PLoS ONE [Electronic Resource]*
7 2013;**8**(6):e67323.
- 8 874. Nyberg ST, Heikkilä K, Fransson EI, et al. Job strain in relation to body mass index: pooled analysis of 160 000
9 adults from 13 cohort studies. *J Intern Med* 2012;**272**(1):65-73.
- 10 875. Nyström L, Wall S, Rutqvist L, et al. Breast cancer screening with mammography: overview of Swedish
11 randomised trials. *Lancet* 1993;**341**(8851):973-78.
- 12 876. Oba K, Kobayashi M, Matsui T, et al. Individual patient based meta-analysis of lentinan for
13 unresectable/recurrent gastric cancer. *Anticancer Res* 2009;**29**(7):2739-45.
- 14 877. Oba MS, Teramukai S, Ohashi Y, et al. The efficacy of adjuvant immunochemotherapy with OK-432 after
15 curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled
16 trials. *Gastric Cancer* 2015.
- 17 878. O'Connor SA, Morice MC, Gilard M, et al. Revisiting Sex Equality with Transcatheter Aortic Valve Replacement
18 Outcomes A Collaborative, Patient-Level Meta-Analysis of 11,310 Patients. *J Am Coll Cardiol*
19 2015;**66**(3):221-28.
- 20 879. Offringa M, Bossuyt PM, Lubsen J, et al. Risk factors for seizure recurrence in children with febrile seizures: a
21 pooled analysis of individual patient data from five studies. *J Pediatr* 1994;**124**(4):574-84.
- 22 880. Ohashi Y, Uemura Y, Fujisaka Y, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for
23 chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized,
24 placebo-controlled trials. *Cancer Sci* 2013;**104**(4):481-5.
- 25 881. Ohashi Y, Watanabe T, Sano M, et al. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared
26 with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled
27 analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial). *Breast Cancer Res Treat*
28 2010;**119**(3):633-41.
- 29 882. Olsen CM, Zens MS, Green AC, et al. Biologic markers of sun exposure and melanoma risk in women: pooled
30 case-control analysis. *Int J Cancer* 2011;**129**(3):713-23.
- 31 883. O'Meara S, Cullum N, Nelson EA, et al. Compression for venous leg ulcers. *Cochrane Database Syst Rev*
32 2012;**11**:CD000265.
- 33 884. O'Neill ID. Efficacy of tumour necrosis factor-alpha antagonists in aphthous ulceration: review of published
34 individual patient data. *J Eur Acad Dermatol Venereol* 2012;**26**(2):231-5.
- 35 885. Ong KT, Delorme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short-
36 term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. *J*
37 *Hypertens* 2011;**29**(6):1034-42.
- 38 886. Opdam NJM, van de Sande FH, Bronkhorst E, et al. Longevity of posterior composite restorations: a
39 systematic review and meta-analysis. *J Dent Res* 2014;**93**(10):943-9.
- 40 887. Orditura M, Galizia G, Morgillo F, et al. Complete response to preoperative chemoradiation and survival in
41 esophageal cancer: a pooled analysis of three single-institution phase II trials. *Dis Esophagus*
42 2012;**25**(2):130-6.
- 43 888. Ordóñez-Mena JM, Schöttker B, Fedirko V, et al. Pre-diagnostic vitamin D concentrations and cancer risks in
44 older individuals: an analysis of cohorts participating in the CHANCES consortium. *Eur J Epidemiol* 2015.
- 45 889. Ossenkuppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia
46 syndromes: a meta-analysis. *JAMA* 2015;**313**(19):1939-49.
- 47 890. Oudshoorn SC, Rinkel GJE, Molyneux AJ, et al. Aneurysm Treatment <24 Versus 24-72 h After Subarachnoid
48 Hemorrhage. *Neurocrit Care* 2014.
- 49 891. Padwal R, McAlister FA, McMurray JJV, et al. The obesity paradox in heart failure patients with preserved
50 versus reduced ejection fraction: a meta-analysis of individual patient data. *Int J Obes* 2014;**38**(8):1110-4.
- 51 892. Pagliaro L, Craxi A, Cammaa C, et al. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment
52 clinical predictors of response. *Hepatology* 1994;**19**(4):820-8.
- 53 893. Palma DA, Senan S, Oberije C, et al. Predicting esophagitis after chemoradiation therapy for non-small cell
54 lung cancer: an individual patient data meta-analysis. *International Journal of Radiation Oncology,*
55 *Biology, Physics* 2013;**87**(4):690-6.
- 56 894. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung
57 cancer: an international individual patient data meta-analysis. *International Journal of Radiation*
58 *Oncology, Biology, Physics* 2013;**85**(2):444-50.
- 59
60

- 1
2
3 895. Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. *J Am Coll Cardiol* 2015;**65**(11):1092-102.
- 4
5
6 896. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncol* 2014;**15**(3):333-42.
- 7
8 897. Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. *Haematologica* 2013;**98**(1):87-94.
- 9
10 898. Pandor A, Thokala P, Goodacre S, et al. Pre-hospital non-invasive ventilation for acute respiratory failure: A systematic review and cost-effectiveness evaluation. *Health Technol Assess* 2015;**19**(42):1-8.
- 11
12 899. Papakostas GI, Montgomery SA, Thase ME, et al. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: A pooled survival analysis of 7 double-blind, randomized clinical trials. *J Clin Psychiatry* 2007;**68**(12):1907-12.
- 13
14 900. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. *J Psychiatr Res* 2008;**42**(2):134-40.
- 15
16
17
18 901. Park D-W, Kim Y-H, Song HG, et al. Long-term outcome of stents versus bypass surgery in diabetic and nondiabetic patients with multivessel or left main coronary artery disease: a pooled analysis of 5775 individual patient data. *Circ Cardiovasc Interv* 2012;**5**(4):467-75.
- 19
20 902. Park D-W, Kim Y-H, Yun S-C, et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. *Eur Heart J* 2013;**34**(22):1662-9.
- 21
22 903. Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. *Cochrane Database Syst Rev* 2012;**12**:CD005225.
- 23
24 904. Patel A, Barzi F, Jamrozik K, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. *Circulation* 2004;**110**(17):2678-86.
- 25
26 905. Patel KV, Semba RD, Ferrucci L, et al. Red cell distribution width and mortality in older adults: a meta-analysis. *Journals of Gerontology Series A-Biological Sciences and Medical Sciences* 2010;**65**(3):258-65.
- 27
28 906. Patra J, Jha P, Rehm J, et al. Tobacco smoking, alcohol drinking, diabetes, low body mass index and the risk of self-reported symptoms of active tuberculosis: Individual Participant Data (IPD) meta-analyses of 72,684 individuals in 14 high tuberculosis burden countries. *PLoS ONE [Electronic Resource]* 2014;**9**(5).
- 29
30 907. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: A collaborative patient-level meta-analysis of 13 randomized studies. *Circulation* 2011;**123**(15):1622-32.
- 31
32 908. Pavlov CS, Casazza G, Nikolova D, et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. *Cochrane Database Syst Rev* 2015;**1**.
- 33
34 909. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. *J Urol* 1996;**156**(6):1934-40.
- 35
36 910. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncol* 2012;**13**(4):385-94.
- 37
38 911. Pearse RM, Belsey JD, Cole JN, et al. Effect of dopexamine infusion on mortality following major surgery: Individual patient data meta-regression analysis of published clinical trials. *Crit Care Med* 2008;**36**(4):1323-29.
- 39
40 912. Peeters M, Kafatos G, Taylor A, et al. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. *Eur J Cancer* 2015.
- 41
42 913. Peinemann F, Smith LA, Bartel C. Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas. *Cochrane Database Syst Rev* 2013;**8**:CD008216.
- 43
44 914. Pereira TV, Kimura L, Suwazono Y, et al. Multivariate meta-analysis of the association of G-protein beta 3 gene (GNB3) haplotypes with cardiovascular phenotypes. *Mol Biol Rep* 2014:1-13.
- 45
46 915. Peter I, Crosier MD, Yoshida M, et al. Associations of APOE gene polymorphisms with bone mineral density and fracture risk: a meta-analysis. *Osteoporos Int* 2011;**22**(4):1199-209.
- 47
48 916. Peters AL, Davidson MB, Schriger DL, et al. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. *JAMA* 1996;**276**(15):1246-52.
- 49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 917. Peters SA, Woodward M, Lam TH, et al. Sex disparities in risk and risk factors for ischemic heart disease in the
4 Asia-Pacific region. *European Journal of Preventive Cardiology* 2014;**21**(5):639-46.
- 5 918. Pettengell R, Schwenkglenks M, Bacon P, et al. Pegfilgrastim primary prophylaxis in patients with non-
6 Hodgkin lymphoma: results from an integrated analysis. *Hematol Oncol* 2011;**29**(4):177-84.
- 7 919. Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill
8 patients during 2009 H1N1 influenza pandemic: A prospective cohort study, systematic review and
9 individual patient data meta-analysis. *Critical Care* 2014;**18**(2).
- 10 920. Phi X-A, Houssami N, Obdeijn I-M, et al. Magnetic resonance imaging improves breast screening sensitivity
11 in BRCA mutation carriers age > 50 years: evidence from an individual patient data meta-analysis. *J Clin
12 Oncol* 2015;**33**(4):349-56.
- 13 921. Piaggio G, Heng Z, von Hertzen H, et al. Combined estimates of effectiveness of mifepristone 10 mg in
14 emergency contraception. *Contraception* 2003;**68**(6):439-46.
- 15 922. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as
16 first-line therapy of patients with metastatic breast cancer. *J Clin Oncol* 2008;**26**(12):1980-86.
- 17 923. Piccolo R, Eitel I, Iversen AZ, et al. Intracoronary versus intravenous bolus abciximab administration in
18 patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial
19 infarction: A pooled analysis of individual patient data from five randomised controlled trials.
20 *EuroIntervention* 2014;**9**(9):1110-20.
- 21 924. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose
22 monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled
23 trials using individual patient data. *BMJ* 2011;**343**:d3805.
- 24 925. Piedbois P, Buyse M, Kemeny N, et al. Reappraisal of hepatic arterial infusion in the treatment of
25 nonresectable liver metastases from colorectal cancer. *J Natl Cancer Inst* 1996;**88**(5):252-8.
- 26 926. Piedbois P, Rougier P, Buyse M, et al. Efficacy of intravenous continuous infusion of fluorouracil compared
27 with bolus administration in advanced colorectal cancer. *Journal of clinical oncology: official journal of
28 the American Society of Clinical Oncology* 1998;**16**(1):301-08.
- 29 927. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart
30 failure (ExTraMATCH).[see comment]. *BMJ* 2004;**328**(7433):189.
- 31 928. Pietschmann S, von Bueren AO, Henke G, et al. An individual patient data meta-analysis on characteristics,
32 treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system
33 metastases reported in literature until 2013. *J Neurooncol* 2014.
- 34 929. Pietschmann S, Von Bueren AO, Kerber MJ, et al. An individual patient data meta-analysis on characteristics,
35 treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central
36 nervous system. *PLoS One* 2015;**10**(4).
- 37 930. Pignon J, Bourhis J, Domenge Co, et al. Chemotherapy added to locoregional treatment for head and neck
38 squamous-cell carcinoma: three meta-analyses of updated individual data. *Lancet* 2000;**355**(9208):949-
39 55.
- 40 931. Pignon J-P, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. *N
41 Engl J Med* 1992;**327**(23):1618-24.
- 42 932. Pignon J-P, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-
43 NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol* 2009;**92**(1):4-14.
- 44 933. Pignon J-P, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE
45 collaborative group. *J Clin Oncol* 2008;**26**(21):3552-59.
- 46 934. Pocock SJ, Lansky AJ, Mehran R, et al. Angiographic Surrogate End Points in Drug-Eluting Stent Trials. A
47 Systematic Evaluation Based on Individual Patient Data From 11 Randomized, Controlled Trials. *J Am Coll
48 Cardiol* 2008;**51**(1):23-32.
- 49 935. Pocock SJ, McCormack V, Gueyffier F, et al. A score for predicting risk of death from cardiovascular disease in
50 adults with raised blood pressure, based on individual patient data from randomised controlled trials.
51 *BMJ* 2001;**323**(7304):75-81.
- 52 936. Pollack MH, Endicott J, Liebowitz M, et al. Examining quality of life in patients with generalized anxiety
53 disorder: Clinical relevance and response to duloxetine treatment. *J Psychiatr Res* 2008;**42**(12):1042-49.
- 54 937. Pond GR, Agarwal N, Bellmunt J, et al. A nomogram including baseline prognostic factors to estimate the
55 activity of second-line therapy for advanced urothelial carcinoma. *BJU Int* 2014;**113**(5b):E137-43.
- 56 938. Porter CK, Riddle MS, Tribble DR, et al. A systematic review of experimental infections with enterotoxigenic
57 *Escherichia coli* (ETEC). *Vaccine* 2011;**29**(35):5869-85.
- 58 939. Potgieter D, Simmers D, Ryan L, et al. N-terminal pro-B-type Natriuretic Peptides' Prognostic Utility Is
59 Overestimated in Meta-analyses Using Study-specific Optimal Diagnostic Thresholds. *Anesthesiology*
60 2015;**123**(2):264-71.

- 1
2
3 940. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal
4 bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in
5 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. *N Engl J Med*
6 1991;**324**(22):1532-8.
- 7 941. Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest
8 in patients with severe obesity: meta analysis of individual patient data. *PLoS ONE [Electronic Resource]*
9 2012;**7**(3):e30325.
- 10 942. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver
11 fibrosis in patients with chronic hepatitis C. *Hepatology* 2000;**32**(5):1131-37.
- 12 943. Poynard T, Munteanu M, Ngo Y, et al. ActiTest accuracy for the assessment of histological activity grades in
13 patients with chronic hepatitis C, an overview using Obuchowski measure. *Gastroenterol Clin Biol*
14 2010;**34**(6-7):388-96.
- 15 944. Preference Collaborative Review Group. Patients' preferences within randomised trials: systematic review and
16 patient level meta-analysis. *BMJ* 2008;**337**:a1864.
- 17 945. Presson A, Moore TB, Kempert P. Efficacy of high-dose chemotherapy and autologous stem cell transplant
18 for recurrent Wilms' tumor: a meta-analysis. *J Pediatr Hematol Oncol* 2010;**32**(6):454-61.
- 19 946. Prodromou ML, Ziakas PD, Poulou LS, et al. FDG PET is a robust tool for the diagnosis of spondylodiscitis: A
20 meta-analysis of diagnostic data. *Clin Nucl Med* 2014;**39**(4):330-35.
- 21 947. Prophylactic Cranial Irradiation Overview Collaborative Group. Cranial irradiation for preventing brain
22 metastases of small cell lung cancer in patients in complete remission. *Cochrane Database Syst Rev*
23 2000;**4**.
- 24 948. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an
25 overview of 22 randomised trials with 3283 deaths in 5710 patients. *Lancet* 1995;**346**(8970):265-9.
- 26 949. Proulx NL, Akbari A, Garg AX, et al. Measured creatinine clearance from timed urine collections substantially
27 overestimates glomerular filtration rate in patients with liver cirrhosis: A systematic review and individual
28 patient meta-analysis. *Nephrology Dialysis Transplantation* 2005;**20**(8):1617-22.
- 29 950. Prowle JR, Ishikawa K, May CN, et al. Renal plasma flow and glomerular filtration rate during acute kidney
30 injury in man. *Ren Fail* 2010;**32**(3):349-55.
- 31 951. Pujol JL, Pirker R, Lynch TJ, et al. Meta-analysis of individual patient data from randomized trials of
32 chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. *Lung*
33 *Cancer* 2014;**83**(2):211-18.
- 34 952. Qizilbash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of
35 the tacrine trials. *Dementia Trialists' Collaboration*. [see comment]. *JAMA* 1998;**280**(20):1777-82.
- 36 953. Quan A, Kerlikowske K, Gueyffier F, et al. Efficacy of treating hypertension in women. *J Gen Intern Med*
37 1999;**14**(12):718-29.
- 38 954. Quarles van Ufford HME, van Tinteren H, Stroobants SG, et al. Added value of baseline 18F-FDG uptake in
39 serial 18F-FDG PET for evaluation of response of solid extracerebral tumors to systemic cytotoxic
40 neoadjuvant treatment: a meta-analysis. *J Nucl Med* 2010;**51**(10):1507-16.
- 41 955. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-
42 analysis of individual patient data from EORTC clinical trials. *Lancet Oncol* 2009;**10**(9):865-71.
- 43 956. Rabinowitz J, Werbeloff N, Caers I, et al. Determinants of antipsychotic response in schizophrenia:
44 Implications for practice and future clinical trials. *J Clin Psychiatry* 2014;**75**(4):e308-e16.
- 45 957. Raboud J, Montaner J, Rae S, et al. Meta-analysis of five randomized controlled trials comparing continuation
46 of zidovudine versus switching to didanosine in HIV-infected individuals. *Antivir Ther* 1997;**2**(4):237-47.
- 47 958. Raboud JM, Diong C, Carr A, et al. A meta-analysis of six placebo-controlled trials of thiazolidinedione
48 therapy for HIV lipoatrophy. *HIV Clin Trials* 2010;**11**(1):39-50.
- 49 959. Raboud JM, Rae S, Montaner JS. Predicting HIV RNA virologic outcome at 52-weeks follow-up in
50 antiretroviral clinical trials. The INCAS and AVANTI Study Groups. *Journal of Acquired Immune Deficiency*
51 *Syndromes: JAIDS* 2000;**24**(5):433-9.
- 52 960. Raboud JM, Rae S, Vella S, et al. Meta-analysis of two randomized controlled trials comparing combined
53 zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in
54 patients with HIV. INCAS study team. *Journal of Acquired Immune Deficiency Syndromes: JAIDS*
55 1999;**22**(3):260-6.
- 56 961. Raftopoulos Y, Senagore AJ, Di GG, et al. Recurrence rates after abdominal surgery for complete rectal
57 prolapse: A multicenter pooled analysis of 643 individual patient data. *Dis Colon Rectum*
58 2005;**48**(6):1200-06.
- 59
60

- 1
2
3 962. Rahman A, Rizwan S, Waycaster C, et al. Pooled analysis of two clinical trials comparing the clinical outcomes
4 of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic
5 suspension for the treatment of acute otitis externa in adults and children. *Clin Ther* 2007;**29**(9):1950-6.
- 6 963. Raja FA, Counsell N, Colombo N, et al. Platinum versus platinum-combination chemotherapy in platinum-
7 sensitive recurrent ovarian cancer: A meta-analysis using individual patient data. *Ann Oncol*
8 2013;**24**(12):3028-34.
- 9 964. Ramey DR, Watson DJ, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of
10 etoricoxib vs non-selective NSAIDs: An updated combined analysis. *Curr Med Res Opin* 2005;**21**(5):715-
11 22.
- 12 965. Rand WM, Pellett PL, Young VR. Meta-analysis of nitrogen balance studies for estimating protein
13 requirements in healthy adults. *Am J Clin Nutr* 2003;**77**(1):109-27.
- 14 966. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from
15 controlled clinical trials in participants with type 2 diabetes. *Cardiovasc Diabetol* 2011;**10**:22.
- 16 967. Ravaud A, Urva SR, Grosch K, et al. Relationship between everolimus exposure and safety and efficacy: Meta-
17 analysis of clinical trials in oncology. *Eur J Cancer* 2014;**50**(3):486-95.
- 18 968. Ravn A-M, Gregersen NT, Christensen R, et al. Thermic effect of a meal and appetite in adults: an individual
19 participant data meta-analysis of meal-test trials. *Food and Nutrition Research* 2013;**57**.
- 20 969. Read JS. Mortality among HIV-1-infected women according to children's feeding modality: An individual
21 patient data meta-analysis. *J Acquir Immune Defic Syndr* 2005;**39**(4):430-38.
- 22 970. Regan MM, O'Donnell EK, Kelly WK, et al. Efficacy of carboplatin-taxane combinations in the management of
23 castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. *Ann Oncol*
24 2010;**21**(2):312-8.
- 25 971. Reigner B, Welker H. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual
26 data from 10 pharmacokinetic studies. *Antimicrob Agents Chemother* 1996;**40**(3):575-80.
- 27 972. Rejnmark L, Avenell A, Masud T, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis
28 of 70,528 patients from eight major vitamin D trials. *J Clin Endocrinol Metab* 2012;**97**(8):2670-81.
- 29 973. Renfro LA, Grothey A, Kerr D, et al. Survival following early-stage colon cancer: An ACCENT-based
30 comparison of patients versus a matched international general population. *Ann Oncol* 2015;**26**(5):950-
31 58.
- 32 974. Rerkasem K, Rothwell PM. Carotid endarterectomy for symptomatic carotid stenosis. *Cochrane Database Syst*
33 *Rev* 2011(4):CD001081.
- 34 975. Rhee S-Y, Blanco JL, Jordan MR, et al. Geographic and Temporal Trends in the Molecular Epidemiology and
35 Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level
36 Meta-Analysis. *PLoS Med* 2015;**12**(4):e1001810.
- 37 976. Richards S, Pui C-H, Gayon P, et al. Systematic review and meta-analysis of randomized trials of central
38 nervous system directed therapy for childhood acute lymphoblastic leukemia. *Pediatric Blood and*
39 *Cancer* 2013;**60**(2):185-95.
- 40 977. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful
41 life events, and risk of depression: a meta-analysis. *JAMA* 2009;**301**(23):2462-71.
- 42 978. Rizk S, Robert A, Vandenhooft A, et al. Activity of chemotherapy in the palliative treatment of salivary gland
43 tumors: review of the literature. *Eur Arch Otorhinolaryngol* 2007;**264**(6):587-94.
- 44 979. Roche H, Conte P, Perez EA, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with
45 reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by
46 performance status of efficacy and safety data from 2 phase III studies. *Breast Cancer Res Treat*
47 2011;**125**(3):755-65.
- 48 980. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative
49 analysis of 18 prospective studies. *J Natl Cancer Inst* 2008;**100**(3):170-83.
- 50 981. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate
51 cancer risk: Analysis of individual patient data from 12 prospective studies. *Ann Intern Med*
52 2008;**149**(7):461-71.
- 53 982. Rodondi N, Maisonneuve P, Razvi S, et al. Subclinical Hypothyroidism and the Risk of Coronary Heart Disease
54 and Mortality: An Individual Participant Data Analysis from Nine Prospective Cohort Studies. *J Gen Intern*
55 *Med* 2010;**25**:394-95.
- 56 983. Rodrigo GJ, Neffen H. Assessment of acute asthma severity in the ED: Are heart and respiratory rates
57 relevant? *Am J Emerg Med* 2015.
- 58 984. Rodseth RN, Biccard BM, Chu R, et al. Postoperative B-type natriuretic peptide for prediction of major cardiac
59 events in patients undergoing noncardiac surgery: systematic review and individual patient meta-
60 analysis. *Anesthesiology* 2013;**119**(2):270-83.

- 1
2
3 985. Rodseth RN, Biccard BM, Le Manach Y, et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. *J Am Coll Cardiol* 2014;**63**(2):170-80.
- 4
5
6
7 986. Rodseth RN, Lurati Buse GA, Bolliger D, et al. The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. *J Am Coll Cardiol* 2011;**58**(5):522-9.
- 8
9
10 987. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. *Ophthalmology* 2010;**117**(2):313-9.e1.
- 11
12
13 988. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. *J Clin Oncol* 2005;**23**(10):2215-23.
- 14
15 989. Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer.[update of Cochrane Database Syst Rev. 2000;(4):CD001768; PMID: 11034727]. [Review] [39 refs]. *Cochrane Database Syst Rev* 2005(1):CD001768.
- 16
17
18 990. Roman E, Fear NT, Ansell P, et al. Vitamin K and childhood cancer: analysis of individual patient data from six case-control studies. *Br J Cancer* 2002;**86**(1):63-9.
- 19
20 991. Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. *Am J Obstet Gynecol* 2012;**206**(2):124.e1-19.
- 21
22
23 992. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. *Cochrane Database Syst Rev* 2013;**5**:CD008107.
- 24
25
26 993. Roseann AE, Koru-Sengul T, Linkins L, et al. Differences in clinical presentation of deep vein thrombosis in men and women. *J Thromb Haemost* 2008;**6**(10):1713-19.
- 27
28 994. Rosenfeld E, Beyerlein A, Hadders-Algra M, et al. IPD meta-analysis shows no effect of LC-PUFA supplementation on infant growth at 18 months. *Acta Paediatr* 2009;**98**(1):91-97.
- 29
30 995. Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. *Cochrane Database Syst Rev* 2010(9):CD004332.
- 31
32 996. Rossi A, Chiodini P, Sun J-M, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. *Lancet Oncol* 2014;**15**(11):1254-62.
- 33
34 997. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. *J Clin Oncol* 2012;**30**(14):1692-8.
- 35
36
37 998. Rothwell PM, Fowkes FGR, Belch JFF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 2011;**377**(9759):31-41.
- 38
39 999. Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet* 2012;**379**(9826):1602-12.
- 40
41
42 1000. Rothwell PM, Wilson M, Elwin C-E, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet* 2010;**376**(9754):1741-50.
- 43
44 1001. Rovers MM, Black N, Browning GG, et al. Grommets in otitis media with effusion: an individual patient data meta-analysis. [Review] [32 refs]. *Arch Dis Child* 2005;**90**(5):480-5.
- 45
46 1002. Rovers MM, Glasziou P, Appelman CL, et al. Antibiotics for acute otitis media: a meta-analysis with individual patient data. *Lancet* 2006;**368**(9545):1429-35.
- 47
48 1003. Rovers MM, Glasziou P, Appelman CL, et al. Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: A meta-analysis of individual patient data. *Pediatrics* 2007;**119**(3):579-85.
- 49
50 1004. Ruijs ACJ, Jaquet J-B, Kalmijn S, et al. Median and ulnar nerve injuries: A meta-analysis of predictors of motor and sensory recovery after modern microsurgical nerve repair. *Plast Reconstr Surg* 2005;**116**(2):484-94.
- 51
52
53 1005. Russ TC, Stamatakis E, Hamer M, et al. Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies. *BMJ* 2012;**345**:e4933.
- 54
55 1006. Russ TC, Stamatakis E, Hamer M, et al. Socioeconomic status as a risk factor for dementia death: individual participant meta-analysis of 86 508 men and women from the UK. *Br J Psychiatry* 2013;**203**(1):10-7.
- 56
57
58
59
60

1007. Russell JM, Weisberg R, Fava M, et al. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. *Depress Anxiety* 2008;**25**(7):E1-11.
1008. Sabaté M, Räber L, Heg D, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: A pooled analysis of the EXAMINATION (clinical evaluation of the xience-V stent in acute myocardial InfArcTION) and COMFORTABLE-AMI. *JACC Cardiovasc Interv* 2014;**7**(1):55-63.
1009. Saber W, Moua T, Williams EC, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. *J Thromb Haemost* 2011;**9**(2):312-9.
1010. Saccone G, Rust O, Althuisius S, et al. Cerclage for short cervix in twin pregnancies: systematic review and meta-analysis of randomized trials using individual patient-level data. *Acta Obstet Gynecol Scand* 2015;**94**(4):352-8.
1011. Sadigh G, Carlos RC, Neal CH, et al. Impact of breast mass size on accuracy of ultrasound elastography vs. conventional B-mode ultrasound: a meta-analysis of individual participants. *Eur Radiol* 2013;**23**(4):1006-14.
1012. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. *International Journal of Radiation Oncology, Biology, Physics* 2015;**91**(4):710-7.
1013. Sakamoto J, Hamada C, Kodaira S, et al. Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. *Jpn J Clin Oncol* 1999;**29**(2):78-86.
1014. Sakamoto J, Hamada C, Rahman M, et al. An individual patient data meta-analysis of adjuvant therapy with capecitabine in patients with curatively resected colon cancer. *Jpn J Clin Oncol* 2005;**35**(9):536-44.
1015. Sakamoto J, Hamada C, Yoshida S, et al. An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. *Br J Cancer* 2007;**96**(8):1170-77.
1016. Sakamoto J, Kodaira S, Hamada C, et al. An individual patient data meta-analysis of long supported adjuvant chemotherapy with oral capecitabine in patients with curatively resected colorectal cancer. *Oncol Rep* 2001;**8**(3):697-703.
1017. Sakamoto J, Ohashi Y, Hamada C, et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. *J Clin Oncol* 2004;**22**(3):484-92.
1018. Sakamoto J, Teramukai S, Koike A, et al. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. *Cancer* 1996;**77**(11):2206-12.
1019. Salah K, Kok WE, Eurlings LW, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European collaboration on Acute decompensated Heart Failure: ELAN-HF Score. *Heart* 2014;**100**(2):115-25.
1020. Salah K, Pinto YM, Eurlings LW, et al. Serum potassium decline during hospitalization for acute decompensated heart failure is a predictor of 6-month mortality, independent of N-terminal pro-B-type natriuretic peptide levels: An individual patient data analysis. *Am Heart J* 2015.
1021. Salah S, Watanabe K, Welter S, et al. Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. *Ann Oncol* 2012;**23**(10):2649-55.
1022. Salameh H, Raff E, Erwin A, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. *Am J Gastroenterol* 2015;**110**(6):846-56.
1023. Salerno F, Camma C, Enea M, et al. Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. *Gastroenterology* 2007;**133**:825-34.
1024. Samara MT, Leucht C, Leeflang MM, et al. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. *Am J Psychiatry* 2015;**172**(7):617-29.
1025. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. *J Clin Endocrinol Metab* 2011;**96**(5):1327-35.
1026. Sarcoma Meta-analysis Collaboration S. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults.[update of Cochrane Database Syst Rev. 2000;(2):CD001419; PMID: 10796873]. [Review] [45 refs]. *Cochrane Database Syst Rev* 2000(4):CD001419.
1027. Sargent D, Shi Q, Yothers G, et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. *Eur J Cancer* 2011;**47**(7):990-6.

- 1
2
3 1028. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected
4 colon cancer in elderly patients.[see comment]. *N Engl J Med* 2001;**345**(15):1091-7.
- 5 1029. Sargent DJ, Kohne CH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the effect of
6 performance status on outcomes in nine first-line treatment trials using individual data from patients
7 with metastatic colorectal cancer. *J Clin Oncol* 2009;**27**(12):1948-55.
- 8 1030. Sargent DJ, Patiyil S, Yothers G, et al. End points for colon cancer adjuvant trials: Observations and
9 recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized
10 trials from the ACCENT group. *J Clin Oncol* 2007;**25**(29):4569-74.
- 11 1031. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point
12 for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. *J*
13 *Clin Oncol* 2005;**23**(34):8664-70.
- 14 1032. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of
15 vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010;**375**(9733):2215-
16 22.
- 17 1033. Satoh M, Ohkubo T, Asayama K, et al. Combined effect of blood pressure and total cholesterol levels on
18 long-term risks of subtypes of cardiovascular death: Evidence for Cardiovascular Prevention from
19 Observational Cohorts in Japan. *Hypertension* 2015;**65**(3):517-24.
- 20 1034. Schacht A, Gorwood P, Boyce P, et al. Depression symptom clusters and their predictive value for treatment
21 outcomes: Results from an individual patient data meta-analysis of duloxetine trials. *J Psychiatr Res*
22 2014;**53**(1):54-61.
- 23 1035. Schaich M, Schlenk RF, Al-Ali HK, et al. Prognosis of acute myeloid leukemia patients up to 60 years of age
24 exhibiting trisomy 8 within a non-complex karyotype: Individual patient data-based meta-analysis of the
25 German Acute Myeloid Leukemia Intergroup. *Haematologica* 2007;**92**(6):763-70.
- 26 1036. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of
27 interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. *J*
28 *Hepatol* 1997;**26**(5):961-6.
- 29 1037. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without
30 cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral
31 Hepatitis. *Gastroenterology* 1999;**117**(2):408-13.
- 32 1038. Scherthaner G, Barnett AH, Patel S, et al. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor
33 linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331
34 individuals aged > 65 years. *Diabetes, Obesity and Metabolism* 2014;**16**(11):1078-86.
- 35 1039. Schinkel J, Spoon WJ, Kroes AC. Meta-analysis of mutations in the NS5A gene and hepatitis C virus
36 resistance to interferon therapy: uniting discordant conclusions. *Antivir Ther* 2004;**9**(2):275-86.
- 37 1040. Schlamann A, Von Bueren AO, Hagel C, et al. An individual patient data meta-analysis on characteristics and
38 outcome of patients with papillary glioneuronal tumor, rosette glioneuronal tumor with neuropil-like
39 islands and rosette forming glioneuronal tumor of the fourth ventricle. *PLoS One* 2014;**9**(7).
- 40 1041. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60
41 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia
42 Intergroup. *J Clin Oncol* 2004;**22**(18):3741-50.
- 43 1042. Schmoll H-J, Twelves C, Sun W, et al. Effect of adjuvant capecitabine or fluorouracil, with or without
44 oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse
45 survival: a pooled analysis of individual patient data from four randomised controlled trials. *Lancet Oncol*
46 2014;**15**(13):1481-92.
- 47 1043. Schottker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-analysis of individual participant data
48 from a large consortium of cohort studies from Europe and the United States. *BMJ* 2014;**348**:g3656.
- 49 1044. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute
50 respiratory tract infections. *Cochrane Database Syst Rev* 2012;**9**:CD007498.
- 51 1045. Schuit E, Amer-Wahlin I, Ojala K, et al. Effectiveness of electronic fetal monitoring with additional ST analysis
52 in vertex singleton pregnancies at >36 weeks of gestation: an individual participant data metaanalysis.
53 *Am J Obstet Gynecol* 2013;**208**(3):187.e1-87.e13.
- 54 1046. Schuit E, Stock S, Rode L, et al. Effectiveness of progestogens to improve perinatal outcome in twin
55 pregnancies: an individual participant data meta-analysis. *BJOG* 2015;**122**(1):27-37.
- 56 1047. Scott JR. Immunotherapy for recurrent miscarriage.[update of Cochrane Database Syst Rev.
57 2000;(2):CD000112; PMID: 10796135]. [Review] [54 refs]. *Cochrane Database Syst Rev* 2003(1):CD000112.
- 58 1048. Scott NW, McCormack K, Graham P, et al. Open mesh versus non-mesh for repair of femoral and inguinal
59 hernia. *Cochrane Database Syst Rev* 2002(4):CD002197.
- 60

- 1
2
3 1049. Sebba AI, Emkey RD, Kohles JD, et al. Ibandronate dose response is associated with increases in bone
4 mineral density and reductions in clinical fractures: Results of a meta-analysis. *Bone* 2009;**44**(3):423-27.
- 5 1050. Serpa Neto A, Hemmes SNT, Barbas CSV, et al. Protective versus Conventional Ventilation for Surgery: A
6 Systematic Review and Individual Patient Data Meta-analysis. *Anesthesiology* 2015;**123**(1):66-78.
- 7 1051. Serpa Neto A, Hemmes SNT, Barbas CSV, et al. Incidence of mortality and morbidity related to
8 postoperative lung injury in patients who have undergone abdominal or thoracic surgery: a systematic
9 review and meta-analysis. *Lancet Respir Med* 2014;**2**(12):1007-15.
- 10 1052. Serpa Neto A, Simonis FD, Barbas CSV, et al. Association between tidal volume size, duration of ventilation,
11 and sedation needs in patients without acute respiratory distress syndrome: an individual patient data
12 meta-analysis. *Intensive Care Med* 2014;**40**(7):950-7.
- 13 1053. Serretti A, Cusin C, Rausch JL, et al. Pooling pharmacogenetic studies on the serotonin transporter: A mega-
14 analysis. *Psychiatry Res* 2006;**145**(1):61-65.
- 15 1054. Seshasai SRK, Bennett RL, Petrie JR, et al. Cardiovascular safety of the glucagon-like peptide-1 receptor
16 agonist taspoglutide in people with type 2 diabetes: An individual participant data meta-analysis of
17 randomized controlled trials. *Diabetes, Obesity and Metabolism* 2015;**17**(5):505-10.
- 18 1055. Seth A, Serruys PW, Lansky A, et al. A pooled gender based analysis comparing the XIENCE V(R) everolimus-
19 eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery
20 disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. *EuroIntervention* 2010;**5**(7):788-
21 94.
- 22 1056. Shaikh N, Craig JC, Rovers MM, et al. Identification of children and adolescents at risk for renal scarring after
23 a first urinary tract infection: a meta-analysis with individual patient data. *Jama, Pediatr*
24 2014;**168**(10):893-900.
- 25 1057. Sharma SK, McIntire DD, Wiley J, et al. Labor analgesia and cesarean delivery: an individual patient meta-
26 analysis of nulliparous women. *Anesthesiology* 2004;**100**(1):142-8; discussion 6A.
- 27 1058. Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the
28 treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. *BJU Int* 2007;**99**(5):1056-65.
- 29 1059. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-
30 blockers in the management of left ventricular systolic dysfunction according to race, gender, and
31 diabetic status: a meta-analysis of major clinical trials. *J Am Coll Cardiol* 2003;**41**(9):1529-38.
- 32 1060. Shepperd S, Doll H, Angus Robert M, et al. Admission avoidance hospital at home. *Cochrane Database Syst*
33 *Rev* 2008(4).
- 34 1061. Shepperd S, Doll H, Broad J, et al. Early discharge hospital at home. *Cochrane Database Syst Rev* 2009(1).
- 35 1062. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatin based combination chemotherapy in patients
36 with invasive bladder cancer: a combined analysis of two Nordic studies. *Eur Urol* 2004;**45**(3):297-303.
- 37 1063. Sherwood M, Thornton AE, Honer WG. A quantitative review of the profile and time course of symptom
38 change in schizophrenia treated with clozapine. *J Psychopharmacol* 2012;**26**(9):1175-84.
- 39 1064. Shi Q, de Gramont A, Grothey A, et al. Individual patient data analysis of progression-free survival versus
40 overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials:
41 findings from the analysis and research in cancers of the digestive system database. *J Clin Oncol*
42 2015;**33**(1):22-8.
- 43 1065. Sieber J, Koberlein J, Mosges R. Sublingual immunotherapy in daily medical practice: effectiveness of
44 different treatment schedules - IPD meta-analysis. *Curr Med Res Opin* 2010;**26**(4):925-32.
- 45 1066. Sieber J, Shah-Hosseini K, Mosges R. Specific immunotherapy for allergic rhinitis to grass and tree pollens in
46 daily medical practice-symptom load with sublingual immunotherapy compared to subcutaneous
47 immunotherapy. *Ann Med* 2011;**43**(6):418-24.
- 48 1067. Siegrist J, Dragano N, Nyberg ST, et al. Validating abbreviated measures of effort-reward imbalance at work
49 in European cohort studies: The IPD-Work consortium. *Int Arch Occup Environ Health* 2014;**87**(3):249-56.
- 50 1068. Signorovitch J, Ramakrishnan K, Ben-Hamadi R, et al. Remission of major depressive disorder without
51 adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake
52 inhibitors.[Erratum appears in *Curr Med Res Opin*. 2011 Sep;27(9):1708]. *Curr Med Res Opin*
53 2011;**27**(6):1089-96.
- 54 1069. Silva IS, De SB, McCormack V, et al. Birth size and breast cancer risk: re-analysis of individual participant
55 data from 32 studies.[see comment]. *PLoS Med* 2008;**5**(9):e193-.
- 56 1070. Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the
57 INSPIRE collaboration. *Circulation* 2014;**130**(13):1062-71.
- 58 1071. Simmonds MC, Brown JVE, Heirs MK, et al. Safety and effectiveness of recombinant human bone
59 morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. *Ann Intern*
60 *Med* 2013;**158**(12):877-89.

- 1
2
3 1072. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-
4 analysis. *Colorectal Cancer Collaborative Group. BMJ* 2000;**321**(7260):531-5.
- 5 1073. Simon GR, Schell MJ, Begum M, et al. Preliminary indication of survival benefit from ERCC1 and RRM1-
6 tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual
7 patient analysis. *Cancer* 2012;**118**(9):2525-31.
- 8 1074. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual
9 patient data. *Lancet* 2009;**374**(9691):712-9.
- 10 1075. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary
11 disease. *Thorax* 2005;**60**(12):992-97.
- 12 1076. Singh JA, Sloan JA, Atherton PJ, et al. Preferred roles in treatment decision making among patients with
13 cancer: a pooled analysis of studies using the Control Preferences Scale. *Am J Manag Care*
14 2010;**16**(9):688-96.
- 15 1077. Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in
16 staging liver fibrosis: A systematic review and meta-analysis of individual participant data. *Clin*
17 *Gastroenterol Hepatol* 2015;**13**(3):440-51.
- 18 1078. Sipahi I, Tuzcu EM, Wolski KE, et al. beta-blockers and progression of coronary atherosclerosis: Pooled
19 analysis of 4 intravascular ultrasonography trials. *Ann Intern Med* 2007;**147**(1):10-18.
- 20 1079. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of patients with advanced-
21 stage Hodgkin's lymphoma: a systematic review and network meta-analysis. *Lancet Oncol*
22 2013;**14**(10):943-52.
- 23 1080. Smart NA, Meyer T, Butterfield JA, et al. Individual patient meta-analysis of exercise training effects on
24 systemic brain natriuretic peptide expression in heart failure. *European Journal of Preventive Cardiology*
25 2012;**19**(3):428-35.
- 26 1081. Smith CT, Marson AG, Chadwick DW, et al. Multiple treatment comparisons in epilepsy monotherapy trials.
27 *Trials* 2007;**8**(34):-.
- 28 1082. Smith-Warner SA, Spiegelman D, Yaun S-S, et al. Alcohol and breast cancer in women: a pooled analysis of
29 cohort studies. *JAMA* 1998;**279**(7):535-40.
- 30 1083. Sofi AA, Silverman AL, Khuder S, et al. Relationship of symptom duration and fecal bacteriotherapy in
31 *Clostridium difficile* infection-pooled data analysis and a systematic review. *Scand J Gastroenterol*
32 2013;**48**(3):266-73.
- 33 1084. Solomon SD, Pfeffer MA, McMurray JJV, et al. Effect of celecoxib on cardiovascular events and blood
34 pressure in two trials for the prevention of colorectal adenomas. *Circulation* 2006;**114**(10):1028-35.
- 35 1085. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled
36 trials: the cross trial safety analysis. *Circulation* 2008;**117**(16):2104-13.
- 37 1086. Song GY, Hong L, Zhang H, et al. Iatrogenic medial patellar instability following lateral retinacular release of
38 the knee joint. *Knee Surgery, Sports Traumatology, Arthroscopy* 2015.
- 39 1087. Sonnenschein-Van Der Voort AMM, Arends LR, De Jongste JC, et al. Preterm birth, infant weight gain, and
40 childhood asthma risk: A meta-analysis of 147,000 European children. *J Allergy Clin Immunol*
41 2014;**133**(5):1317-29.
- 42 1088. Soriano JB, Lamprecht B, Ramirez AS, et al. Mortality prediction in chronic obstructive pulmonary disease
43 comparing the GOLD 2007 and 2011 staging systems: A pooled analysis of individual patient data.
44 *Lancet Respir Med* 2015;**3**(6):443-50.
- 45 1089. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to
46 inhaled corticosteroids or placebo. *Chest* 2007;**131**(3):682-9.
- 47 1090. Sormani MP, Stubinski B, Cornelisse P, et al. Magnetic resonance active lesions as individual-level surrogate
48 for relapses in multiple sclerosis. *Mult Scler* 2011;**17**(5):541-9.
- 49 1091. Souverein OW, de Vries JHM, Freese R, et al. Prediction of fruit and vegetable intake from biomarkers using
50 individual participant data of diet-controlled intervention studies. *Br J Nutr* 2015;**113**(9):1396-409.
- 51 1092. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with
52 bare-metal stents. *N Engl J Med* 2007;**356**(10):989-97.
- 53 1093. Specht L, Gray R, Clarke M, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on
54 long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving
55 3,888 patients. *International Hodgkin's Disease Collaborative Group. J Clin Oncol* 1998;**16**(3):830-43.
- 56 1094. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of
57 patients with depression. *Biol Psychiatry* 2002;**52**(12):1166-74.
- 58 1095. Staples MP, Kallmes DF, Comstock BA, et al. Effectiveness of vertebroplasty using individual patient data
59 from two randomised placebo controlled trials: meta-analysis. *BMJ* 2011;**343**:d3952.
- 60

- 1
2
3 1096. Staszewski S, DeMasi R, Hill AM, et al. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and
4 death during treatment with HIV-1 reverse transcriptase inhibitors. *AIDS* 1998;**12**(15):1991-97.
- 5 1097. Steele KM, Damiano DL, Eek MN, et al. Characteristics associated with improved knee extension after
6 strength training for individuals with cerebral palsy and crouch gait. *J Pediatr Rehabil Med* 2012;**5**(2):99-
7 106.
- 8 1098. Stefanini GG, Kalesan B, Pilgrim T, et al. Impact of sex on clinical and angiographic outcomes among
9 patients undergoing revascularization with drug-eluting stents. *JACC Cardiovasc Interv* 2012;**5**(3):301-10.
- 10 1099. Steiner TJ, Voelker M. Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia
11 for short-lasting acute pain. *J Clin Pharm Ther* 2009;**34**(2):177-86.
- 12 1100. Stempel DA, Stanford RH, Thwaites RM, et al. Cost-efficacy comparison of inhaled fluticasone propionate
13 and budesonide in the treatment of asthma. *Clin Ther* 2000;**22**(12):1562-74.
- 14 1101. Stengel D, Bauwens K, Rademacher G, et al. Emergency ultrasound-based algorithms for diagnosing blunt
15 abdominal trauma. *Cochrane Database Syst Rev* 2013;**7**:CD004446.
- 16 1102. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual
17 patient data from 12 randomised trials. [Review] [36 refs]. *Lancet* 2002;**359**(9311):1011-8.
- 18 1103. Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic brain injury: Development
19 and international validation of prognostic scores based on admission characteristics. *PLoS Med*
2008;**5**(8):1251-61.
- 20 1104. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for
21 pancreatic cancer. *Br J Cancer* 2005;**92**(8):1372-81.
- 22 1105. Stojkovic M, Zwahlen M, Teggi A, et al. Treatment response of cystic echinococcosis to benzimidazoles: a
23 systematic review. *PLoS Negl Trop Dis* 2009;**3**(9):e524.
- 24 1106. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of
25 death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. *Circulation*
2007;**115**(22):2842-7.
- 26 1107. Storosum JG, Elferink AJ, van Zwieten BJ, et al. Short-term efficacy of tricyclic antidepressants revisited: a
27 meta-analytic study. *Eur Neuropsychopharmacol* 2001;**11**(2):173-80.
- 28 1108. Strand V, Conaghan PG, Lohmander LS, et al. An integrated analysis of five double-blind, randomized
29 controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in
30 osteoarthritis of the knee. *Osteoarthritis Cartilage* 2006;**14**(9):859-66.
- 31 1109. Straube S, Moore RA, Paine J, et al. Interference with work in fibromyalgia: effect of treatment with
32 pregabalin and relation to pain response. *BMC Musculoskelet Disord* 2011;**12**:125.
- 33 1110. Struik FM, Lacasse Y, Goldstein RS, et al. Nocturnal noninvasive positive pressure ventilation in stable COPD:
34 A systematic review and individual patient data meta-analysis. *Respir Med* 2014;**108**(2):329-37.
- 35 1111. Sun JC, Xu T, Chen KF, et al. Assessment of cauda equina syndrome progression pattern to improve
36 diagnosis. *Spine* 2014;**39**(7):596-602.
- 37 1112. Sun X, Xu D, Luo F, et al. A cross-cultural perspective on the preference for potential effect: An individual
38 participant data (IPD) meta-analysis approach. *PLoS One* 2015;**10**(3).
- 39 1113. Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a
40 systematic review and meta-analysis. *Ann Intern Med* 2015;**162**(3):184-91.
- 41 1114. Sweeting MJ, Thompson SG, Brown LC, et al. Meta-analysis of individual patient data to examine factors
42 affecting growth and rupture of small abdominal aortic aneurysms. *Br J Surg* 2012;**99**(5):655-65.
- 43 1115. Sweeting MJ, Ulug P, Powell JT, et al. Ruptured Aneurysm Trials: The Importance of Longer-term Outcomes
44 and Meta-analysis for 1-year Mortality. *Eur J Vasc Endovasc Surg* 2015.
- 45 1116. Sylaja PN, Dong W, Grotta JC, et al. Safety outcomes of Alteplase among acute ischemic stroke patients
46 with special characteristics. *Neurocrit Care* 2007;**6**(3):181-85.
- 47 1117. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic Review and Individual Patient Data Meta-analysis
48 of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral
49 Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the
50 Bladder: Which Patients Benefit from the Instillation? *Eur Urol* 2015.
- 51 1118. Sylvester RJ, Van Der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual
52 patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients
53 from seven EORTC trials. *Eur Urol* 2006;**49**(3):466-75.
- 54 1119. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival.
55 A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study
56 Group.[see comment]. *Ann Intern Med* 1998;**128**(10):817-26.
- 57 1120. Takenaka Y, Cho H, Nakahara S, et al. Chemoradiation therapy for squamous cell carcinoma of the external
58 auditory canal: A meta-analysis. *Head Neck* 2015;**37**(7):1073-80.
- 59
60

- 1
2
3 1121. Tandon P, Abbraldes JG, Berzigotti A, et al. Renin-angiotensin-aldosterone inhibitors in the reduction of
4 portal pressure: a systematic review and meta-analysis. *J Hepatol* 2010;**53**(2):273-82.
- 5 1122. Tanvetyanon T, Finley DJ, Fabian T, et al. Prognostic factors for survival after complete resections of
6 synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. *Ann Oncol*
7 2013;**24**(4):889-94.
- 8 1123. Taylor S, Tudur Smith C, Williamson PR, et al. Phenobarbitone versus phenytoin monotherapy for partial
9 onset seizures and generalized onset tonic-clonic seizures. [Review] [16 refs]. *Cochrane Database Syst*
10 *Rev* 2001(4):CD002217.
- 11 1124. Terasawa T, Nihashi T, Hotta T, et al. F-FDG PET for posttherapy assessment of Hodgkin's disease and
12 aggressive non-Hodgkin's lymphoma: A systematic review. *J Nucl Med* 2008;**48**(1):13-21.
- 13 1125. Terwee CB, Nieveen Van Dijkum EJ, Gouma DJ, et al. Pooling of prognostic studies in cancer of the
14 pancreatic head and periampullary region: the Triple-P study. Triple-P study group. *Eur J Surg*
15 2000;**166**(9):706-12.
- 16 1126. Teulings H-E, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV
17 melanoma receiving immunotherapy and its association with survival: a systematic review and meta-
18 analysis. *J Clin Oncol* 2015;**33**(7):773-81.
- 19 1127. Teunis T, Lubberts B, Reilly BT, et al. A systematic review and pooled analysis of the prevalence of rotator
20 cuff disease with increasing age. *J Shoulder Elbow Surg* 2014;**23**(12):1913-21.
- 21 1128. Thakkinstian A, Dmitrienko S, Gerbase-DeLima M, et al. Association between cytokine gene polymorphisms
22 and outcomes in renal transplantation: A meta-analysis of individual patient data. *Nephrology Dialysis*
23 *Transplantation* 2008;**29**(9):3017-23.
- 24 1129. Thakkinstian A, Nickel JC. Efficacy of intravesical chondroitin sulphate in treatment of interstitial
25 cystitis/bladder pain syndrome (IC/BPS): Individual patient data (IPD) meta-analytical approach. *Journal*
26 *of the Canadian Urological Association* 2013;**7**(5-6 JUN):195-200.
- 27 1130. Thankappan K. Basaloid squamous cell carcinoma of the larynx--A systematic review. *Auris, Nasus, Larynx*
28 2012;**39**(4):397-401.
- 29 1131. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed
30 patients. *J Clin Psychiatry* 1998;**59**(10):502-08.
- 31 1132. Thase ME, Demyttenaere K, Earley WR, et al. Extended release quetiapine fumarate in major depressive
32 disorder: analysis in patients with anxious depression. *Depress Anxiety* 2012;**29**(7):574-86.
- 33 1133. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or
34 selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled
35 trials. *J Clin Psychiatry* 2005;**66**(8):974-81.
- 36 1134. Thase ME, Kornstein SG, Germain J-M, et al. An integrated analysis of the efficacy of desvenlafaxine
37 compared with placebo in patients with major depressive disorder. *Cns Spectrums* 2009;**14**(3):144-54.
- 38 1135. Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake
39 inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment
40 of major depression. *Int Clin Psychopharmacol* 2010;**25**(4):189-98.
- 41 1136. Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors:
42 Comparisons as assessed by remission rates in patients with major depressive disorder. *J Clin*
43 *Psychopharmacol* 2007;**27**(6):672-76.
- 44 1137. The International Study Group on Improved ORS. Impact of glycine-containing ORS solutions on stool
45 output and duration of diarrhoea: a meta-analysis of seven clinical trials. *Bull World Health Organ*
46 1991;**69**(5):541-8.
- 47 1138. The SYROCOT study group. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-
48 analysis of individual patients' data. *Lancet* 2007;**369**(9556):115-22.
- 49 1139. Thirion P, Piedbois P, Buyse M, et al. Alpha-interferon does not increase the efficacy of 5-fluorouracil in
50 advanced colorectal cancer. *Br J Cancer* 2001;**84**(5):611-20.
- 51 1140. Thirion P, Wolmark N, Haddad E, et al. Survival impact of chemotherapy in patients with colorectal
52 metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and
53 4 meta-analyses. Meta-Analysis Group in Cancer. *Ann Oncol* 1999;**10**(11):1317-20.
- 54 1141. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease,
55 stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet* 2010;**375**(9725):1536-44.
- 56 1142. Thompson DD, Murray GD, Candelise L, et al. Targeting aspirin in acute disabling ischemic stroke: An
57 individual patient data meta-analysis of three large randomized trials. *Int J Stroke* 2015.
- 58 1143. Thorgrimsen L, Spector A, Wiles A, et al. Aroma therapy for dementia. [Review] [46 refs]. *Cochrane Database*
59 *Syst Rev* 2003(3):CD003150.
- 60

- 1
2
3 1144. Thrift AP, Cook MB, Vaughan TL, et al. Alcohol and the risk of Barrett's esophagus: a pooled analysis from
4 the International BEACON Consortium. *Am J Gastroenterol* 2014;**109**(10):1586-94.
- 5 1145. Tierney J, Benedetti-Panici P, Bermudez A, et al. Neoadjuvant chemotherapy for locally advanced cervix
6 cancer. *Cochrane Database Syst Rev* 2009(4).
- 7 1146. Timmer JR, Ottervanger JP, De BM-J, et al. Primary percutaneous coronary intervention compared with
8 fibrinolysis for myocardial infarction in diabetes mellitus: Results from the primary coronary angioplasty
9 vs thrombolysis-2 trial. *Arch Intern Med* 2007;**167**(13):1353-59.
- 10 1147. Timmermans A, Opmeer BC, Khan KS, et al. Endometrial thickness measurement for detecting endometrial
11 cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. *Obstet Gynecol*
12 2010;**116**(1):160-7.
- 13 1148. Tonkin AM. Clinical relevance of statins: their role in secondary prevention. [Review] [10 refs].
14 *Atherosclerosis Supplements* 2001;**2**(1):21-5.
- 15 1149. Tornvall P, Gerbaud E, Behaghel A, et al. Myocarditis or "true" infarction by cardiac magnetic resonance in
16 patients with a clinical diagnosis of myocardial infarction without obstructive coronary disease: A meta-
17 analysis of individual patient data. *Atherosclerosis* 2015;**241**(1):87-91.
- 18 1150. Touze E, Varenne O, Chatellier G, et al. Risk of myocardial infarction and vascular death after transient
19 ischemic attack and ischemic stroke: A systematic review and meta-analysis. *Stroke* 2005;**36**(12):2748-55.
- 20 1151. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal
21 cancer. *Cochrane Database Syst Rev* 2009(4):CD007045.
- 22 1152. Trépo E, Nahon P, Bontempi G, et al. Association between the PNPLA3 (rs738409 C>G) variant and
23 hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. *Hepatology* 2014.
- 24 1153. Trialists' Collaborative Group C. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis
25 of the randomized trials. *J Natl Cancer Inst* 1999;**91**(10):861-68.
- 26 1154. Trialists' Collaboration SU. How do stroke units improve patient outcomes? A collaborative systematic
27 review of the randomized trials. *Stroke* 1997;**28**(11):2139-44.
- 28 1155. Trivella M, Pezzella F, Pastorino U, et al. Microvessel density as a prognostic factor in non-small-cell lung
29 carcinoma: a meta-analysis of individual patient data. *Lancet Oncol* 2007;**8**(6):488-99.
- 30 1156. Troughton RW, Frampton CM, Brunner-La Rocca H-P, et al. Effect of B-type natriuretic peptide-guided
31 treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-
32 analysis. *Eur Heart J* 2014;**35**(23):1559-67.
- 33 1157. Trumper M, Ross PJ, Cunningham D, et al. Efficacy and tolerability of chemotherapy in elderly patients with
34 advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. *Eur J Cancer*
35 2006;**42**(7):827-34.
- 36 1158. Tsang AC, Ahmadi Pirshahid S, Virgili G, et al. Hydroxychloroquine and chloroquine retinopathy: a
37 systematic review evaluating the multifocal electroretinogram as a screening test. *Ophthalmology*
38 2015;**122**(6):1239-51.e4.
- 39 1159. Tudur Smith C, Marson AG, Clough HE, et al. Carbamazepine versus phenytoin monotherapy for epilepsy.
40 [Review] [47 refs]. *Cochrane Database Syst Rev* 2002(2):CD001911.
- 41 1160. Tudur Smith C, Marson AG, Williamson PR. Phenytoin versus valproate monotherapy for partial onset
42 seizures and generalized onset tonic-clonic seizures. [Review] [40 refs]. *Cochrane Database Syst Rev*
43 2001(4):CD001769.
- 44 1161. Tudur Smith C, Marson AG, Williamson PR. Carbamazepine versus phenobarbitone monotherapy for
45 epilepsy. [Review] [21 refs]. *Cochrane Database Syst Rev* 2003(1):CD001904.
- 46 1162. Tyson SF, Crow JL, Connell L, et al. Sensory impairments of the lower limb after stroke: a pooled analysis of
47 individual patient data. *Top Stroke Rehabil* 2013;**20**(5):441-9.
- 48 1163. Ueberall MA, Mueller-Schwefe GHH, Terhaag B. Efficacy and tolerability of flupirtine in subacute/ chronic
49 musculoskeletal pain - results of a patient level, pooled re-analysis of randomized, double-blind,
50 controlled trials. *Int J Clin Pharmacol Ther* 2011;**49**(11):637-47.
- 51 1164. Unverzagt S, Machemer M, Solms A, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial
52 infarction complicated by cardiogenic shock. *Cochrane Database Syst Rev* 2015;**3**.
- 53 1165. Unverzagt S, Machemer M-T, Solms A, et al. Intra-aortic balloon pump counterpulsation (IABP) for
54 myocardial infarction complicated by cardiogenic shock. *Cochrane Database Syst Rev* 2011(7):CD007398.
- 55 1166. Uronis HE, Currow DC, McCrory DC, et al. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic
56 patients with cancer: A systematic review and meta-analysis. *Br J Cancer* 2008;**98**(2):294-99.
- 57 1167. Vale C, Tierney JF, Stewart LA, et al. Reducing uncertainties about the effects of chemoradiotherapy for
58 cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized
59 trials. *J Clin Oncol* 2008;**26**(35):5802-12.
- 60

- 1
2
3 1168. Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-
4 analysis of individual patient data. *Eur Urol* 2005;**48**(2):202-05.
- 5 1169. Valery PC, Williams G, Sleigh AC, et al. Parental occupation and Ewing's sarcoma: pooled and meta-analysis.
6 *Int J Cancer* 2005;**115**(5):799-806.
- 7 1170. Valgimigli M, Sabate M, Kaiser C, et al. Effects of cobalt-chromium everolimus eluting stents or bare metal
8 stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. *BMJ* 2014;**349**:g6427.
- 9 1171. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis
10 of two randomised trials. *Ann Oncol* 2014;**25**(2):391-98.
- 11 1172. Van Beek JGM, Mushkudiani NA, Steyerberg EW, et al. Prognostic value of admission laboratory parameters
12 in traumatic brain injury: Results from the IMPACT study. *J Neurotrauma* 2007;**24**(2):315-28.
- 13 1173. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis
14 of individual patient data. *Lancet Neurol* 2010;**9**(3):254-63.
- 15 1174. van der A DL, Rovers MM, Grobbee DE, et al. Mutations in the HFE gene and cardiovascular disease risk: an
16 individual patient data meta-analysis of 53 880 subjects. *Circulation Cardiovascular Genetics*
17 2008;**1**(1):43-50.
- 18 1175. van der Pas MH, Meijer S, Hoekstra OS, et al. Sentinel-lymph-node procedure in colon and rectal cancer: a
19 systematic review and meta-analysis. *Lancet Oncol* 2011;**12**(6):540-50.
- 20 1176. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher
21 albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of
22 high-risk population cohorts. *Kidney Int* 2011;**79**(12):1341-52.
- 23 1177. Van Grunsven P, Van Schayck C, Derenne J, et al. Long term effects of inhaled corticosteroids in chronic
24 obstructive pulmonary disease: a meta-analysis. *Thorax* 1999;**54**(1):7-14.
- 25 1178. van Leeuwen N, Lingsma HF, Perel P, et al. Prognostic value of major extracranial injury in traumatic brain
26 injury: an individual patient data meta-analysis in 39,274 patients. *Neurosurgery* 2012;**70**(4):811-8;
27 discussion 18.
- 28 1179. Van Loo HM, Van Den Heuvel ER, Schoevers RA, et al. Sex dependent risk factors for mortality after
29 myocardial infarction: Individual patient data meta-analysis. *BMC Med* 2014;**12**(1).
- 30 1180. van Oostwaard MF, Langenveld J, Schuit E, et al. Recurrence of hypertensive disorders of pregnancy: an
31 individual patient data metaanalysis. *Am J Obstet Gynecol* 2015;**212**(5):624.e1-17.
- 32 1181. van Stel HF, Busschbach JJV, Hunink MGM, et al. Impact of secondary cardiovascular events on health
33 status. *Value Health* 2012;**15**(1):175-82.
- 34 1182. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an
35 individual patient meta-analysis. *JAMA* 2002;**288**(19):2441-8.
- 36 1183. Vansteenkiste J, Glaspy J, Henry D, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs)
37 in lung cancer patients: study-level and patient-level meta-analyses. *Lung Cancer* 2012;**76**(3):478-85.
- 38 1184. Vegter S, Tolley K, Wilson Waterworth T, et al. Meta-analysis using individual patient data: efficacy and
39 durability of topical alicaforsen for the treatment of active ulcerative colitis. *Aliment Pharmacol Ther*
40 2013;**38**(3):284-93.
- 41 1185. Veldt BJ, Hansen BE, Eijkemans MJC, et al. Dynamic decision analysis to determine optimal treatment
42 duration in chronic hepatitis C. *Aliment Pharmacol Ther* 2005;**21**(5):539-47.
- 43 1186. Veldt BJ, Hansen BE, Ikeda K, et al. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic
44 hepatitis C patients with non-response or relapse to interferon. *Scand J Gastroenterol* 2006;**41**(9):1087-
45 94.
- 46 1187. Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained
47 virological response to interferon monotherapy. [Review] [35 refs]. *Gut* 2004;**53**(10):1504-8.
- 48 1188. Velez JCQ, Nietert PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase
49 in mean arterial pressure: a pooled analysis of clinical trials. *Am J Kidney Dis* 2011;**58**(6):928-38.
- 50 1189. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in
51 metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
52 *Clin Cancer Res* 2014;**20**(20):5322-30.
- 53 1190. Venkatesan M, Gadalla NB, Stepniewska K, et al. Polymorphisms in Plasmodium falciparum chloroquine
54 resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment
55 outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.[Erratum
56 appears in *Am J Trop Med Hyg.* 2015 May;**92**(5):1084; PMID: 25948561]. *Am J Trop Med Hyg*
57 2014;**91**(4):833-43.
- 58 1191. Verberg MFG, Eijkemans MJC, Macklon NS, et al. The clinical significance of the retrieval of a low number of
59 oocytes following mild ovarian stimulation for IVF: a meta-analysis. *Hum Reprod Update* 2009;**15**(1):5-
60 12.

- 1
2
3 1192. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat
4 hypertension. *Hypertension* 2005;**45**(2):203-8.
- 5 1193. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide
6 on ad libitum energy intake in humans. *J Clin Endocrinol Metab* 2001;**86**(9):4382-9.
- 7 1194. Verdoux H, Geddes JR, Takei N, et al. Obstetric complications and age at onset in schizophrenia: an
8 international collaborative meta-analysis of individual patient data.[see comment]. *Am J Psychiatry*
9 1997;**154**(9):1220-7.
- 10 1195. Vergouw CG, Heymans MW, Hardarson T, et al. No evidence that embryo selection by near-infrared
11 spectroscopy in addition to morphology is able to improve live birth rates: results from an individual
12 patient data meta-analysis. *Hum Reprod* 2014;**29**(3):455-61.
- 13 1196. Vergouw CG, Heymans MW, Hardarson T, et al. No evidence that embryo selection by near-infrared
14 spectroscopy in addition to morphology is able to improve live birth rates: Results from an individual
15 patient data meta-analysis. *Hum Reprod* 2014;**29**(3):455-61.
- 16 1197. Verheul R, Leheret P, Geerlings PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of
17 seven European trials including 1485 alcohol-dependent patients. *Psychopharmacology (Berl)*
18 2005;**178**(2-3):167-73.
- 19 1198. Verschure DO, Veltman CE, Manrique A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy
20 have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual
21 patient data meta-analysis. *Eur Heart J Cardiovasc Imaging* 2014;**15**(9):996-1003.
- 22 1199. Vickers AJ, Cronin AM, Maschino AC, et al. Acupuncture for chronic pain: individual patient data meta-
23 analysis. *Arch Intern Med* 2012;**172**(19):1444-53.
- 24 1200. Virtanen M, Jokela M, Nyberg ST, et al. Long working hours and alcohol use: systematic review and meta-
25 analysis of published studies and unpublished individual participant data. *BMJ* 2015;**350**:g7772.
- 26 1201. Virtanen M, Nyberg ST, Batty GD, et al. Perceived job insecurity as a risk factor for incident coronary heart
27 disease: systematic review and meta-analysis. *BMJ* 2013;**347**:f4746.
- 28 1202. von Bueren AO, Gerss J, Hagel C, et al. DNA copy number alterations in central primitive neuroectodermal
29 tumors and tumors of the pineal region: an international individual patient data meta-analysis. *J*
30 *Neurooncol* 2012;**109**(2):415-23.
- 31 1203. von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast
32 cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia
33 management: results from an integrated analysis. *Eur J Cancer* 2009;**45**(4):608-17.
- 34 1204. von Minckwitz G, Untch M, Nuesch E, et al. Impact of treatment characteristics on response of different
35 breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. *Breast*
36 *Cancer Res Treat* 2011;**125**(1):145-56.
- 37 1205. Von Oppell UO, Dunne TT, De Groot MK, et al. Traumatic aortic rupture: twenty-year metaanalysis of
38 mortality and risk of paraplegia. *The Annals of Thoracic Surgery* 1994;**58**(2):585-93.
- 39 1206. Vranckx P, Boersma E, Garg S, et al. Cardiovascular risk profile of patients included in stent trials; a pooled
40 analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials
41 in Europe. *EuroIntervention* 2011;**7**(7):859-71.
- 42 1207. Wade C, Grady J, Kramer G. Efficacy of saline dextran (HSD) in patients with traumatic hypotension: meta-
43 analysis of individual patient data of hypertonic. *Acta Anaesthesiol Scand Suppl* 1997;**110**:77-9.
- 44 1208. Wade CE, Grady JJ, Kramer GC, et al. Individual patient cohort analysis of the efficacy of hypertonic
45 saline/dextran in patients with traumatic brain injury and hypotension. [Review] [22 refs]. *Journal of*
46 *Trauma-Injury Infection and Critical Care* 1997;**42**(5 Suppl):S61-5.
- 47 1209. Waldman AT, Stull LB, Galetta SL, et al. Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of
48 observational studies. *Journal of Aapos: American Association for Pediatric Ophthalmology and*
49 *Strabismus* 2011;**15**(5):441-6.
- 50 1210. Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic
51 kidney disease: a meta-analysis of randomized trials. *Circ Heart Fail* 2011;**4**(1):18-26.
- 52 1211. Walker MF, Leonardi-Bee J, Bath P, et al. Individual patient data meta-analysis of randomized controlled
53 trials of community occupational therapy for stroke patients. *Stroke* 2004;**35**(9):2226-32.
- 54 1212. Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in patients with newly diagnosed
55 antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Care Res* 2011;**63**(7):1055-61.
- 56 1213. Walsh SR, Boyle JR, Lynch AG, et al. Suprarenal endograft fixation and medium-term renal function:
57 Systematic review and meta-analysis. *J Vasc Surg* 2008;**47**(6):1364-70.
- 58 1214. Walti H, Paris-Llado J, Egberts J, et al. Prophylactic administration of porcine-derived lung surfactant is a
59 significant factor in reducing the odds for peri-intraventricular haemorrhage in premature infants. *Biol*
60 *Neonate* 2002;**81**(3):182-7.

- 1
2
3 1215. Wang D, Connock M, Barton P, et al. 'Cut down to quit' with nicotine replacement therapies in smoking
4 cessation: A systematic review of effectiveness and economic analysis. *Health Technol Assess*
5 2008;**12**(2):i-156.
- 6 1216. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term
7 blood pressure variability: Evidence from randomized controlled trials. *J Am Soc Hypertens*
8 2014;**8**(5):340-49.
- 9 1217. Wang J-G, Staessen JA, Franklin SS, et al. Systolic and diastolic blood pressure lowering as determinants of
10 cardiovascular outcome. *Hypertension* 2005;**45**(5):907-13.
- 11 1218. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by
12 surveillance: a pooled analysis.[see comment]. *J Clin Oncol* 2002;**20**(22):4448-52.
- 13 1219. Wardlaw JM, Chappell FM, Stevenson M, et al. Accurate, practical and cost-effective assessment of carotid
14 stenosis in the UK. *Health Technol Assess* 2006;**10**(30):iii-128.
- 15 1220. Warkentin TE, Sheppard J-A, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-
16 induced thrombocytopenia. *Blood* 2006;**108**(9):2937-41.
- 17 1221. Watts NB, Geusens P, Barton IP, et al. Relationship between changes in BMD and nonvertebral fracture
18 incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change
19 in BMD. *J Bone Miner Res* 2005;**20**(12):2097-104.
- 20 1222. Wedzicha JA, Dahl R, Buhl R, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and
21 glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
22 *Respir Med* 2014;**108**(10):1498-507.
- 23 1223. Weinberg DV, Shapiro H, Ehrlich JS. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes:
24 an individual patient data analysis of 2 phase 3 trials. *Ophthalmology* 2013;**120**(6):1278-82.
- 25 1224. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease
26 and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol*
27 2004;**15**(5):1307-15.
- 28 1225. Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease
29 and mortality. *Am J Kidney Dis* 2004;**44**(2):198-206.
- 30 1226. Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast
31 milk, and nursing infants. *Am J Psychiatry* 2004;**161**(6):1066-78.
- 32 1227. Welten CC, Koeter M, Wohlfarth TD, et al. Efficacy of drug treatment for acute mania differs across
33 geographic regions: An individual patient data meta-analysis of placebo-controlled studies. *J*
34 *Psychopharmacol* 2015;**29**(8):923-32.
- 35 1228. Welten CCM, Koeter MWJ, Wohlfarth T, et al. Placebo response in antipsychotic trials of patients with acute
36 mania. Results of an individual patient data meta-analysis. *Eur Neuropsychopharmacol* 2015;**25**(7):1018-
37 26.
- 38 1229. Westerhout CM, Bonnefoy E, Welsh RC, et al. The influence of time from symptom onset and reperfusion
39 strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic
40 strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. *Am Heart J*
41 2011;**161**(2):283-90.
- 42 1230. Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-
43 cell lung cancer: a pooled analysis of five randomized trials. *Ann Oncol* 2010;**21**(10):2023-8.
- 44 1231. Wheatley-Price P, Ma C, Ashcroft LF, et al. The strength of female sex as a prognostic factor in small-cell
45 lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical
46 Research Council Clinical Trials Unit. *Ann Oncol* 2010;**21**(2):232-7.
- 47 1232. Whegang Youdom S, Samson A, Basco LK, et al. Multiple treatment comparisons in a series of anti-malarial
48 trials with an ordinal primary outcome and repeated treatment evaluations. *Malar J* 2012;**11**:147.
- 49 1233. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-
50 analysis of randomized clinical trials. *Am J Cardiol* 2007;**99**(1):91-8.
- 51 1234. Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to
52 moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled
53 trials.[see comment]. [Review] [40 refs]. *Int J Geriatr Psychiatry* 2004;**19**(7):624-33.
- 54 1235. Whiteley WN, Adams HP, Jr., Bath PMW, et al. Targeted use of heparin, heparinoids, or low-molecular-
55 weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-
56 analysis of randomised controlled trials. *Lancet Neurol* 2013;**12**(6):539-45.
- 57 1236. Whittmore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12
58 US case-control studies II. Invasive epithelial ovarian cancers in white women. *Am J Epidemiol*
59 1992;**136**(10):1184-203.
- 60

- 1
2
3 1237. Wilcock GK, Birks J, Whitehead A, et al. The effect of selegiline in the treatment of people with Alzheimer's
4 disease: a meta-analysis of published trials. *Int J Geriatr Psychiatry* 2002;**17**(2):175-83.
- 5 1238. Williams CJ, Stewart L, Parmar M, et al. Meta-analysis of the role of platinum compounds in advanced
6 ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. *Semin Oncol* 1992;**19**(1 Suppl 2):120-8.
- 7 1239. Williamson PR, Marson AG, Tudur C, et al. Individual patient data meta-analysis of randomized anti-
8 epileptic drug monotherapy trials. *J Eval Clin Pract* 2000;**6**(2):205-14.
- 9 1240. Willmann O, Wennberg R, May T, et al. The role of magnetic resonance spectroscopy in pre-operative
10 evaluation for epilepsy surgery. A meta-analysis. *Epilepsy Res* 2006;**71**(2-3):149-58.
- 11 1241. Woodward M, Barzi F, Feigin V, et al. Associations between high-density lipoprotein cholesterol and both
12 stroke and coronary heart disease in the Asia Pacific region. *Eur Heart J* 2007;**28**(21):2653-60.
- 13 1242. Woodward M, Huxley R, Lam TH, et al. A comparison of the associations between risk factors and
14 cardiovascular disease in Asia and Australasia. *Eur J Cardiovasc Prev Rehabil* 2005;**12**(5):484-91.
- 15 1243. Woodward M, Martiniuk A, Ying Lee CM, et al. Elevated total cholesterol: its prevalence and population
16 attributable fraction for mortality from coronary heart disease and ischaemic stroke in the Asia-Pacific
17 region. *Eur J Cardiovasc Prev Rehabil* 2008;**15**(4):397-401.
- 18 1244. Woodward M, Zhang X, Barzi F, et al. The effects of diabetes on the risks of major cardiovascular diseases
19 and death in the Asia-Pacific region. *Diabetes Care* 2003;**26**(2):360-6.
- 20 1245. Woopen H, Richter R, Chekerov R, et al. The influence of comorbidity and comedication on grade III/IV
21 toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual
22 participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology
23 (NOGGO). *Gynecol Oncol* 2015.
- 24 1246. Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group. The effect of dose on
25 the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of
26 individual patient data. *Lancet Infect Dis* 2015;**15**(6):692-702.
- 27 1247. WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group. The effect of dosing strategies
28 on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of
29 individual patient data. *BMC Med* 2015;**13**:66.
- 30 1248. Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index
31 and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.
32 *Lancet* 2011;**377**(9771):1085-95.
- 33 1249. Wu IC, Lin CC, Hsiung CA, et al. Epidemiology of sarcopenia among community-dwelling older adults in
34 Taiwan: A pooled analysis for a broader adoption of sarcopenia assessments. *Geriatr Gerontol Int*
35 2014;**14**(SUPPL.1):52-60.
- 36 1250. Wu Y-L, Zhong W-Z, Li L-Y, et al. Epidermal growth factor receptor mutations and their correlation with
37 gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated
38 individual patient data from six medical centers in mainland China. *J Thorac Oncol* 2007;**2**(5):430-39.
- 39 1251. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and
40 surveillance of melanoma patients: a meta-analysis. *J Natl Cancer Inst* 2011;**103**(2):129-42.
- 41 1252. Xu GJ, Li ZJ, Ma JX, et al. Anterior versus posterior approach for treatment of thoracolumbar burst fractures:
42 A meta-analysis. *Eur Spine J* 2013;**22**(10):2176-83.
- 43 1253. Yablon SA, Brin MF, VanDenburgh AM, et al. Dose response with onabotulinumtoxinA for post-stroke
44 spasticity: a pooled data analysis. *Mov Disord* 2011;**26**(2):209-15.
- 45 1254. Yang Y, Wang X, Mao Q, et al. Survival analysis for valproic acid use in adult glioblastoma multiforme: A
46 meta-analysis of individual patient data and a systematic review. *Seizure* 2014;**23**(10):830-35.
- 47 1255. Yap YG, Duong T, Bland M, et al. Potential demographic and baseline variables for risk stratification of
48 high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator - A
49 prognostic indicator. *Int J Cardiol* 2008;**126**(1):101-07.
- 50 1256. Yap YG, Duong T, Bland M, et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in
51 high-risk patients after myocardial infarction: A combined analysis from multicentre trials. *Eur Heart J*
52 2005;**26**(14):1385-93.
- 53 1257. Yatsuya H, Toyoshima H, Yamagishi K, et al. Body mass index and risk of stroke and myocardial infarction in
54 a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data. *Circ Cardiovasc*
55 *Qual Outcomes* 2010;**3**(5):498-505.
- 56 1258. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy.
57 *Diabetes Care* 2012;**35**(3):556-64.
- 58 1259. Yazici C, Mutlu E, Bonkovsky HL, et al. Risk factors for severe or fatal drug-induced liver injury from
59 amoxicillin-clavulanic acid. *Hepatol Res* 2015;**45**(6):676-82.
- 60

- 1
2
3 1260. Yetgin S, Olcay L, Dibar E, et al. Systematic review of the addition of vincristine plus steroid pulses in
4 maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-
5 analysis involving 5659 children. *Br J Haematol* 2010;**149**(5):722-33.
- 6 1261. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes among black patients with stage II and III colon cancer
7 receiving chemotherapy: an analysis of ACCENT adjuvant trials. *J Natl Cancer Inst* 2011;**103**(20):1498-
8 506.
- 9 1262. Young J, De SA, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a
10 meta-analysis of individual patient data. *Lancet* 2008;**371**(9616):908-14.
- 11 1263. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-
12 year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists
13 Collaboration.[see comment][erratum appears in *Lancet* 1994 Nov 19;344(8934):1446]. *Lancet*
14 1994;**344**(8922):563-70.
- 15 1264. Zhang H, Li P, Ju H, et al. Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original
16 study and individual participant data meta-analysis. *Cancer Epidemiology, Biomarkers and Prevention*
17 2014;**23**(12):2783-92.
- 18 1265. Zhang X, Patel A, Horibe H, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region.
19 *Int J Epidemiol* 2003;**32**(4):563-72.
- 20 1266. Zhao F-H, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary
21 screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies
22 from China.[Erratum appears in *Lancet Oncol*. 2011 Jan;12(1):11]. *Lancet Oncol* 2010;**11**(12):1160-71.
- 23 1267. Zhao X-Q, Krasuski RA, Baer J, et al. Effects of combination lipid therapy on coronary stenosis progression
24 and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined
25 analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment
26 Study (HATS), and the Armed Forces Regression Study (AFREGS). *Am J Cardiol* 2009;**104**(11):1457-64.
- 27 1268. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases--report
28 for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese
29 adults. *Biomed Environ Sci* 2002;**15**(3):245-52.
- 30 1269. Ziegler R, Grossarth-Maticsek R. Individual patient data meta-analysis of survival and psychosomatic self-
31 regulation from published prospective controlled cohort studies for long-term therapy of breast cancer
32 patients with a mistletoe preparation (iscador). *Evid Based Complement Alternat Med* 2010;**7**(2):157-66.
- 33 1270. Zinkstok SM, Vergouwen MDI, Engelter ST, et al. Safety and functional outcome of thrombolysis in
34 dissection-related ischemic stroke: a meta-analysis of individual patient data. *Stroke* 2011;**42**(9):2515-20.
- 35 1271. Zinman B, Schmidt WE, Moses A, et al. Achieving a clinically relevant composite outcome of an HbA1c of
36 <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical
37 trial programme. *Diabetes Obes Metab* 2012;**14**(1):77-82.
- 38 1272. Zong L, Chen P. Prognostic value of KIT/PDGFR mutations in gastrointestinal stromal tumors: a meta-
39 analysis. *World J Surg Oncol* 2014;**12**:71.
- 40 1273. Zong L, Seto Y. CpG island methylator phenotype, Helicobacter pylori, Epstein-Barr virus, and microsatellite
41 instability and prognosis in gastric cancer: A systematic review and meta-analysis. *PLoS ONE [Electronic
42 Resource]* 2014;**9**(1).
- 43 1274. Zugna D, Galassi C, Annesi-Maesano I, et al. Maternal complications in pregnancy and wheezing in early
44 childhood: A pooled analysis of 14 birth cohorts. *Int J Epidemiol* 2015;**44**(1):199-208.
- 45 1275. Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and
46 Drug Administration meta-analysis of patient-level data. *JAMA Intern Med* 2014;**174**(8):1340-8.
- 47 1276. Zwang J, Ashley EA, Karema C, et al. Safety and efficacy of dihydroartemisinin-piperazine in falciparum
48 malaria: a prospective multi-centre individual patient data analysis. *PLoS One* 2009;**4**(7):e6358.
- 49 1277. Zwang J, Dorsey G, Djimde A, et al. Clinical tolerability of artesunate-amodiaquine versus comparator
50 treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized
51 controlled trials in sub-Saharan Africa. *Malaria Journal* 2012;**11**:260.
- 52 1278. Zwang J, Dorsey G, Mårtensson A, et al. Plasmodium falciparum clearance in clinical studies of artesunate-
53 amodiaquine and comparator treatments in sub-Saharan Africa, 1999-2009. *Malaria Journal* 2014;**13**(1).
- 54
55
56
57
58
59
60